Synthesis and evaluation of narciclasine analogues by Judd, Katie
  
Synthesis and Evaluation of 
Narciclasine Analogues 
 
 
 
Katie Elizabeth Judd 
A thesis submitted for the degree of Doctor of Philosophy 
University of Bath 
Department of Pharmacy and Pharmacology 
February 2011 
 
 
This research has been carried out under the supervision of Dr Lorenzo Caggiano 
 
 
 
 
 
 
 
 
 
COPYRIGHT 
Attention is drawn to the fact that copyright of this thesis rests with its author. A 
copy of this thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with the author and they must not 
copy it or use material from it except as permitted by law or with the consent of the 
author. 
 
This thesis may be made available for consultation within the University library and 
may be photocopied or lent to other libraries for the purposes of consultation 
 
 
Signed...................................................... 
 
Date......................................................... 
 
 i 
 
ABSTRACT 
Narciclasine was isolated from the common daffodil in 1967 and was shown to 
exhibit potent and selective anti-cancer activity. However, current synthetic routes are 
generally long and low yielding, hampering its progress as a clinical candidate. This 
project aims to synthesise bioactive analogues using a short, elegant and scalable 
synthesis. 
A one-pot procedure has been developed whereby a carboxylic acid is converted 
to an isocyanate using a modified Curtius rearrangement, which is then captured by a 
tethered electron-rich aromatic ring in a Lewis-acid mediated intramolecular Friedel-
Crafts acylation. This methodology was then applied to produce a series of 
dihydroisoquinolinones as simplified AB-ring analogues in 73-90 % yields. 
Interestingly, the cyclisation of 3,4,5-(trimethoxyphenyl)propionic acid proceeds with 
selective demethylation at the 8-position when BF3·OEt2 is employed as the Lewis acid. 
To mimic the sp2 centre at the 10b position of narciclasine, the analogues were oxidised 
using palladium on activated carbon in 39-89 % yields.  
This synthetic methodology has been applied to the synthesis of the more 
complex ABC-ring analogues. Acetophenones were readily converted to β-ketoesters, 
which were then condensed with methyl vinyl ketone using a Robinson annulation 
reaction to generate modified Hagemann’s esters. Reduction followed by saponification 
of this ester provided the corresponding acid for cyclisation using the Curtius 
rearrangement and Friedel-Crafts acylation. Three analogues have been synthesised 
using this approach in 6 steps and overall yields of 10-18 %. 
These analogues have been evaluated against HT29 colon cancer cell lines, 
showing a range of activities from 715 μM to 15 μM, with patterns in the structure-
activity relationship that mirror those in the natural products. 
 
The prenyl and chroman groups are medicinally important functional groups 
found in a number of natural products. During our investigations, a mild method of 
prenylating an aromatic ring using Bi(OTf)3 as a catalyst was discovered. The procedure 
was optimised and applied to a range of aryl rings to identify the scope and limitations 
of the reaction. It was also found that applying the same procedure to phenols gave 
chromans as the products. This reaction was applied to the synthesis of the natural 
product 2-(3-methyl-2-butenyl)-3,4,5-trimethoxyphenol, in 34 % overall yield.  
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1. INTRODUCTION 
1.1. NARCICLASINE; SYNTHESIS AND BIOLOGICAL 
ACTIVITY 
1.1.1. Isolation 
The Amaryllidaceae family of plants have long been known to have 
medicinal properties and there are reports of their use throughout history in treating a 
number of ailments including cancer. A review by Hartwell found that many of the 
plants in the family have been used in civilisations across the world and throughout 
history to treat symptoms of what we now know as cancer.
1
 In particular, oil isolated 
from the bulbs of the plants from the Narcissus genus has been used as a treatment 
by Hippocrates in Ancient Greece and Pliny the Elder in Ancient Rome. Commonly, 
the plants of the Narcissus genus are known as the daffodil. In herbal medicine, 
Culpeper describes daffodils being used to treat a range of ailments from healing 
wounds to treating fevers.
2
 Daffodils have also been found to have a negative effect 
on the length of vase life of cut flowers.
3
  
 
 
Figure 1: Daffodils at University of Bath 
 
Narciclasine has since been discovered to be the compound responsible for 
these effects. Ceriotti initially described narciclasine as “A potent antimitotic 
 2 
 
substance which was isolated from several varieties of Narcissus bulbs” in 1967.4 In 
the following year, the group published 1 as what they believed to be the structure of 
narciclasine (Figure 2).
5
 Meanwhile, Okamoto et al. had isolated lycoricidinol from 
the bulbs of Lycoris radiate and published its structure as 2 along with initial growth 
inhibition studies.
6
 After a chemical study
7
 and X-ray crystallography,
8
 narciclasine 
and lycoricidinol were identified as the same substance and the structure was 
assigned with absolute stereochemistry as 3.  
 
 
Figure 2: Debated structures of narciclasine 
 
To date, narciclasine has been isolated from many different plants of the 
Amaryllidaceae family, but it is found in the bulbs of all species of Narcissus genus 
at 30-200 mg/kg depending on the variety of plant.
9
 This yield from the natural 
sources is not sufficient to progress narciclasine as a clinical candidate. However, 
there have been many investigations into the biological activity and chemical 
synthesis of narciclasine and its analogues.  
 
1.1.2. Biological Activity 
Narciclasine’s anticancer properties were first described in 1967 by Ceriotti 
when he tested the substance in vivo in mice on sarcoma 180 cells, observing an anti-
mitotic activity at high doses.
4
 Okamoto et al. also studied narciclasine and its anti-
cancer effects in Ehrlich carcinoma and observed a significant drop in cell viability 
after treatment with 100 µg of narciclasine over 30 days.
6
 Mondon and Krohn 
published the first structure-activity relationship study in 1975.
10
 They found that in 
HeLa (cervical cancer) and HEPH (laryngeal cancer) cell lines that narciclasine was 
toxic in concentrations of >0.1 µg/mL and showed an effect between 0.025-0.1 
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µg/mL. Since then, narciclasine has been shown to have a number of mechanisms of 
action for its anti-cancer activity. 
In 1975, Vazquez et al. published a series of letters investigating the 
ribosomal mechanism of action of narciclasine in yeast. They found narciclasine 
blocks peptide synthesis by interacting with the 60S ribosome subunit, preventing 
the tRNA at the A site of the ribosome binding to the peptidyl-transferase centre so 
the next amino acid in the sequence cannot be attached to the growing peptide chain 
(Figure 3).
11
 This was proved by studying strains of yeast ribosomes with a mutation 
in the peptidyl-transferase centre and these strains showed resistance to 
narciclasine.
12
 
 
 
Figure 3: Role of the ribosome in protein synthesis 
 
Kiss et al. have shown that narciclasine can induce apoptosis selectively in 
cancer cells, but not in normal cells.
13
 They found that the mechanism for apoptosis 
is dependent on the type of cancer cell, but in both types of cell apoptosis goes via 
the death receptor pathway (Figure 4). The cascade begins with the narciclasine-
promoted activation of death receptors FAS and DR4, followed by formation of the 
Death Inducing Signalling Complex (DISC). Procaspase-8 is recruited to DISC and 
activated to give caspase-8 and it is from here that the two types of cell differ. In 
type I cells, such as the PC-3 prostate cancer cells, a high concentration of caspase-8 
is recruited and activated which in turn directly recruits the effector caspases to 
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trigger apoptosis.
14
 In type II cells, such as MCF-7 breast cancer cells, the 
recruitment of caspase-8 is low, so further amplification of this signal is required to 
initiate the effector caspases. This amplification occurs through the mitochondria, 
affecting the potential of the outer mitochondrial membrane,
15
 thus allowing the 
release of cytochrome c, which forms part of the apoptosome. This structure then 
activates the effector caspases, triggering apoptosis.
16
  
 
 
Figure 4: Apoptosis pathways in MCF-7 and PC-3 cells, representing type II and type I cells
13
 
 
These observations nicely complement observations made on pancratistatin, a 
closely related analogue of narciclasine, which has also found to selectively induce 
apoptosis in cancer cells
17,18
 and leukaemia.
19
 There are also no signs of DNA 
damage caused by pancratistatin in either cancer cells or normal cells. Matching 
Kiss’ observations on effects of narciclasine on MCF-7 breast carcinoma, 
pancratistatin has shown to affect the mitochondrial membrane potential in SHSY-
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5Y neuroblastoma cells, making the outer membrane more permeable and so 
allowing the release of cytochrome c.
17
 However this may be a downstream effect of 
activation of caspase-3,
18
 a protein which is also related to the activation of caspase-
8.
20
  
Ingrassia and Lefranc have also performed an in-depth study of narciclasine 
and various analogues.
21
 They found that narciclasine impairs cell proliferation and 
cell migration in cancer cell lines to a greater extent than in normal cell lines (Figure 
5). The natural product displays activity in cell lines that are both resistant (e.g. 
U373 glioblastoma cells) and sensitive (e.g. PC-3 prostate cancer cells) to apoptosis 
as it works through non-apoptotic mechanisms. These include promoting actin 
polymerisation, which in turn rigidifies the actin cytoskeleton, impairing growth and 
movement of the cancer cells (Figure 6). 
 
 
Figure 5: Results from scratch wound healing assays of human PC-3, U373 and Ccd-25-Lu 
normal human lung fibroblasts 
 
 
 
Figure 6: Effects of narciclasine on actin polymerisation in PC-3, U373 and Ccd-25-Lu cells (F-
actin shown in green and G-actin shown in red)
21
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This work in the U373 glioblastoma cells has been extended to glioblastomas 
GL19 and Hs683 and into xenograft models.
22
 The investigation found that 
narciclasine decreases the rate of mitosis by increasing the time between cell 
division. It decreases cell migration and an increase in fibrillary actin is observed. 
This effect is due to the activation of Rho, a family of proteins which are key 
regulators of the actin cytoskeleton (Figure 7). This has the effect of activating its 
downstream substrates ROCK-1 and LIMK-1 by phosphorylation. Activated LIMK-
1 then phosphorylates the Serine3 on cofilin, rendering it inactive. Cofilin is an 
actin-severing protein, so its inactivation means that the growing actin filaments are 
not depolymerised, leading to extensive filament formation and cell rigidity, 
rendering the cell immobile.
23
 Although to date, only glioblastoma cells have been 
investigated for this effect, narciclasine could prove to be effective in other 
metastasising cell lines, such as breast cancers. 
 
 
Figure 7: Mechanism of Rho activation leading to increase fibrillary acting within the cell 
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Despite the many modes of action of narciclasine and its congener 
pancratistatin, the compounds display a selective anti-cancer activity, whilst showing 
little effect on normal human cell lines. This gives a strong advantage over many 
other chemotherapies which have toxicity issues associated with them.  
 
1.1.3. Structure-Activity Relationship 
During the numerous investigations on narciclasine, a large number of 
analogues have been accessed by either isolation from natural sources or synthesised 
as part of SAR studies or total synthesis attempts. Many of these compounds have 
been tested for their anti-cancer activity allowing the formation of a structure activity 
relationship. Narciclasine can be described as a phenanthridinone with a tricyclic 
core structure consisting of an aromatic, polyoxygenated A-ring, a lactam B-ring and 
a polyhydroxylated C-ring (Figure 8).  
 
 
Figure 8: Nomenclature and numbering for the structure of narciclasine 
 
The A-ring in narciclasine 3 has a 7-hydroxy-8,9-methylenedioxy 
substitution pattern (Figure 9). 7-Deoxynarciclasine 4, also a natural product shows a 
10-fold decrease in mean GI50 of 145 nM compared to narciclasine’s 15.5 nM in the 
NCI 60 cell line screen. A decrease in activity is also seen when comparing 7-
hydroxy-trans-dihydronarciclasine 5 and 7-deoxy-trans-dihydronarciclasine 6 with 
GI50 values of 12.6 nM and 67.6 nM, although the difference is not so pronounced.
24
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Figure 9: Narciclasine 3, 7-deoxynarciclasine 4 and their dihydro-analogues 5 and 6 
 
Hudlicky et al. have synthesised a number of analogues of the related 
compound pancratistatin 7 with changes made to the A-ring (Figure 10). The 9-
methoxy analogue 8 had an average GI50 value of 3.7 µg/mL across 6 solid tumour 
cell lines and a leukaemia cell line,
25
 a 100-fold reduction in activity when compared 
to pancratistatin’s activity of 0.034 µg/mL in the same cell lines. This means that in 
general there is a 10-fold loss in activity with the removal of each subsequent oxygen 
group. Hudlicky also synthesised analogue 9 where the A-ring was replaced with an 
indole, with the reasoning that the NH would mimic the hydroxyl and the aromatic 
ring would mimic the lipophilic methylenedioxy substituent.
26
 The compound was 
approximately 100-fold less active than pancratistatin in P388 leukaemia and 
inactive against the 3 human cancer cell lines that were tested showing that despite 
the modelling comparing the two compounds, they do behave differently in a cellular 
environment.  
 
 
Figure 10: Pancratistatin 7 and some synthetic analogues 
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The B-ring in both narciclasine and pancratistatin is a δ-lactam. Reduction of 
this lactam to a cyclic amine has a detrimental effect on activity. Pettit et al. 
synthesised amines 10 and 11 by reduction of the corresponding amides.
27
 The 
amines and their HCl salts were evaluated against a panel of human cancer cell lines 
and displayed growth inhibition values of >1 µg/mL compared with those of 
corresponding amides of <0.15 µg/mL. 
 
 
Figure 11: Cyclic amine analogues of lycoricidine and dihydrolycoricidine
27
 
 
Chapleur et al. have investigated changes to the B-ring, synthesising lactone 
analogues of narciclasine 12 which were found to be inactive (Figure 12).
28
 They 
also synthesised a series of seco-analogues 13 where the A and C-rings were not 
connected between the 10a and 10b positions and again these were found to be 
devoid of activity.
29
 
 
 
Figure 12: Chapleur's B-ring analogues
28,29
 
 
Arylcyclitol analogues have also been reported by Kornienko et al. where the 
B-ring has been removed completely (Figure 13).
30
 These have also shown to be 
completely inactive, complementing Chapleur’s findings that the B-ring needs to 
remain intact with an amide NH for biological activity. 
 10 
 
 
Figure 13: Kornienko's arylcyclitol analogues
30
 
 
Narciclasine 3 has an sp
2
 centre at the 10b position and a stereogenic centre 
at the 4a position which is in the R-configuration. Analogues of narciclasine with 
changes to the ring junction have been isolated from natural sources and tested in the 
NCI 60 cell line screen (Figure 14).
24
 When the ring junction was a double bond 
between the 4a and 10b positions in 14, the activity was reduced significantly to 
1180 nM. Changing the 10b position to an R-configured sp
3
 centre to give 5 with a 
trans-geometry at the ring junction had little effect on the activity with a slight 
increase from 15.5 nM to 12.6 nM.  However, when the 10b position was an S-
configured sp
3
 centre, giving 15 with a cis-geometry at the ring junction there was a 
large loss in activity to 380 nM.  
 
 
Figure 14: Changes at the B/C-ring junction and its effect on activity
24
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The C-ring in narciclasine can be described as an amino-inositol ring. Many 
analogues of narciclasine have been isolated or synthesised with changes made in the 
C-ring. A number of analogues have been made in the trans-dihydrolycoricidine 
series, testing how many hydroxyl groups are needed for activity (Figure 15).
25,31 
  
The mono-alcohol 16 displayed only a moderate activity against P388 murine 
leukaemia of 40.1 µg/mL, whereas the diols proved to be more active in the same 
cell line. The 3,4-diol 17 had an ED50 of 1.39 µg/mL, but the most active analogue 
was the 2,3-diol 18 with an ED50 of 0.45 µg/mL. This is much less active than 
pancratistatin (ED50 = 0.039 µg/mL) or narciclasine (ED50 = 0.0012 µg/mL) in the 
same cell line; however, a direct comparison should not be drawn as the analogues 
do not contain the 7-hydroxyl group.
 
The 2,4-diol 19 was not tested against P388 
leukaemia, but has been shown to be inactive against MCF-7 breast cancer cells.
32
 
 
 
Figure 15: C-ring analogues in the dihydrolycoricidine series 
 
Hudlicky et al. have synthesised the C1 homologue of 7-deoxypancratistatin 
20, which showed between 2 and 20 fold loss of activity depending on the cell line 
when compared to trans-dihydrolycoricidine 6 which bears no substituent at the C1 
position (Figure 16).
33
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Figure 16: C1-homologue of 7-deoxypancratistatin
33
 
 
Kornienko et al. have also investigated modifications on the C-ring by 
opening the ring and contracting the ring to a furan (Figure 17).
34
 All three 
compounds 21, 22 and 23 showed at 10-12 fold loss in activity in HeLa and MCF-7 
cells when compared to narciclasine. The cyclic system is more rigid in the natural 
product, holding the hydroxyls group in a favourable conformation compared to the 
acyclic analogues. 
 
 
Figure 17: Kornienko's truncated C-ring analogues
34
 
 
A series of 28 analogues based on 24 were synthesized and tested by 
Ingrassia and Lefranc (Figure 18).
21
 They found that protection of all the 
heteroatoms resulted in a reduction in activity; and in particular, the loss of the NH 
upon protection of the amide always resulted in a complete loss of activity. The 
hydroxyl at the C2 position was not sensitive to protection and a range of 
substituents were attached here without any affect on the activity. The 7-hydroxyl 
group proved to be much more sensitive, especially towards alkyl substituents, 
although acyl and sugar substituents were tolerated more. Acetal protection of the 
3,4-diol was also tolerated. The only changes in the C-ring that gave comparable 
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activities to narciclasine were the C2-hydroxyl esters, but this was not surprising as 
it was found on closer inspection that these decomposed in the biological media to 
give narciclasine. 
 
 
Figure 18: General structure and substituents of synthesised analogues of narciclasine
21
 
 
In summary for biological activity, the A-ring needs to be a poly-oxygenated 
aryl ring, the B-ring must be a lactam, with the 4a position in the R-configuration 
and the 10b position either being sp
2
 or in the R-configuration. The C-ring should be 
cyclised and contain a minimum of three hydroxyl groups. 
 
1.1.4. Pro-drug Synthesis 
A major problem with advancing narciclasine or its analogues as clinical 
candidates has been the poor solubility of the compounds; pancratistatin has a 
solubility of only 53 µg/mL. To overcome this, pro-drugs have been investigated. 
Work has mostly been performed on pancratistatin 7 rather than narciclasine 3, but 
the ideas can be applied to both compounds. Pancratistatin has 5 free hydroxyl 
groups and these provide the perfect handles to make pro-drugs. Synthesis of 
phosphate esters has been the most investigated method of making pancratistatin and 
narciclasine more soluble.  
The sodium 7-O-phosphate 25 has a greatly improved aqueous solubility of 
20 mg/mL at 25 °C and showed comparable activities against a panel of cancer cell 
lines when compared to pancratistatin (Figure 19).
35
 Other counterions were also 
investigated and showed a range of solubility and activity values. 
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Figure 19: Sodium pancratistatin-7-O-phosphate 25 
 
A number of 4-O-phosphate esters of pancratistatin 26 and 3,4-O-cyclic 
phosphate esters of narciclasine 27 and pancratistatin 28 have also been synthesised 
and tested against a panel of cancer cell lines (Figure 20).
36
 Generally, the 
phosphates showed a 10-fold reduction in activity when compared to the parent 
compounds but this was dependant on the cell line and the counterion used. The 
solubility of these compounds has not been assessed quantitatively as the increase in 
solubility had previously been demonstrated with 25. The improved solubility of 
sodium pancratistatin 3,4-O-cyclic phosphate 28 has allowed in-vivo studies to be 
performed in Human colon tumour xenograft models. At 100 mg/kg, 28 gave an 
increase in tumour necrosis and a disruption in mitochondrial membrane potential 
was also observed, complementing the in-vitro observations.
37
 
 
 
Figure 20: Pancratistatin-4-O-phosphates 26, narciclasine-3,4-O-cyclic phosphates 27 and 
pancratistatin-3,4-O-cyclic phosphates 28 
 
Phenstatin 29 is the 1-benzoyl adduct of pancratistatin and displays up to a 
300-fold increase in activity across a panel of 6 cell lines when compared to 
pancratistatin and up to an 80-fold increase when compared to narciclasine across the 
same cell lines (Figure 21).
36,38
 However, as the solubility of phenstatin has not been 
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determined, it is not known whether this increase is due purely to improvements in 
solubility or due to improved potency.  
 
 
Figure 21: Phenstatin 29 
 
1.1.5. Synthetic Attempts 
Since 1997 there have been four syntheses of narciclasine, each taking a 
different approach. 
Rigby et al. published the first total synthesis of narciclasine 3 in 1997 in 22 
steps and 0.3 % overall yield (Scheme 1).
39
 In this approach, the A-ring originated 
from 2,3-dihydroxybenzaldehyde 30 and the C-ring is synthesised from methyl 
cyclohex-3-ene carboxylate 33. The two portions were connected by capturing the 
isocyanate 32 with the aryl lithium carbanion 35 to give the amide 36 in 52 % yield. 
Then a photochemical cyclisation formed the bond between the 10a and 10b 
positions in 46 %. The C-ring was manipulated to install the hydroxyl substituents 
and finally deprotection revealed the natural product 3.  
 16 
 
 
Scheme 1: Rigby's synthesis of narciclasine
39
 
  
Although Rigby reported the first total synthesis, the step count and overall yield 
was poor. This was addressed in 1999 when two different syntheses were published 
by Hudlicky and Keck.  
Hudlicky has a great interest in enzymatic dihydroxylation, which was used 
as a key step together with a Diels-Alder reaction in the synthesis of the C-ring. The 
A-ring originated from o-vanillin and was transformed in four steps into the borate 
coupling partner for a Suzuki reaction with the C-ring bromide 41. A modified 
Bischler-Napieralski reaction formed the B-ring lactam 44 in 40 %. Finally 
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deprotection revealed narciclasine 3 in a much improved 14 steps from o-vanillin but 
a poorer overall 0.13 % yield (Scheme 2).
40
  
 
 
Scheme 2: Hudlicky's synthesis of narciclasine
40
 
 
Keck et al. used a radical cyclisation as the key step in his synthesis to form 
the C-ring (Scheme 3).
41
 His approach employed a Sonogashira coupling of alkyne 
47 and aryl iodide 50 to provide the precursor 51 for the radical cyclisation in 89 % 
yield. After the radical cyclisation, the AC-ring intermediate 52 was isolated in an 
excellent 88 %. A number of transformations were then required to cyclise the B-
ring, remove the thioether installed during the radical reaction and deprotect the 
hydroxyl groups to reveal the natural product 3 in 14 steps and a much improved 13 
% overall yield.  
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Scheme 3: Keck's synthesis of narciclasine
41
 
 
Yan et al. published the most recent synthesis of narciclasine in 2002, a 9 
step route in a 19 % overall yield, making it the most efficient synthesis of the 
natural product to date (Scheme 4).
42
 This synthesis used the same disconnections as 
Rigby et al., but instead the A-ring is tethered to the C-ring by an N-alkylation to 
afford amine 56, then the A/C-ring junction was formed by the ring opening of an 
epoxide to give the tricyclic compound 57. An oxidation step afforded the amide 58 
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and further manipulations gave the natural product 3. As with Hudlicky’s synthesis, 
the oxygenation pattern in the C-ring is set early on before the cyclisation of the B-
ring.  
 
 
Scheme 4: Yan's synthesis of narciclasine
42
 
 
Despite the improvements to the synthesis of narciclasine, the step counts 
and yields are still less than desirable for taking the natural product forward as a 
clinical candidate. These approaches have targeted the natural product for academic 
interest and to develop new chemical reactions; however, they are not ideal for use in 
creating libraries of compounds to further investigate structure-activity relationships. 
To efficiently build libraries of biologically active analogues, an efficient synthesis 
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of a late-stage intermediate is required, which can then be easily functionalised to 
give a diverse set of compounds. Developing a route based on this approach should 
enhance the appeal of the compound as a clinical candidate. 
 
1.2. PROPOSED SYNTHESIS OF ANALOGUES 
The initial target of the synthesis will be the tricyclic late stage intermediate 
63. This intermediate can be made from simple commercially available starting 
materials and there is scope for it to be easily functionalised at several of stages 
within the synthesis to generate diverse libraries of compounds. 
 
 
Scheme 5: Proposed synthesis of ABC-ring analogues 
 
The synthesis will begin with the condensation of an acetophenone 59 to 
generate a β-ketoester 60 (Scheme 5). There are many acetophenones commercially 
available, allowing different substitution patterns to be investigated on the A-ring. 
There are two available routes from the β-ketoester to the tricyclic core 63. In route 
A, the acid generated from saponification of the β-ketoester will undergo a Curtius 
rearrangement and intramolecular Friedel-Crafts acylation to give the AB-ring 
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lactam 61. This will be followed by a Robinson annulation with a vinyl ketone to 
install the C-ring. Route B will use the same reactions but applied in the opposite 
order, so the β-ketoester will be condensed with a vinyl ketone in a Robinson 
annulation to give a modified Hagemann’s ester 62. After saponification of the ester, 
the acid will then undergo a Curtius rearrangement and intermolecular Friedel-Craft 
acylation to give the B-ring lactam 63. The Robinson annulations will be optimised 
using methyl vinyl ketone (MVK), however a range of vinyl ketones can be used to 
install functional groups at the C1 and C4 positions of the phenanthridone core.  
Once the intermediate 63 has been synthesised, a range of methods are 
available to decorate the C-ring further with different functional groups. For 
example, the ketone can undergo Rubottom oxidation to install a hydroxyl group at 
the C3-position (Scheme 6a). Enolate chemistry can be used to install a number of 
functional groups at the C3 position (Scheme 6b). The ketone can also be reduced to 
the alcohol using a Luche reduction (Scheme 6c) and the hydroxyl group substituted 
by different nucleophiles to give variation at the C2 position (Scheme 6d).  
 
 
Scheme 6: Possible methods to further functionalise the C-ring 
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1.3. THE CURTIUS REARRANGEMENT 
The Curtius rearrangement is the thermal decomposition of an acyl azide, 
generated from a carboxylic acid, to an isocyanate with the loss of nitrogen. The 
isocyanate can then be trapped with a range of nucleophiles to afford various groups 
such as amines, amides, carbamates or ureas (Scheme 7). 
 
 
Scheme 7: The Curtius rearrangement 
 
Curtius first described the rearrangement of acyl azides in 1890,
43
 and in the 
following years published a number of papers investigating the reaction.
44
 There 
have been a number of reviews into the rearrangement, experimental procedures and 
its applications,
45,46,47
 including the comprehensive review of the first 50 years of the 
reaction by Smith.
48
  
There are several methods of accessing the acyl azide from the carboxylic 
acid, as there are many ways of activating the carboxylic acid towards nucleophilic 
substitution including three commonly used methods (Scheme 8). The acid can be 
converted to the acid chloride using oxalyl chloride,
49
 or thionyl chloride.
50,51
 
Alternatively, the acid can be activated as the mixed anhydride using a 
chloroformate, as described by Weinstock.
52
 This approach has been taken by Ohta 
and Kimoto in their synthesis of lycoricidine,
53
 where they used ethyl chloroformate 
in the presence of base to form the mixed anhydride. In both of these methods, an 
external source of azide is added to the reaction to form the acyl azide and an 
aqueous wash is performed before the reaction is heated to promote the 
rearrangement. The third method of activating the acid is to use diphenylphosphoryl 
azide (DPPA) to generate the phosphoryl ester. The use of DPPA for the Curtius 
rearrangement was first reported in the synthesis of urethanes by Yamada et al.
54
 
They also commented on the ease of the experimental procedure as DPPA acts to 
both activate the acid and provide a source of azide and that the reaction proceeds 
without racemisation of existing stereocentres.  
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Scheme 8: Three commonly used methods of activating the carboxylic acid 
 
The rearrangement of the acyl azide is normally induced thermally; however 
photolytic,
55
 protic acid
56
 and Lewis acid 
57
 catalysed methods have also been 
reported. The mechanism for the rearrangement could follow two possible 
mechanisms (Figure 22). In the concerted mechanism, the loss of nitrogen and the 
migration of the R-group occur at the same time. Alternatively, initial elimination of 
nitrogen leads to an electron deficient nitrene intermediate which then rearranges to 
give the isocyanate. There is much debate over the mechanism, but under thermal 
conditions, it is most likely to proceed via the concerted mechanism, as the nitrene 
intermediate was not trapped in investigations by Hauser et al.
58
 and Lowowski et 
al.
59,60
 
 
 
Figure 22: Two mechanisms of isocyanate formation 
 
A number of products can be generated from the isocyanate by adding 
different nucleophiles to the reaction mixture (Scheme 9).  
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Scheme 9: Products formed by the addition of different nucleophiles to the isocyanate 
 
The free amine can be accessed by adding aqueous acid or base to the 
isocyanate, as initially the carbamic acid is formed which decomposes with the loss 
of carbon dioxide to reveal the amine.
61
 The reaction can be performed using an 
alcohol as the solvent, which traps the isocyanate once it is formed to give a 
carbamate.
62
 In particular, t-BuOH can be used as the nucleophile, giving a Boc-
protected amine as the product.
63
 This is an approach which has been taken in the 
synthesis of pancratistatin; Kim et al. used a Curtius rearrangement to transform a 
carboxylic acid 68 on the C-ring to a methyl carbamate 69. The aryl ring was then 
reacted with the carbamate in a Bischler-Napieralski reaction give the B-ring lactam 
70 (Scheme 10).
64
  
 
 
Scheme 10: Kim's use of the Curtius rearrangement in the synthesis of pancratistatin
64
 
 
A number of carbon-based nucleophiles have also been described giving 
amide products. Padwa et al. reported the addition of Grignard reagents to an 
isocyanate to form a series of 2-amidofurans.
50
 In Trost’s synthesis of pancratistatin, 
an isocyanate was trapped by a tethered aryl lithium to give the B-ring lactam,
65
 and 
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in Rigby’s synthesis of narciclasine, a vinyl isocyanate was trapped by an aryl 
lithium in an intermolecular reaction to give the amide bond which would later form 
part of the B-ring (Scheme 1, p. 16).
39
  
Electron rich aromatic rings have been used as nucleophiles, although the 
addition is often promoted by Lewis acids. Boron trichloride has been used by 
Piccolo et al. to catalyse the ortho-acylation of a phenol with an isocyanate.
66
 AlCl3 
has also been described to catalyse the addition to an isocyanate (Scheme 11). 
Hanessian et al. used AlCl3 to catalyse the addition of a tethered aromatic ring to an 
isocyanate 71 to form tetrahydroisoquinolinones 72 in good yields.
67
 Afarinkia et al. 
also used AlCl3 in their synthesis of phenanthridones to catalyse the addition of the 
aryl A-ring to the isocyanate on the C-ring giving the B-ring lactam 75.
68
  
 
 
Scheme 11: AlCl3-catalysed intramolecular addition of a tethered aryl ring to an isocyanate 
 
BF3·OEt2 is a commonly used Lewis acid and has been employed to the 
promote addition of an aryl ring to an isocyanate. Hilton et al. successfully acylated 
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indoles using tert-butylisocyanate catalysed by BF3·OEt2 to afford 2-amidoindoles 
77 (Scheme 12).
69
 Ohta and Kimoto treated the isocyanate 79 with BF3·OEt2 to 
promote the cyclisation to the lactam 80 in their synthesis of lycoricidine.
53
 Finally 
and possibly most interestingly in the synthesis of narciclasine analogues, Tőke et al. 
used BF3·OEt2 to promote addition to an isocyanate and cyclisation to give the 
tricyclic core 82.
70
 However, they also noted that when the substrate contained a 
methoxy- group at the 7-position, BF3·OEt2 also promoted selective demethylation 
to give the substitution pattern seen in the A-ring of narciclasine. 
 
 
Scheme 12: Examples of BF3·OEt2 catalysed addition of aryl rings to isocyanates 
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The examples of Afarinkia et al., Tőke et al. and Ohta and Kimoto are of 
particular interest to this project due to their use in the synthesis of narciclasine 
analogues. Afarinkia et al. accessed the carboxylic acid precursor in only 3 steps, 
giving only a 4-step synthesis of the tricyclic core structure. Tőke et al. generated the 
isocyanates from the corresponding carboxylic acids; however, they do not report the 
route they used to make the carboxylic acids. Ohta and Kimoto synthesised the 
tricyclic core in 4 steps from a benzaldehyde and then manipulated the C-ring the 
incorporate the hydroxyl groups.  These examples prove that the Curtius 
rearrangement is a viable method of cyclising the B-ring, however they have not 
been investigated further as a synthetically practical and high yielding reaction in the 
synthesis of narciclasine analogues.  
 
1.4. THE ROBINSON ANNULATION 
The Robinson annulation was discovered by Robert Robinson in 1935 whilst 
he was working on the synthesis of sterol derivatives.
71
 He found that the sodium 
enolate of cyclohexenone 83 reacted with methyl styryl ketone to give 
cyclohexenone 85 (Scheme 13). 
 
 
Scheme 13: Reaction of cyclohexanone and methyl styryl ketone using sodamide 
 
Reviews by Gawley
72
 and Jung
73
 discuss the mechanism and applications of 
the Robinson annulation, showing how the reaction has become a staple of the 
chemists’ toolbox. The reaction has been used in the synthesis of many natural 
products to build the carbon skeleton, including milbemycin 86,
74
 tanabalin 87,
75
 
lycorine 88,
76
 aspidospermidine 89
77
 and codeine 90
78
  (Figure 23).  
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Figure 23: Application of the Robinson annulation in the synthesis of natural products with the 
rings synthesised using the annulation highlighted. 
 
The Robinson annulation proceeds via a Michael addition followed by an 
intramolecular aldol cyclisation, as shown by the mechanism in Scheme 48. 
Typically the reaction is performed by making a sodium enolate 92 using either 
NaOH or NaOMe/NaOEt and treating it with a Michael acceptor such as methyl 
vinyl ketone. The product of the conjugate addition is also an enolate 93 which can 
isomerise to give enolate 94 and then react nucleophilically with the ketone in an 
intramolecular aldol reaction to form a 6 membered ring 95. Finally, dehydration 
installs the double bond to give conjugated cyclohexenone 97.
72
 
 
 
Scheme 14: Mechanism of the Robinson annulation
72
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An aprotic variation using the strong base LDA in THF was reported in 1983 
to give a regioselective annulation of dihydrocarvone 98 with ethyl vinyl ketone 
(EVK) to give the bicyclic enone 101 (Scheme 15).
79
 The regioselectivity arises 
from the formation of the thermodynamic enolate 99, which reacts with the EVK 
selectively at the axial position to give the intermediate 100 in the 
thermodynamically favourable chair conformation.  
 
Scheme 15: Aprotic variation of the Robinson annulation using LDA 
 
In addition to the one-pot annulation procedure, the transformation has been 
performed in two steps, isolating the Michael adduct prior to cyclisation. This 
approach has allowed stereochemical control to be applied at either stage. In the 
synthesis of Saudin,
80
 a chiral enamine 103 was formed to direct the Michael 
addition, before the cyclisation step took place, giving the 6-membered ring 105 in 
87 % yield and 95 % e.e. (Scheme 16). 
 
 
Scheme 16: Stereoselective Michael addition and annulation in the synthesis of Saudin
80
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Christoffers et al. also carried out work on asymmetric copper-catalysed 
Michael additions, where the products can then be cyclised in a Robinson annulation. 
In work similar to the approach used in the synthesis of Saudin, chiral amines were 
investigated to direct the Michael addition, giving chiral products in modest to good 
enantioselectivity.
81
 The conditions were then applied in the synthesis of indoles 
(Scheme 17).
82
  
 
 
Scheme 17: Christoffers’ application of his copper-catalysed, stereoselective Michael addition 
and Robinson annulation in the synthesis of indoles.
82
 
 
The mechanism, scope and limitations and some applications of chiral imines 
and enamines in the asymmetric Michael addition have been reviewed by 
d’Angelo.83 
Once the chiral Michael adduct has been synthesised, there are a number of 
methods reported in the literature for promoting the cyclisation. The use of p-TsOH 
in toluene heated at reflux was reported by Liu et al. to induce the annulation of 
ketone 112 to afford enone 113 (Scheme 18).
84
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Scheme 18: Liu's p-TsOH catalysed cyclisation of Michael adduct 112 in the synthesis of 
nanaimoal
84
 
 
As shown in the examples of the enamine catalysed Michael addition, 
pyrrolidine and piperidine can also be used to perform the annulation. In 1956, 
Plieninger et al. demonstrated that enone 116 could be formed by the cyclisation of 
Michael adduct 115 using piperidinium acetate.
85
 Golding et al. developed the 
conditions in 1972 when synthesising Hagemann’s ester 118 from 117 using 
pyrrolidine and acetic acid (Scheme 19).
86
 
 
 
Scheme 19: Cyclisation of Michael adducts using piperidinium acetate or pyrrolidinium acetate 
 
The method has since been used in the synthesis of a number of natural 
products or medicinally active compounds, including Saudin,
80
 Hagemann’s ester 
118 
87
 and fluorenones.
88
 
 Related to these conditions is the Hajos-Parrish-Eder-Sauer-Wiechert 
(HPESW) reaction, a stereoselective variant of the Robinson annulation which used 
a proline catalyst to promote the cyclisation of a pro-chiral triketone 119 to give a 
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chiral bicyclic product 121 (Scheme 20). The reaction was described almost 
simultaneously by Eder, Sauer and Wiechert in 1971
89
 and by Hajos and Parrish in 
1974.
90
  
 
 
Scheme 20: Hajos-Parrish's cyclisation of triketone 119 using a proline catalyst
90
 
 
The mechanism for the reaction has attracted much debate, with at least four 
different models of the transition state in the reaction. However, the widely accepted 
explanation for the stereoselectivity was proposed by Houk et al. after examining 
experimental evidence and computational modelling.
91
 
 
 
Figure 24: Houk's transition state model for the stereoselectivity in the annulation
91
 
 
The use of amino acid catalysts for this reaction has been briefly reviewed by 
Jarvo and Miller.
92
 Other amino acids have been investigated for the catalysis of this 
reaction. Phenylalanine
93,94,95
 and proline derivatives containing substitution on the 
heterocyclic ring
91,96 
have also been employed for the cyclisation of a range of 
substrates. Davies et al. have investigated β-amino acids as chiral catalysts for the 
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transformation and found that (1R,2S)-cispentacin 124 catalysed the HPESW 
reaction with comparable or higher enantioselectivity to (S)-proline.
97
  
 
 
Scheme 21: Davies' use of (1R,2S)-cispentacin 124 to catalyse the cyclisation of (S)-121.
97
 
 
There have also been efforts to access bicyclic ketones by performing the 
Michael addition and aldol cyclisation in one step using proline catalysis. Barbas III 
et al. found that using (S)-proline in DMSO, ketone 127 can be synthesised in 49 % 
yield and 76 % e.e. (Scheme 22).
 98
 This research prompted Swaminathan et al. to 
publish their work on the same substrate, where 127 was isolated after a separate 
dehydration step in 68 % yield and 63 % e.e..
99
 
 
 
Scheme 22: One-step synthesis of 127 using (S)-proline catalysis 
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 This literature provides the basis for the work in this project on the Robinson 
annulation, showing the route to be viable. Although the synthesis will initially be 
performed racemically, these reports show that a stereoselective synthesis may also 
be achieved.  
 
1.5. AIMS 
The aim of this project is to synthesise simplified analogues of narciclasine, 
via a late stage intermediate, which retain biological activity, using a short synthetic 
sequence that can be applied on a larger scale. 
Initially, a series of simplified AB-ring analogues will be generated to 
develop the conditions for the Curtius rearrangement and intramolecular Friedel-
Crafts acylation. These compounds will also be tested for their anti-cancer activity.  
Then a route to the ABC-ring analogues will be developed, which will use a 
Robinson annulation to generate the C-ring and incorporate the Curtius 
rearrangement and intramolecular Friedel-Crafts acylation reaction optimised on the 
AB-ring analogues. This route will be used to produce a series of ABC-ring 
analogues which will also be evaluated for their biological activity in cancer cell 
lines.  
   
The theme of the group is the efficient synthesis of biologically active 
compounds using known and new methodologies. In view of this, interesting or 
unexpected results will also be investigated with the aim of developing new reactions 
that will be useful to the synthetic and medicinal chemist. 
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2. SYNTHESIS AND EVALUATION OF AB-RING 
ANALOGUES 
2.1. SYNTHESIS OF AB-RING ANALOGUES USING THE 
CURTIUS REARRANGEMENT 
2.1.1. 3,4-Dihydroisoquinolin-1-ones 
Narciclasine and pancratistatin contain a 3,4-dihydroisoquinolinone as their 
AB-ring. As previously discussed in Section 1.2 (p. 20), it was envisaged that this 
motif would be formed in a one-pot procedure from a dihydrocinnamic acid 128 
through a Curtius rearrangement to generate an isocyanate 129, followed by a Lewis 
acid mediated intramolecular Friedel-Crafts acylation (Scheme 23) 
 
 
Scheme 23: Dihydroisoquinolinone formation via the isocyanate 
 
Two different methods were investigated for the Curtius rearrangement. 
Following the step-wise procedure reported by Ohta and Kimoto,
53
 the 
hydrocinnamic acid was first treated with ethyl chloroformate in the presence of a 
base to generate the corresponding mixed anhydride 131, which upon reaction with 
sodium azide afforded the acyl azide 132. The by-products were removed by 
extraction and heated in toluene to afford the isocyanate 129, then a Lewis acid was 
added to promote the cyclisation to give the lactam 130. 
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Scheme 24: Step-wise method of making an isocyanate using EtOCOCl to activate the acid 
 
Diphenylphosphoryl azide (DPPA) was also used to generate the isocyanate 
in a one-pot procedure. This is a dual functional reagent, comprising of a phosphoryl 
group to activate the acid as the phosphoryl ester 133 and the azide group to make 
the acyl azide precursor 132 for the Curtius rearrangement (Scheme 25).
54
 The acid 
128 was heated with DPPA at 90 °C for 1 hr before the solvent was removed and the 
isocyanate 129 treated with a Lewis acid to furnish the isoquinolinone 130. 
 
 
Scheme 25: Mechanism for DPPA mediated azide formation 
 
When hydrocinnamic acid 134 was treated with DPPA and Et3N in toluene at 
90 °C without the addition of a Lewis acid, the desired cyclised material was not 
observed; instead the symmetrical urea 138 was isolated in a 64 % yield (Scheme 
26). The mechanism for urea formation involves a molecule of water. The isocyanate 
is hydrolysed to give the carbamic acid 136 which undergoes decarboxylation to 
furnish amine 137. The urea 138 is then generated by nucleophilic addition of the 
amine to isocyanate 135. However, it is not known whether this was formed in the 
 37 
 
reaction or upon aqueous workup as the reaction was performed under anhydrous 
conditions.  
 
 
Scheme 26: Mechanism of urea formation 
 
However, the formation of the urea 138 demonstrates that the isocyanate is 
formed during the reaction and that the subsequent ring closing step proves to be 
problematic. Addition of Lewis acids BF3·OEt2, AlCl3 and ZnCl2 were investigated 
to promote cyclisation; however, these gave either the urea or a mixture of 
compounds which could not be separated by column chromatography. It was found 
that increasing the temperature of the BF3·OEt2 mediated step to 80 °C promoted 
some cyclisation; however, the dihydroisoquinolinone 139 was isolated in only 5 % 
yield (Scheme 27).  
 
 
Scheme 27: Cyclisation of dihydrocinnamic acid 134  
 
It was shown that the Thorpe-Ingold effect can have a positive effect on the 
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outcome of the reaction. The Thorpe-Ingold effect is the increase in the rate of a 
ring-forming reaction due the presence of substituents on the ring.
100
 Using an AlCl3-
catalysed Michael addition of benzene to 3-methylbut-2-enoic acid 140, 3,3-
dimethyl-3-phenylpropionic acid 141 was synthesised in 99 % yield. The acid was 
then subjected to the stepwise reaction conditions, performing the BF3·OEt2 
mediated cyclisation at room temperature, to give the 4,4-dimethylisoquinolinone 
142 in 8 % yield (Scheme 28).  
 
 
Scheme 28: The Thorpe-Ingold effect increases the rate of cyclisation 
 
An unsubstituted aryl group is a poor nucleophile due to the lack of electron-
donating substituents on the ring. Substrates with electron-rich, oxygenated aryl 
rings were investigated as they would be better nucleophiles and because 
narciclasine contains an oxygenated A-ring  
3-(3,4-Methylenedioxyphenyl)propionic acid 143 was subjected to three 
different sets of conditions for the rearrangement and cyclisation. When the step-
wise conditions were applied and BF3·OEt2 was used to promote the cyclisation, the 
isoquinolinone 144 was isolated in 63 % yield. Using the step-wise conditions and 
AlCl3 as the Lewis acid afforded 144 in 67 % yield. When the reaction was 
performed using DPPA the lactam 144 was isolated in 81% yield (Scheme 29). Only 
regioisomer 144 was formed in the reactions and isomer 145 was not observed. This 
was proved with the 
1
H NMR spectra where the aromatic region contained only two 
singlets at 6.64 ppm and 7.49 ppm. Two doublets with a coupling constant of around 
8 Hz would be expected for regioisomer 145. 
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Scheme 29: Cyclisation of 3-(3,4-methylenedioxyphenyl)propionic acid 143 
 
3,4-(Dimethoxyphenyl)propionic acid 146 was also investigated as a 
substrate for the reaction; however using the DPPA reaction conditions, lactam 147 
was isolated in only 55 % yield. Heating the BF3·OEt2 mediated cyclisation step at 
50 °C increased the yield to 76 % (Scheme 30). 
 
 
Scheme 30: Cyclisation of 3-(3,4-methylenedioxyphenyl)propionic acid 146  
 
As narciclasine contains a trioxygenated A ring, the cyclisation of (3,4,5-
trimethoxyphenyl)propionic acid 148 was investigated. When the acid was submitted 
to the step-wise set of conditions, using BF3·OEt2 as the Lewis acid, the 
1
H NMR 
spectrum of the product showed the loss of a methyl group, however the site of 
demethylation could not be determined. Regioselective demethylation by BF3·OEt2 
has been reported in similar systems and was discussed in Section 1.3 (p. 26).
70
 As 
the product was a thermally stable and highly crystalline solid, an X-ray crystal 
structure was obtained to determine the site of demethylation (Figure 25).  
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Figure 25: Crystal structure of demethylated compound 148, coordinated with boron difluoride  
 
The structure shows the demethylated product coordinated to boron 
difluoride through the phenol and carbonyl groups. Presumably, as the boron 
trifluoride coordinates to the product, there is loss of a fluoride ion which can act as 
a nucleophile to perform the demethylation, allowing the resulting phenol to bind 
more strongly to the boron to give the thermally stable adduct 148 (Scheme 31). 
 
 
Scheme 31: Proposed mechanism of selective demethylation of the 8-methoxy group 
 
The trimethoxy-product 150 was not observed and the BF2-adduct was 
isolated in an unoptimised 21 % yield (Scheme 32). Nicolau et al. reported similar 
chelate structures and described their hydrolysis using refluxing methanol/water or 
THF/water.
101
 The dissociation of 148 was achieved using 2M NaOH and EtOAc at 
50 °C and the free phenol 151 was isolated in an unoptimised 24 % yield from the 
propionic acid 149. 
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Scheme 32: Cyclisation and demethylation of 3-(3,4,5-trimethoxyphenyl)propionic acid 149 
using the unoptimised stepwise procedure 
 
When the rearrangement and cyclisation of (3,4,5-
trimethoxyphenyl)propionic acid 149 was attempted using DPPA, lactam 151 was 
isolated in 73 % yield on a 5 mmol scale, but only in 52 % yield on a 25 mmol scale. 
After optimisation, the BF2-adduct 148 could be isolated in 62 % yield on a 25 mmol 
scale without column chromatography. Subsequent hydrolysis was performed using 
2M NaOH and EtOAc, giving lactam 151 in an 85-92 % yield on a 5 mmol scale. 
 
 
Scheme 33: Synthesis of 8,9-dimethoxy-7-hydroxy-3,4-dihydroisoquinolinone 151  
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2.1.2. Indole Analogues  
Hudlicky et al. proposed that in pancratistatin the A-ring could be substituted 
for an indole where the NH mimics the hydroxyl group.
26
 Indole is an electron rich 
aromatic ring that can capture an isocyanate, as demonstrated by Hilton et al.,
69
 a 
range of indole carboxylic acids were investigated as substrates for the reaction. 
 
 
Figure 26: Pancratistatin 7 and Hudlicky's indole analogue 9 
 
Indole-3-propionic acid 152 was treated with DPPA and Et3N in toluene at 
90 °C, followed by cyclisation mediated by BF3·OEt2 to afford carbolinone 153 in  
87 % yield which is a natural product isolated from an Indonesian sponge.
102
 When 
AlCl3 was employed as the Lewis acid, the lactam was isolated in 153 in 79 % 
(Scheme 34). 
 
 
Scheme 34: Cyclisation of indole-3-propionic acid 152 
 
The mechanism for the Curtius rearrangement is the same as that for the 
oxygenated aryl ring analogues. However, the cyclisation step proceeds with more 
complexity due to the electronics of the indole ring (Scheme 35). In indole, the lone 
pair on the nitrogen atom is involved in the aromaticity of the ring, so can be 
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delocalised onto the 3-position, making this the most nucleophilic position within the 
ring. This means that the isocyanate is trapped by the 3-position to give a spirocyclic 
intermediate 155, which must undergo a migration and deprotonation to restore 
aromaticity to the indole. This spirocyclic intermediate has been described 
previously in related systems with substitution at the 2-position, which prevented 
migration and allowed the compounds to be isolated and characterised.
103
 Only a 1,2-
acyl migration was observed, the product of a 1,2-alkyl migration was never isolated. 
This is because as the group migrates, a positive charge develops at the 3-position 
and this will be affected by the remaining adjacent group. An adjacent acyl group is 
electron withdrawing so would destabilise the cation, whereas an adjacent alkyl 
group is slightly electron-donating so will act to stabilise the positive charge. This 
leads to migration of the acyl group, giving carbolinone 153 as the product. 
 
 
Scheme 35: Mechanism for the cyclisation of indole-carboxylic acids 
 
The structure was determined by 2D 
1
H NMR experiments and X-ray 
crystallography, where the N-H and carbonyl can be seen on the same side of the 
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molecule, indicating a 1,2-acyl migration. The crystal structure also showed the 
ribbon-like arrangement of molecules formed by hydrogen bonding. 
 
 
 
Figure 27: X-ray crystal structures of carbolinone 153 
 
The N-methylated analogues were also synthesised. Following the 
methylation procedure reported by Compernolle using iodomethane in the presence 
of KOH, followed by base hydrolysis of the ester, N-methylindole-3-propionic acid 
159 was synthesised in 87 % yield (Scheme 36).
104
 The acid 159 was then subjected 
to the optimised reaction conditions to afford the carbolinone in 87 % from indole-3-
propionic acid 160.  
 
 
Scheme 36: Synthesis of methylated carbolinone 160 
 
The N,N-dimethylcarbolinone 160 was synthesised by methylation of 
carbolinone 153. Using iodomethane and KOH as described by Compernolle 
resulted in the methylation of only the indole to give 160 in 69 % yield, whereas the 
use of NaH as the base as reported by Hamann
105
 gave the dimethyl-analogue 161 in 
55 % yield (Scheme 37).  
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Scheme 37: Methylation of carbolinone 153 
 
Other chain lengths linking the indole and the carboxylic acid were also 
investigated. When the reaction conditions were applied to indole-3-carboxylic acid 
and indole-3-acetic acid, mixtures of products inseparable by column 
chromatography were observed. This is possibly due to the mechanism of the 
reaction, where the substrates must proceed via 3- and 4- membered ring spirocyclic 
structures, which are thermodynamically unfavourable. 
 
Azepinones are 7-membered ring homologues of the carbolinones and have 
been shown to be interesting as anti-mitotic compounds which inhibit tubulin 
polymerisation by Dodd et al.
106
 and Joseph et al.
107
   
The commercially available indole-3-butyric acid 162 was submitted to the 
optimised cyclisation conditions and the product 163 was isolated in only 40 % yield 
(Scheme 38). The yield was increased to 68 % and 90 % when the BF3·OEt2 
mediated cyclisation was performed at 50 °C and 80 °C respectively. Presumably, 
the elevated temperatures aid the energetically unfavourable ring expansion from the 
6-membered spirolactam to the 7- membered azepinone.  
 
 
Scheme 38: Cyclisation of indole-3-butyric acid 162 
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The methylated derivatives were also synthesised to probe the role of the 
acidic protons in the molecule. Surprisingly, when indole-3-butyric acid 162 was 
subjected to the conditions previously used for the methylation of indole-3-propionic 
acid 152 as reported by Compernolle,
104
 only the starting material was recovered. 
However, methylation of the indole nitrogen and the ester was achieved using t-
BuOK and iodomethane in DMF as reported by Perregaard, to give ester 164 in 73 
% yield.
108
 The ester was then hydrolysed in aqueous KOH to provide the crude acid 
165 which was cyclised at 50 °C to give 166 in 85 % yield from the ester 164 
(Scheme 39). 
  
Scheme 39: Synthesis of mono-methylated azepinone derivative 166 
 
The dimethylated analogue 167 was also synthesised in 86 % yield by the 
dimethylation of azepinone 163 using NaH and iodomethane in THF (Scheme 40).  
 
 
Scheme 40: Methylation of azepinone 163 
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2.2. SYNTHESIS OF AB-RING ANALOGUES BY THE 
DEHYDROGENATION OF LACTAMS 
2.2.1. Dehydrogenation of Lactams using DDQ 
To emulate the sp
2
 centre at the 10b position of narciclasine, the oxidation of 
the previously synthesised AB-ring analogues was investigated. There are a number 
of reported methods of performing the oxidation and one of the approaches that was 
explored was the use of 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ).  
 
 
Scheme 41: Examples of DDQ mediated dehydrogenation 
 
DDQ has been described extensively in the literature for performing 
dehydrogenations at benzylic positions and a review of its reactions was published in 
1967.
109
 Since then, DDQ in dioxane or THF heated at reflux has been reported for 
the oxidation of dihydroisoquinolinones 168;
110
 in the synthesis of Bauerines A, B 
and C 171 
111,112
 and in the synthesis of carbolines
113
 (Scheme 41). 
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Scheme 42: Dehydrogenation of 144 using DDQ 
 
Following the literature precedent, the methylenedioxy-derivative 144 was 
treated with 4 eq. DDQ in dioxane heated at reflux (Scheme 42). After 4 hrs, 
1
H 
NMR analysis of the crude material showed a 2:1 mixture of starting material to 
product 172. Increasing the reaction time to 22 hrs increased the conversion to 75 % 
by 
1
H NMR; however, the isolated yield of 172 was only 37 % (Table 1, entry 1). 
Portion-wise addition of DDQ to the reaction mixture did not increase the yield and 
isoquinolinone 172 was isolated in only 31 % yield after the addition of 4 eq. DDQ 
in three portions over 32 hrs.  
 
Table 1: Oxidative aromatisation of lactam rings using DDQ 
Entry Starting material Product eq. DDQ Yield (%) 
1 
 
144 
 
172 
4 37 
2 
 
147 
 
173 
4 31 
3 
 
151 
 
174 
4 - 
4 
 
153 
 
175 
4 
3
a
 
25 
58 
5 
 
160 
 
176 
4 
3
a
 
- 
22 
a: Performed using 3 eq. DDQ for 1 hr 
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The remaining analogues were oxidised using 4 eq. DDQ added in one 
portion (Table 1). The dimethoxy derivative 173 was isolated in 31 % yield (Entry 
2). When the 6,7-dimethoxy-8-hydroxy analogue 151 was subjected to the reaction 
conditions, full conversion was not achieved and the oxidised product 174 could not 
be separated from the starting material by column chromatography (Entry 3). A 
mixture of products resulting from the conjugate addition of the substrate to DDQ 
was also observed. The carbolinone 175 was isolated in 25 % yield (Entry 4); 
however the oxidation of N-methylcarbolinone 160 led to demethylation. Altering 
the reaction conditions to 3 eq. DDQ for only 1 hr gave the desired N-
methylcarbolinone 176 in 20 % yield (Entry 5). These conditions were also applied 
to the carbolinone 153 to give the oxidised product 175 in 58 % yield (Entry 4). 
  
The driving force for this transformation is the formation of an extended 
aromatic system, so unsurprisingly the azepinones could not be oxidised using these 
conditions and in these cases unchanged starting material was recovered. 
 
Due to the poor yields of these reactions, alternative methods of performing 
the oxidation were investigated. Following literature reported by Snider,
114
 and 
Ciganek;
115
 MnO2 and Ag2O were briefly investigated as oxidants, however only the 
starting material was recovered from the reactions. 
 
2.2.2. Dehydrogenation of Lactams using Palladium on Carbon 
Palladium on carbon (Pd/C) is typically used as a hydrogen transfer agent in 
the presence of hydrogen gas for the reduction of double bonds, but it has also been 
described in the formation of double bonds in the absence of hydrogen. The 
oxidation of dihydroisoquinolinones has been reported by Hutchinson,
116
 and 
Bracher described the dehydrogenation of carbolinones.
117
  
 
Following the procedure reported by Dufour,
118
 the 6,7-methylenedioxy-
derivative 144 was oxidised using 7 mol% Pd/C in xylene heated at reflux and after 
24 hrs, the catalyst was removed by filtration and the product 172 was isolated in 53 
% yield (Table 2, entry 1a). Using the same procedure, the dimethoxy analogue 147 
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was oxidised in to afford isoquinolinone 173 in 61 % yield (Entry 2a) and the 8-
hydroxy derivative 174 was isolated in 51 % yield (Entry 3a). Dehydrogenation of 
the carbolinones 153 and 160 was also achieved in 39 % in 60 % yields respectively 
(Entries 4 and 5).  
 
Table 2: Dehydrogenation of lactam rings using Pd/C 
Entry 
Starting 
material 
Product 
Thermal yield 
(%) 
Microwave 
yield (%) 
1 
 
144 
 
172 
54
a
 
42
b
 
67
c
 
- 
2 
 
147 
 
173 
61
a
 
87
c
 
98
d
 
3 
 
151 
 
174 
51
a
  
49
b
 
38
c
 
80 
4 
 
153 
 
175 
39
a
 90 
5 
 
160 
 
176 
60
a
 - 
a: achieved using 7 mol% Pd/C and the catalyst was removed by filtration through celite.  
b: achieved using 33 mol% Pd/C and the catalyst was removed by filtration through celite. 
c: achieved using 15 mol% Pd/C and the catalyst was removed column chromatography.  
d: performed by Gemma Tunbridge 
 
The reactions were found to be capricious and starting material was often 
recovered when the reactions were repeated. Increasing the amount of Pd/C used to 
33 mol% did not improve the reliability or yield of the reactions. The oxidation of 
the 6,7-methylenedioxy derivative 144 was performed on an 8 mmol scale using 33 
mol% Pd/C and the product 172 was isolated in 42 % yield (Entry 1b). Oxidation of 
the 8-hydroxy derivative 151 on a 5.95 mmol scale was achieved to give the product 
174 in 49 % yield (Entry 3b).  
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1
H NMR analysis of the reaction mixtures showed clean conversion of the 
starting materials to products, implying that the poor yields were due to problems in 
the purification of the products. Changing the method of removing the catalyst from 
filtration through celite to column chromatography generally increased the yields in 
the reactions. Using 15 mol% Pd/C, the methylenedioxy derivative 172 was isolated 
in 67 % yield and the dimethoxy derivative 173 was isolated in 87 % yield (Entries 
1c and 2c).  
 
Different solvents, including EtOH, EtOAc, t-BuOH and AcOH, were also 
examined as for the dehydrogenation; however, the products were not observed and 
the starting materials reclaimed. Cyclohexene has been described in the literature as 
an additive to dehydrogenation reactions as it acts a hydrogen sink, removing the 
hydrogen taken from the lactam ring by its reduction to cyclohexane.
116
 This had no 
effect on the reaction and only the starting materials were isolated. 
 
Microwave technology has provided the greatest amount of success with 
these reactions, allowing temperatures of up to 200 °C to be reached and the reaction 
times to be reduced dramatically whilst achieving high yields. After 1 hr at 200 °C,  
6,7-dimethoxy-8-hydroxyisoquinolinone 151 was oxidised to give 174 in 80 % yield; 
and after only ½ hr, carbolinone 175 was isolated in an 89 % yield. The reactions 
conditions have since been repeated within the group using the dimethoxy analogue 
147, affording 173 in an excellent yield of 98 %! 
 
The oxidation of the N,N-dimethyl analogue 161 was not performed, 
however the carbolinone 177 was synthesised by methylation of carbolinone 175 
using iodomethane and NaH in 54 %. 
 
 
Scheme 43: Methylation of carbolinone 175 
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2.3. BIOLOGICAL EVALUATION 
The compounds have all been tested in an MTS cell proliferation assay using 
human HT29 colon cancer cells with a 72 hr exposure time. The compounds were 
tested twice and an average taken. 
 
The AB-ring analogues did not possess potent anti-cancer activity (Figure 
28). In the series of dihydroisquinolinones, the methylenedioxy and dimethoxy 
derivatives 144 and 147 were found to be inactive and the 8-hydroxy analogue 151 
displayed a weak activity of 386 µM. The series of isoquinolinones 172, 173 and 174 
were more active with IC50 values of 398 µM to 71 µM and the 8-hydroxy analogue 
174 was the most active compound in the series. Despite the weak activity, the trends 
in the potency of these compounds do mirror those in the natural product discussed 
in Section 1.1.3 (p. 7). The presence of the 8-hydroxyl group increases the activity 
and the oxidation of the C4 position to an sp
2
 centre also increases the activity. 
Interestingly, the methylenedioxy analogue 172 is less active than the dimethoxy 
analogue 173, implying that the substitution pattern on the A-ring of narciclasine 
may not be optimal for activity.  
 
 
Figure 28: Biological activity of the isoquinolinones 
 
In addition to these results, two of the compounds have biological data 
reported in the literature. The dimethoxy-derivative 147 shows some anti-tumour 
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promoting activity,
119
 and its oxidised analogue 173 has been shown to be a weak 
inhibitor of TNF-α, a protein involved in inflammation and apoptosis.120  
 
The indole analogues 153, 160, 161, 175, 176 and 177 were also found to be 
only mildly active in HT29 cells with IC50 values of 260 µM to 86 µM (Figure 29). 
As with the isoquinolinones, oxidation of the lactam ring increases the activity of the 
analogues. However, there is not a definite pattern for the effect of N-methylation on 
activity, as within the unoxidised series 153 is the least active analogue yet its 
oxidised 175 counterpart is the most active within its series.  This may be due to the 
compounds having an effect at more than one target within the cell. For example, 
carbolinones have been found to be inhibitors of MK2,
121
 a kinase involved in the 
inflammatory response and apoptosis.  
 
 
Figure 29: Biological activity of carbolinones 
 
In addition to Hudlicky’s use of the indole moiety as a substitute for the 
oxygenated aryl ring in narciclasine analogues, carbolinones are interesting 
medicinal compounds in their own right. Carbolinone 153 has been tested for its 
anti-leishmaniasis activity, but was found to be inactive.
105
 Its oxidised analogue 175  
has been found to be inactive against HeLa cells.
122
 
 
The azepinone analogues 163, 166 and 167 were less active than the 
carbolinones, displaying activities of 120 µM, 302 µM and 373 µM respectively 
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(Figure 30). However, the structure-activity relationship is much easier to see; N-
methylation drastically reduces activity implying that these protons are important for 
interactions with the target. 
 
 
Figure 30: Biological activity of azepinones 
 
Azepines have been described by Dodd et al.
106
 and Joseph et al.
107
 as 
inhibitors of tubulin polymerisation, so these compounds could possibly act by this 
mechanism either instead, or in addition to, the mechanisms by which narciclasine 
works. A method of investigating this would be to submit the compounds to a 
tubulin-binding assay, whereby the amount of tubulin polymerisation or 
depolymerisation is assessed by measuring changes in turbidity of the assay mixture.  
 
2.4. SYNTHESIS OF PRO-DRUGS 
As previously discussed in the introduction, narciclasine and its congeners 
suffer from poor solubility so pro-drugs have been synthesised to improve their in 
vivo properties. The synthesis of a series of pro-drugs was undertaken in this project 
to investigate if their use could improve the physical properties and activity of the 
AB-ring analogues. The approach taken in this project was the use of carbamates and 
carbonates to mask the amide and phenol groups. As shown by the X-ray crystal 
structure of the carbolinone 174 (Figure 27), the lactams are able to form a series of 
hydrogen bonds which must be broken in order to dissolve the compound. Formation 
of the pro-drugs removes the hydrogen bond donors, preventing the number of bonds 
the product can form and aiding solubility. The lipophilicity of the phenol 174 has 
been increased by the synthesis of its pro-drugs (Figure 31),
123
 but remains below 5; 
the limits of Lipinski’s Rules for absorption of drugs in-vivo.124 Only the most active 
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6,7-dimethoxy-8-hydroxyisoquinolinone 174 was used in the first instance as a proof 
of principle.  
 
 
Figure 31: Partition coefficients of the parent compound 174 and the pro-drugs 178 and 179 
 
Ethyl and benzyl carbamates and carbonates were synthesised using the 
corresponding chloroformate and NaH in THF in 12-41 % yields (Scheme 44). The 
poor yields may partly be due to the instability of the carbonate. The ethyl and 
benzyl carbonates 180 and 181 were found to hydrolyse on standing to give the 
carbamates 178 and 179. 
 
 
Scheme 44: Synthesis of ethyl and benzyl pro-drugs 
   
As with the previously synthesised analogues, the pro-drugs were tested in an 
MTS cell proliferation assay using human HT29 colon cancer cells with a 72 hr 
exposure time (Table 3). The activities of the compounds were found to be 
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comparable to that of the parent compound, showing that the addition of carbamate 
and carbonate groups to the compound did not have a deleterious effect on activity.  
 
Table 3: Activities of parent compound 174 and its pro-drugs 
Compound 174 178 179 
Activity (µM) 71 83 95 
 
It was not known what the active species was within the assay, or at what 
point, if at all, the carbamate groups were hydrolysed. To evaluate this, the benzyl 
pro-drug 179 was incubated in the assay medium for 72 hrs, to mimic the assay 
conditions without the cells present. Aliquots of the media were taken at intervals an 
analysed by mass spectroscopy for the degradation of the pro-drug and appearance of 
the parent compound. The mass spectra showed the pro-drug to remain intact 
throughout the 72 hrs, without the appearance of the parent compound 174. This 
shows that the pro-drug must be entering the cell, where it is either then hydrolysed 
to give the active compound or it stays intact and shows cytotoxicity itself.  
 
2.5. CONCLUSIONS AND FUTURE WORK 
A one-pot method to synthesise a series of AB-ring analogues of narciclasine 
from their corresponding carboxylic acids has been developed and optimised, using a 
modified Curtius rearrangement and Lewis-acid catalysed intramolecular Friedel-
Crafts alkylation. Using this procedure, twelve analogues have been synthesised in 
moderate to good yields. This procedure can now be applied in the synthesis of the 
more complex ABC-ring analogues. 
The 6-membered ring analogues were all oxidised to give their fully aromatic 
counterparts which mimic the sp
2
 position in narciclasine. Although DDQ was able 
to perform the oxidation of most of the analogues, the yields were generally poor and 
the procedure was not successful on all of the analogues. There was more success 
using palladium on carbon, especially when the reactions were performed in a 
microwave and in future this procedure should be used for the dehydrogenation of 
dihydroisoquinolinones and carbolinones. 
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These analogues have been tested against HT29 colon cancer cells and were 
found to be poor to moderately cytotoxic. Despite these activities, these compounds 
are privileged structures which have been reported to be active against a range of 
targets when incorporated into larger molecules (Figure 32). The oxidised electron 
rich aromatic motif is found in the cytotoxic topoisomerase I inhibitor NSC 314622 
182 developed by Cushman.
125
 4-Aryl-1-isoquinolinone derivatives 183 have been 
found to inhibit phosphodiesterase 5, a target in the treatment of cardiovascular 
diseases.
126
 Carbolinones, such as 184, have also found to be glutamate receptor 
(mGluR) antagonists.
127
 A series of carbolinones including 185 have been 
investigated as potent inhibitors of MK2, a kinase involved inflammation, cell 
proliferation and apoptosis.
121
 
 
Figure 32: Examples of AB-ring analogues incorporated into larger, bioactive molecules 
 
To extend the work on the carbolinone series, preliminary experiments were 
performed into the Friedel-Crafts acylation of 153 at the 5-position using acetyl 
chloride and AlCl3. Unfortunately, despite following literature precedent,
128
 the 
compounds were not isolated during these initial investigations. However, further 
optimisation could provide a route to these medicinally interesting compounds.  
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In addition it has been found that triketone 186 is a caspase-3 inhibitor so is 
an inhibitor of apoptosis.
129
 Ruthenium tetroxide, generated by the oxidation of 
ruthenium dioxide by sodium periodate, has been described for the oxidation of 3,4-
dihydroisoquinolinones to the corresponding triketones.
130
 In preliminary 
investigations, following this protocol, the oxidation of the methylenedioxy analogue 
144 and its Boc-protected derivative 187 was investigated, however the 
corresponding triketones 188 and 189 were not observed. 
 
 
Scheme 45: Triketone 186 and the attempted oxidation of dihydroisoquinolinones  
 
The benzyl and ethyl carbamate pro-drugs 178 and 179 have been prepared 
and evaluated using the HT29 colon carcinoma cell line and displayed only a small 
reduction in activity when compared to the parent compound. As the carbonate 
groups on the phenol in 180 and 181 were unstable under ambient conditions, other 
functional groups can be investigated to make use of this handle (Figure 33). 
Carbamates 190 can be synthesised using carbamoyl chlorides in the presence of 
strong base. Esters 191 can also be investigated as groups which are stable in 
ambient conditions, but susceptible to hydrolysis within the body. Within studies on 
narciclasine, the 1-phenyl ester was found to be active, however the 7-phenyl ester 
was not prepared. Phosphate esters 192, similar to those of narciclasine discussed in 
section 1.1.4 (p. 14) can also be investigated.  
 
 
Figure 33: Examples of possible pro-drugs that could be investigated 
 59 
 
3. SYNTHESIS AND EVALUTATION OF ABC-
RING ANALOGUES 
3.1. SYNTHESIS OF THE DIMETHOXY-ANALOGUE 
3.1.1. Synthesis of the β-Ketoester 
For the synthesis of the tricyclic core, the dimethoxy-substituted analogue 
was chosen as the model system as it simplifies the cyclisation of the B-ring in 
comparison to the trimethoxy-derivative which undergoes selective demethylation. 
The cost and availability of the starting acetophenone favoured the use of 
dimethoxyacetophenone over methylenedioxyacetophenone. The optimised synthetic 
route would then be applied to the synthesis of other analogues. 
 
 
Scheme 46: Synthesis of β-ketoester 194 
 
The first step in the synthesis was a Claisen condensation of 3,4-
dimethoxyacetophenone 193 with diethyl carbonate (Scheme 46). Following the 
procedure reported by Jung et al.,
131
 on a 10 mmol scale using sodium hydride as the 
base at 80 °C, the β-ketoester 194 was isolated in 97 % yield. The reaction has been 
repeated on a 50 mmol scale with a yield of 96 %, demonstrating the consistency and 
scalability in the reaction. Condensation of the β-ketoester with another molecule of 
the carbonate was not observed.  
 
Following the proposed synthesis discussed in Section 1.2 (p. 20), there were 
two possible routes that could be taken from the β-ketoester to form the tricyclic core 
structure. 
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3.1.2. Route A  
Following Route A, saponifaction of the β-ketoester was attempted, to 
provide the carboxylic acid for the Curtius rearrangement. Herbert et al. reported the 
saponification of ethyl ester 194 using aqueous KOH and isolated the resulting acid 
196 in 82 % yield.
132
 However, in our hands acid 196 could not be isolated, instead 
only ketone 193, the product from decarboxylation was isolated (Scheme 47). 
 
 
Scheme 47: Saponification and decarboxylation of β-ketoester 
 
Treatment of β-ketoester 194 with KOH in EtOH gave the potassium 
carboxylate 195 in 84 % yield after filtration from the reaction mixture. As the free 
acid could not be isolated, the potassium carboxylate was subjected to the 
rearrangement and cyclisation conditions optimised with the AB-ring analogues 
(Section 1.2.1.), however the product was not isolated. As gas evolution had not 
been observed, it was believed that the isocyanate was not formed due to poor 
solubility of the potassium salt in toluene. In an attempt to solubilise the carboxylate 
195, 18-crown-6 was added to the reaction mixture to chelate to the potassium ion; 
however, the cyclised product was still not observed. Instead, the corresponding 
ethyl ester was isolated in 33 % yield, indicating that some of carboxylate had been 
activated, but residual ethanol from the saponification had acted as the nucleophile 
instead of the azide. The remainder of the mass could not be identified. 
These experiments indicated that the cyclisation in route A would require 
further investigation and since the alternative route was more successful, further 
work on Route A was not performed.  
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3.1.3. Route B 
The first step in route B is the reaction of the β-ketoester 60 with methyl 
vinyl ketone (MVK) in a Robinson annulation to give a modified Hagemann’s ester 
63. As previously discussed in the introduction; the mechanism proceeds via a 
Michael addition to the MVK, followed by an intramolecular aldol condensation to 
give the cyclohexenone (Scheme 48). 
 
 
Scheme 48: Simplified mechanism of the Robinson annulation 
 
There are many examples of Robinson annulations in the literature, providing 
confidence in the approach. Using NaOH in MeOH, as reported by Ziegler,
133
 
Umbezawa
134
 and Turnbull,
135
 followed by acidification with sulfuric acid and 
heating to 70 °C gave a number of compounds, most of which could not be 
identified. However, two compounds were identified as the acetophenone 193 in 4 % 
yield and cyclised material 198 in 17 % yield (Scheme 49). 
 
 
Scheme 49: Reaction of β-ketoester 194 with NaOH as the base 
 
The appearance of these compounds is due to hydrolysis of the ester group 
and subsequent decarboxylation. As previously described in Route A; the acidic 
work-up results in decarboxylation of the β-ketoacid 194 when hydrolysis occurs 
before the Robinson annulation resulting in acetophenone 193. When hydrolysis 
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occurs in the cyclised material 199, the extended conjugated system proves a route 
for decarboxylation under basic conditions as the ketone acts as an electron sink 
(Scheme 50). This observation has been reported Counsell et al. in their synthesis of 
androstenedione analogues.
136
  
 
 
Scheme 50: Mechanism of decarboxylation in cyclised material 
 
As the cause of the saponification was due to the hydroxide, other bases were 
investigated. Sodium methoxide in methanol has been reported in similar systems by 
Kitahara in the synthesis of tanabalin 87,
75
 and MaGee in the synthesis of 
decahydroisoquinolines 201 (Scheme 51).
137
  
 
 
Scheme 51: Kitahara's
75
 and MaGee's
137
 examples of NaOMe/MeOH mediated Robinson 
annulations 
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To prevent the formation of a mixture of the ethyl and methyl esters, sodium 
ethoxide in ethanol was used instead.  Following a procedure reported by Aubé,
77
 the 
β-ketoester 194 was treated with the MVK and NaOEt in EtOH, at 70 °C as reported 
and at room temperature. However, the main product from both reactions was the 
decarboxylated ketone 198. Ethanol was used directly without distillation, so 
residual water could have led to de-esterification. The reactions were repeated with a 
preformed solution of NaOEt in EtOH under anhydrous conditions and after heating 
at both 50 °C and 90 °C, the main product isolated from the reaction was the β-
ketoester 194, with a small amount of the acetophenone 193. This shows that in the 
absence of water de-esterification does not occur, but that NaOEt is still not a 
suitable base for the transformation. This may be because the enolate formed by the 
deprotonation of a β-ketoester can chelate a sodium ion, stabilising the negative 
charge and rendering it a poor nucleophile (Figure 34). A solution to this would be to 
use a base with a larger cation that is unable to coordinate so strongly to the enolate. 
 
 
Figure 34: Chelation of sodium ion 
 
Potassium carbonate was investigated as a non-nucleophilic base, with a 
larger counterion to avoid the problems of saponification and chelation. There is 
some literature precedent for the use of K2CO3, using alcohols as the solvent.
138
 
Alcohols are nucleophilic and generally hygroscopic, so to avoid the use of a 
nucleophilic solvent or the possible introduction of water, anhydrous acetonitrile was 
employed instead (Scheme 52).  
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Scheme 52: Michael addition of ester to MVK in presence of K2CO3 
 
Using 2.5 eq. of the base and MVK for 18 hrs at room temperature gave two 
products; the mono-addition product 202 in 72 % yield and the bis-addition product 
203 in 9 % yield (Table 4, entry 1). Increasing temperature and reaction time were 
investigated to promote cyclisation to the modified Hagemann’s ester 204 (Table 4, 
entries 2-4). However any cyclised material observed had also undergone a second 
Michael addition. As there are three sets of acidic protons in the cyclohexenone 
adjacent to a carbonyl group, there are three possible sites for this second addition to 
occur leading to three possible regioisomers, but the structure of the product could 
not be deduced by spectroscopic methods. Interestingly, the Michael addition 
product 202 can be formed in good yield under mild conditions (Entry 5).  
 
Table 4: Optimisation of the reaction of β-ketoester 194 and MVK with K2CO3 in acetonitrile 
Entry K2CO3  
(eq) 
MVK 
(eq) 
Time 
(hrs) 
Temp 
(°C) 
Yield 
202 (%) 
Yield 
203 (%) 
Yield 
204 (%) 
1 2.5 2.5 18 r.t. 72 9 - 
2 2.5 2.5 24 50 11 18 56 
3 1.5 1.5 24 50 34 5 28 
4 1.5 1.5 5 80 
Not 
recorded 
Not 
recorded 
40 
5 1.1 1.1 2.5 0-rt 97 - - 
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Dehydration of the cyclised material 204 under acidic conditions was 
performed to install the double bond (Scheme 53). Conditions similar to those 
reported by Jørgensen
96
 utilising 4M HCl in dioxane yielded 66 % of the dehydrated 
product 205 and 20 % starting material. When p-TsOH in refluxing toluene was 
employed, as described by Agami,
93
 only the dehydrated product 205 was isolated in 
a 72 % yield. The site of the second Michael addition could still not be deduced by 
spectroscopic methods, but the absence of an alkenyl proton in the 
1
H NMR 
spectrum implied that the second Michael addition did not occur adjacent to the ester 
group.  
 
 
Scheme 53: Dehydration of alcohol 204 to give one of three possible regioisomers 205a, b or c 
 
Due to the success of the mild Michael addition reaction conditions it was 
decided to approach the annulation as a two step process. There was literature 
precedent for performing the cyclisation and dehydration in one step from the 
Michael addition product 202 in acidic conditions including the use of pyrrolidine or 
piperidine and acetic acid as described by Golding
86
 and Christoffers.
82
 Following 
the conditions reported by Boeckman,
80
 ester 202 was heated in toluene in refluxing 
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conditions with 3 eq. pyrrolidine and 4 eq. of acetic acid for 24 hrs, giving the 
desired cyclised product 206 in only 16 % yield (Table 5, entry 1). In addition 
aniline 207 was also isolated in a 25 % yield, presumably generated by the 
condensation with pyrrolidine and subsequent oxidation to give the aromatic ring 
(Scheme 54). 
 
 
Scheme 54: Cyclisation of Michael addition product 202 using pyrrolidine and acetic acid 
 
Formation of similar aniline products has been described by Padwa where a 
cyclisation of a Michael addition product was carried out in the presence of an 
excess of pyrrolidine and catalytic p-TsOH acid in refluxing toluene.
139
 To avoid the 
formation of the aniline, different conditions were investigated (Table 5).  
 
Table 5: Optimisation of pyrrolidinium acetate promoted cyclisation 
Entry Pyrrolidine 
(eq) 
AcOH 
(eq) 
Time 
(hrs) 
Temp 
(°C) 
Yield 206 
(%) 
Yield 207 
(%) 
1 3 4 24 Reflux 16 25 
2 0.8 0.95 1.5 80 65
a
 - 
3 0.8 0.95 2.5 80 52 - 
a
 isolated as a mixture of starting material 202 and product 206 in a 15:85 ratio. 
 
Following the conditions reported by Nour, the reaction was performed using 
a substoichiometric amount of pyrrolidine and AcOH at 80 °C and the aniline was 
not observed (Table 5, entries 2 and 3). However, full conversion of the starting 
material to product was not achieved when the reaction was stirred for only 1.5 hrs 
(Entry 2). Full conversion of the starting material to the product was essential as the 
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compounds could not be separated by column chromatography and this was achieved 
in 2.5 hrs (Entry 3).  
As lowering the temperature from reflux to 80 °C resulted in an increase in 
yield, further increases in yield may be achieved by reducing the temperature further 
but increasing the reaction time. This method holds promise in also providing an 
enantioselective route to the cyclohexenone by using chiral secondary amines or 
proline derivatives; an approach which has been used by Jørgensen et al. in the 
enantiomeric synthesis of cyclohexenones.
96
  
 
 
Scheme 55: p-TsOH catalysed cyclisation of 202 
 
Liu
84
 and Agami
93
  have reported the use of p-TsOH in toluene to affect the 
cyclisation and dehydration (Scheme 55). Initially 10 mol% of the p-TsOH catalyst 
was employed; however there was only a 30 % conversion of the starting material to 
product after 24 hrs (Table 6, entry 1). As previously highlighted, full conversion 
was essential for a successful reaction as the starting material and product could not 
be separated by column chromatography. When the amount of the catalyst was 
increased to 30 mol%, there was an increase in conversion to 66 % (Entry 2) and full 
conversion was only achieved using 40 mol% of the catalyst (Entry 3). Increasing 
the amount of catalyst to 60 mol% did not increase the yield further (Entry 4).  
When the reaction was performed on a larger scale, a basic work-up was 
included to remove the increased quantity of p-TsOH; however an increase in yield 
was not observed so this was excluded from subsequent reactions (Entry 6).  
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Table 6: Optimisation of the acid catalysed cyclisation 
Entry Scale 
(mmol) 
p-TsOH 
(mol%) 
Time 
(hrs) 
% 
Product 
202 
% 
Starting material 
207 
1 0.5 10 24 30 70 
2 0.5 30 24 66 34 
3 0.5 40 20 89 - 
4 0.5 60 24 74 - 
5 3 40 38 70 - 
6 9.3 40 20 70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           -
 
With a route to the modified Hagemann’s ester 207 in hand, investigations 
began on the saponification of the ester and the rearrangement and cyclisation of the 
resulting acid. There had already been indications the acid may be difficult to handle 
due to the extended conjugated system allowing decarboxylation. However, it was 
thought that if the acid could be kept cool until the acyl azide intermediate had been 
formed then decomposition could be avoided.  
 
 
Scheme 56: Saponification of ester 206 
 
There was some literature precedent for the saponification reaction, all of 
which kept the reactions cool to avoid decarboxylation. Using LiOH.H2O in 
MeOH/H2O at 10 °C for 5 hrs as described by Bannerjee,
140,141
 or NaOH in 
MeOH/H2O at 5 °C for 24 hrs as described by Rosenberger,
142
 both gave mixtures of 
products which could not be separated. The most successful conditions found were 
those reported by Oritani,
143
 using 1.1 eq. of KOH in EtOH/H2O at 5 °C overnight. 
This reaction was performed several times during the investigation with yields of 
acid 208 of 80 % to quantitative. Practically, the reaction was easy to execute as it 
could be left in the fridge overnight. It was found that extractions needed to be 
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performed with diethyl ether as the organic phase because hydrolysis of ethyl acetate 
was observed leading to trace amounts of acetic acid contaminating the product.  
 
Cyclisation of the acid 208 was attempted using the procedure optimised on 
the AB-ring analogues, but to activate the acid and form the acyl azide without 
concurrent decarboxylation, the reaction was cooled to 5 °C for 1 hr before heating 
to 90 °C. Two products were isolated from the reaction in a 1:1 ratio, but could they 
not be separated by column chromatography; the decarboxylated material 209 and 
what was thought to be the acyl azide 210 as determined by a characteristic peak in 
the IR at 2145 cm
−1
 correlating to an azide stretching frequency (Scheme 57).  
 
 
Scheme 57: Attempted cyclisation of acid 208 
 
To prevent the problem of decarboxylation, it was decided that the extended 
conjugated system should be removed before the further cyclisation conditions were 
attempted.  This was achieved by reduction of the ketone, followed by protection of 
the resulting alcohol to prevent interference with the cyclisation reaction.  
The Luche reduction uses sodium borohydride and ceric chloride to 
selectively reduce an α,β-unsaturated ketone whilst leaving the alkene intact.144 
Following the method of Hudlicky et al.,
145
 the ketone 206 was successfully reduced 
to afford alcohol 211 in 80 % yield and an 80:20 mixture of diastereoisomers 
(Scheme 58). It was not possible to identify which was the major isomer by 
spectroscopic methods. However, mechanistically the hydride would be 
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preferentially delivered to the least hindered face of the carbonyl. This would place 
the hydroxyl and ester groups on the same face of the ring in the major isomer. 
 
 
Scheme 58: Luche reduction of unsaturated ketone 206 
 
Protection of an alcohol using a silyl group is a common protection 
strategy,
146
 as the protection is straightforward to perform under basic conditions and 
the deprotection can be affected by either fluoride or under acidic conditions. It was 
also anticipated that using BF3·OEt2 as the Lewis acid in the cyclisation would 
provide a source of F
−
, negating the need for a formal deprotection at the end of the 
synthesis. tert-Butyldimethylsilyl (TBDMS) chloride was chosen to protect the 
alcohol, as the TBDMS group would be more stable to the acidic work-up involved 
in the saponification step. The conditions chosen were those reported by both 
Shimizu,
147
 and Petit,
148
 using 1.1 eq. TBDMSCl and 1.1 eq. imidazole in DMF and 
produced the protected alcohol 212 in 63 % yield when performed on a 0.4 mmol 
scale and a 76 % yield when the scale was increased to 3 mmol (Scheme 59). The 
product remained an 80:20 mixture of diastereoisomers, but again the configuration 
of the major isomer could not be determined by 
1
H NMR analysis. 
 
 
Scheme 59: Silyl protection of the alcohol 211 
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The ester 212 was exposed to the same saponification conditions previously 
used, however it was discovered that this ester was more stable to these conditions 
and so heating was required to force the reaction (Scheme 60). The acid was isolated 
in approximately 71 % yield, but the product contained minor impurities by 
1
H NMR 
analysis. Cyclisation was attempted on the material using DPPA and Et3N in toluene 
at 90 °C followed by treatment with BF3·OEt2. However, a mixture of products was 
isolated which could not be identified by spectroscopic methods.  
 
 
Scheme 60: Saponification and attempted cyclisation of ester 212 
 
3.2. SYNTHESIS OF THE TRIMETHOXY-ANALOGUE 
3.2.1. Synthesis of the Modified Hagemann’s Ester 
The initial steps in the synthesis were straightforward as the route previously 
developed from 3,4-dimethoxyacetophenone could be used. The Claisen 
condensation using NaH in diethyl carbonate was successful and the reaction was 
performed 3 times on scales of 5-50 mmol, with yields of 67-95 % (Scheme 61). 
 
 
Scheme 61: Condensation of acetophenone with diethyl carbonate 
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The Michael addition using 1.1 eq. MVK and 1.1 eq. K2CO3 in MeCN was 
also efficient, with yields of the Michael adduct 217 of 72-98 % over the 3 times the 
reaction was performed (Scheme 62). Both steps have been performed on scales of 
up to 50 mmol, showing the robustness of the reactions. Column chromatography 
was used to purify the products; however there is opportunity to telescope the 
products through to the solid Hagemann’s ester 218, which can be purified by 
recrystallisation, avoiding the use of chromatography on a large scale. 
 
 
Scheme 62: Preparation of 217 by the Michael addition of MVK to β-ketoester 216 
 
The conditions used for the cyclisation were those previously developed on 
the dimethoxy-analogue using 0.4 eq. of p-TsOH in refluxing toluene (Scheme 63). 
The reaction was performed on 26-40 mmol scale using Dean-Stark trap to afford the 
ester 218 in 47-54 % yield. 
 
Scheme 63: Acid catalysed cyclisation of 217  
 
The remainder of the mass balance was not determined. However, as 
1
H 
NMR analysis of the crude reaction mixture showed clean conversion of the starting 
material to product, the poor yield was believed to be due to problems during 
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purification. In future, column chromatography might be avoided and yields 
increased by employing a basic work-up and recrystallisation to purify the product.  
 
3.2.2. Saponification and Cyclisation of Modified Hagemann’s Ester 
The optimised conditions for the hydrolysis of the dimethoxy- analogue 206 
using 1.1 eq. KOH in EtOH/H2O were unsuccessful, giving a mixture of products 
that could not be separated. A screen of bases and solvents was undertaken, leaving 
the reactions at 5 °C for 16 hrs, with the best results obtained with 5 eq. of 
LiOH.H2O in EtOH/H2O (Table 7, entry 1). The 
1
H NMR spectra of the crude acid 
219 were cleaner when the reaction was performed in EtOH/H2O than when 
THF/H2O was used. After the initial screen it was found that the reactions could be 
performed at room temperature, giving yields of 75-97 % in just 1 hr.  
 
Table 7: Screen for conditions for the saponification of ester 218 
Entry Base Solvent Result 
1 LiOH.H2O EtOH/H2O Clean, complete conversion by 
1
H NMR and TLC 
2  THF/H2O Complete conversion by TLC but impurities 
present by 
1
H NMR 
3 NaOH EtOH/H2O Clean, complete conversion by 
1
H NMR and TLC 
4  THF/H2O Incomplete conversion. 
 
For the first attempt at the Curtius rearrangement, the acid was stirred at 
room temperature with triethylamine and DPPA in toluene for 45 mins before the 
reaction has heated at 90 °C. As was observed during the rearrangement of the 
dimethoxy- analogue under similar conditions (Section 3.1.3, p. 69), the reaction 
yielded a mixture of products which could not be separated by column 
chromatography. However the decarboxylated product 220 could be identified in the 
1
H NMR spectrum of the crude material. It was believed that the acid was not 
converted to the acyl azide before the reaction was heated, allowing decarboxylation 
to occur when the temperature was raised.  
 
The isolation of acyl azides has been reported by Padwa
149
 and Katrizky,
150
 
so to further investigate the activation of the acid isolation of the acyl azide 221 was 
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attempted. When reaction of acid 219 with DPPA and Et3N was performed at room 
temperature, the acyl azide 221 was isolated in a disappointing 6 % yield, along with 
another product which appeared to be a carbamoyl azide 222 (Scheme 64). The IR 
spectrum of the compound 222 showed both amide and azide stretches at 1667 cm
−1
 
and 2145 cm
−1
 respectively and the 
1
H NMR spectrum of the compound contained 2 
aromatic protons, indicating that cyclisation had not taken place. Carbamoyl azides 
have been reported, along with their synthesis from isocyanates and a source of 
azide.
151,152,153
 Interestingly, to form this product the azide must undergo a room 
temperature Curtius rearrangement.  
 
 
Scheme 64: Attempted synthesis of the acyl azide 
 
Activation of the acid using a mixed anhydride, as previously discussed in 
the synthesis of the AB-ring analogues, was also investigated. The reaction was 
performed at room temperature using ethyl chloroformate and Et3N in acetone/water 
followed by the addition of NaN3 to generate the acyl azide, however the acyl azide 
was not observed. Instead, the starting acid 219 was isolated in 45 % yield and the 
corresponding ethyl ester 218 was isolated in 47 % yield. The initial step in the 
mechanism of the formation of the ester is the activation of the acid as the mixed 
anhydride, with the liberation of a chloride anion. This can react as a nucleophile 
with the ester carbonyl, to give the acyl chloride with concurrent decomposition of 
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the carbonate moiety releasing carbon dioxide and ethoxide. Finally, the ethoxide 
displaces the chloride to give the ester 218 (Scheme 65).  
 
 
Scheme 65: Mechanism for the formation of ethyl ester 223 from acid 219 and EtOCOCl 
 
As the acid 219 had been sensitive to the base used during the saponification 
step, other bases were considered for this transformation. Pyridine was identified as 
an alternative organic base. With a pKa of 5.21, it is weaker than Et3N with a pKa of 
10.75 but still basic enough to deprotonate the acid. Using DPPA to activate the acid, 
only the decarboxylated material 220 was observed (Scheme 66).  
 
 
Scheme 66: Using pyridine as the base in the Curtius rearrangement 
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Inorganic bases were also investigated as the saponification of ester 218 was 
successful when LiOH.H2O and NaOH were used, so these bases were known to be 
compatible with the carboxylate. However, hydroxide is nucleophilic so to avoid 
degradation of the DPPA or the activated acid, sodium, potassium and caesium 
carbonates were investigated instead. To improve the solubility of the base, the 
solvent was changed to acetone. In addition, the final step was also modified; after 
stirring the acid, carbonate and DPPA in acetone at room temperature, the solvent 
was removed and methanol added. This modification was an attempt to simplify the 
final step of the reaction, using the methanol to trap the isocyanate to give the 
carbamate instead of performing the cyclisation and demethylation (Scheme 67).  
The carbamate 223 was isolated in 19 % yield when Na2CO3 was employed 
as the base. Carbamate 223 was also observed in the reaction using K2CO3 although 
the major product was that of decarboxylation 220. The reaction with Cs2CO3 also 
gave predominantly decarboxylated material. These results were unsurprising as in 
the initial saponification reactions using KOH had given a mixture of products. It 
was believed that the carboxylate was unstable when accompanied by larger 
counterions. 
Sodium and potassium carbonate were also employed as bases when ethyl 
chloroformate was used to activate the acid. It was believed these reactions would 
work well as the base would be fully dissolved in the acetone/water solvent system 
normally used. However; the predominant product in both reactions was the 
corresponding ethyl ester 218 that had previously been observed, isolated in 32 % 
yield using sodium carbonate and 42 % using potassium carbonate. The carbamate 
223 was isolated in both reactions in a 5 % yield with Na2CO3 and 2 % with K2CO3.  
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Scheme 67: Attempted cyclisation using carbonates as the base 
 
Activating the acid as either a mixed anhydride or phosphoric anhydride was 
proving to be a difficult strategy, so the acid chloride was explored as a possible 
route of activation. In the attempted synthesis of α-amino acids from malonic half 
esters, it was found that using DPPA led to the formation of esters as the major 
product (Scheme 68).
154
 It has been discussed more recently by Peterson et al. that 
this observation is due to the presence of acid protons alpha to the carboxylic acid 
leading to the formation of a ketene by the release of hydrazoic acid,
155
 and they 
extended this idea to the presence of benzylic protons α- to the carboxylic acid. To 
avoid this, the acid can be activated as an acid chloride using oxalyl chloride and 
catalytic DMF. 
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Scheme 68: Formation of esters using DPPA via the loss of HN3 
 
Following the procedure reported by Peterson et al.,
155
 the acid chloride 
formation was carried out at 0 °C for 1 hr, then the NaN3 was added and finally the 
reaction mixture was treated with BF3·OEt2. Neither the lactam nor the 
decarboxylated products were observed in the reaction, instead fluorenones 224 and 
225 were isolated in a 9 % and 28 % yields (Scheme 69).  
 
 
Scheme 69: Formation of fluorenones 224 and 225 via the acid chloride 
 
This shows that the acid can be activated as an acid chloride however the 
intramolecular nucleophilic attack of the electron-rich trimethoxyaryl group is much 
faster than the intermolecular attack of the sodium azide. Reducing the temperature 
of the reaction was explored as a way of reducing the rate of the intramolecular 
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reaction and increasing the chance of the intermolecular reaction. Targeting the acyl 
azide to ensure the intermolecular reaction had taken place, the acid chloride 
formation was carried out at −13 °C for 5 mins before the addition of sodium azide, 
but the 72 % of the starting material was reclaimed. When the reaction was left for 
15 mins at −13 °C before the addition of azide only 65 % of the starting material was 
reclaimed. In these two reactions some decarboxylated cyclohexenone 220 was also 
observed, but the fluorenones were not seen. The acid chloride formation was also 
carried out at −10 °C for 1 hr before the addition of sodium azide and using 
methanol in the final step to target the carbamate 223. The decarboxylated material 
220 was isolated in 23 % yield and the fluorenone 225 isolated in 57 % yield but the 
carbamate was not observed. This final reaction shows that the intramolecular 
cyclisation of the acyl chloride is too fast in comparison to the formation of the acyl 
azide, so this method of activation was not suitable for this synthesis.  
It was concluded that the difficulties in activating the acid 219 towards 
nucleophilic attack of azide, without concurrent decarboxylation or cyclisation, were 
due to the extended conjugated system with unsaturated ketone. It was believed that 
removing this system would allow the rearrangement to work, without the 
complications experienced so far.  
 
3.2.3. Removing the Conjugated System to Aid Cyclisation  
Several methods of removing conjugation connecting the ester and ketone 
have been considered (Scheme 70). Luche reduction and silyl protection of the 
resulting alcohol had already been examined, but provided difficulties in 
saponification and cyclisation. Considering these problems, it seemed unwise to 
follow this route at this point. The other avenues investigated were to remove the 
cyclohexenyl double bond by hydrogenation leaving the ketone intact; protecting the 
ketone as either an acetal or dithioacetal; or completely removing the allyl ketone by 
reduction  
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Scheme 70: Considered methods of removing the conjugated system in ketone 218 
 
The first method investigated was the hydrogenation of the double bond, 
leaving the ketone in place.  Reduction of an α,β-unsaturated carbonyl with hydrogen 
and palladium on carbon is a well known transformation described extensively in the 
literature including examples by Cieplak,
156
 Mateos in the synthesis of ohchinolide 
analogues
157
 and Li in the synthesis of Cephalotaxine.
158
 Using 5 mol% Pd/C in 
EtOAc, the double bond was reduced to furnish 226 in a 49 % yield, but concurrent 
over-reduction also gave alcohol 230 in a 48 % yield (Scheme 71). 
 
 
Scheme 71: Hydrogenation of the α,β-unsaturated ketone 
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 The desired product 226 was isolated as a single diastereoisomer, believed to 
be the cis-diastereomer by 
1
H NMR analysis and mechanistic insights. As shown in 
Figure 35, generated using an MM2 calculation in Chem3D, the ester group sits 
directly over one face of the cyclohexyl ring, preventing the catalyst accessing this 
face, resulting in the hydrogen being delivered to the opposite face, pushing the 
aromatic ring onto the same face as the ester.  
 
 
Figure 35: Origins of stereoselectivity in the hydrogenation 
 
The protons at the C1 and C2 position of the cyclohexene ring have a 
coupling constant of 10.0 Hz in the 
1
H NMR spectrum, so using the Karplus curve 
the protons and therefore the substituents have a syn-relationship (Figure 36). 
 
 
Figure 36: Coupling constants of protons on the cyclohexyl ring 
 
Over-reduction using Pd/C has been reported by Ohashi,
159
 and Doering,
 160
 
although they describe longer reaction times and higher pressures than were applied 
in this reaction. The alcohol 230 appears to be a single diastereoisomer by 
1
H NMR 
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analysis, though the stereochemistry cannot by confirmed by the coupling constants. 
However, using the same mechanistic arguments as applied to the ketone 226, a syn-
relationship should exist between the alcohol, aryl ring and ester. The effect of 
changing the solvent to ethanol or acetic acid on the selectivity of the reaction was 
investigated, however over-reduction was always observed. 
 
 
Scheme 72: Epimerisation and saponification of ester 226 
 
Saponification of ester 226 was investigated using LiOH.H2O and NaOH and 
higher yields of acid 231 were achieved with shorter reaction times using NaOH 
(Table 8, entries 2 and 3).  
Table 8: Epimerisation and hydrolysis of ester 226 
Entry Base Reaction 
time (hrs) 
Reaction 
temperature (°C) 
Yield 
(%) 
Diastereomeric 
ratio 
1 LiOH.H2O 5 r.t. 32 59:41 
2 NaOH 1.5 Reflux 99 35:65 
3 NaOH 3 Reflux 82 33:67 
 
The natural product has an anti-relationship at the B/C ring junction, so it 
was envisioned that this geometry could be installed in acid 231 by concurrent base-
catalysed epimerisation at the C1 position (Scheme 72). Some epimerisation was 
observed with the best conversions seen in the reactions using NaOH (entries 2 and 
3); however, full conversion was not achieved in the timeframes investigated. This 
may be because mechanistically the epimerisation must occur before the 
saponification as otherwise the base needs to deprotonate an anionic species which is 
energetically unfavourable. This means if the saponification reaction is faster than 
epimerisation, full conversion of the stereocentre would be slow. If this route was to 
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be pursued further then a non-hydrolytic base should be employed to do the 
epimerisation as a separate step before the saponification. 
 
The cyclisation of acid 231 was attempted using DPPA and Et3N in toluene 
and after treatment with BF3·OEt2, the demethylated lactam 232 was isolated in 6 % 
yield. Hydrolysis of the BF2-adduct using NaOH in EtOAc was omitted and this may 
have lead to the low yield. This result does show that removal of the conjugated 
system does allow rearrangement and cyclisation, however further work would need 
to be carried out to optimise this approach. 
 
 
Scheme 73: Cyclisation and demethylation of acid 231 
 
Protecting the carbonyl as either an acetal 227 or a dithioketal 228 was 
considered for removing the conjugated system as this approach protects the ketone 
without changing its oxidation state, leaving a handle to further functionalise the C-
ring (Scheme 74). 
 
 
Scheme 74: Acetal/dithioacetal protection of a ketone 
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Acetal protection is a common strategy used to mask ketones,
161
 performed 
under dry acidic conditions, for example p-TsOH or pyridinium para-
toluenesulfonate in refluxing benzene as reported by Carreño et al.,
162
 and Murakata 
et al.,
163
 or oxalic acid in acetonitrile as reported by Kadas et al. in the synthesis of a 
narciclasine analogue.
164
 Deprotection is also straightforward using aqueous acid,
162
 
which causes a problem with this strategy as the acetal would not be stable to the 
acidic conditions in the work up for the saponification. The dithioketal protecting 
group is more robust so would withstand the acidic conditions.
 165
 The protection can 
be performed under Lewis acidic conditions as described by Craig et al.,
166
 and 
Muthuisamy et al.,
167
 but taken off under oxidative conditions as reported by Shi et 
al.,
168
 and Wu et al..
169
 Although this strategy was not investigated it provides a 
robust method of masking the ketone without complete removal. 
 
The route that has been most successful thus far is the complete removal of 
the ketone using sodium borohydride and trifluoroacetic acid. The method and 
conditions were first described by Gribble et al. in 1977 during his work on sodium 
borohydride reductions in acidic media,
170
 but has been applied selectively reduce 
unsaturated ketones as described by Winterfeldt et al.,
171
 Hanson et al.,
172
 De 
Riccadis et al.,
173
 and Bayón et al..
174
 The mechanism is believed to proceed via a 
stabilized cationic species which is then quenched by the hydride.  
Following the procedure reported by Bayón et al., the complete reduction of 
the ketone 218 was achieved in 98 % yield after 4 hrs (Scheme 75). Interestingly, 
after only 90 mins, two products were isolated from the reaction, cyclohexene 229 in 
72 % yield and acetate 233 in 16 % yield. The acetate 233 may be an intermediate in 
the reaction; however it is not known whether its substitution by a hydride occurs via 
an SN1 or SN2 process. 
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Scheme 75: Reduction of 218 to cyclohexene 229 and acetate 233 
 
Saponification of ester 229 was attempted with LiOH.H2O, but only the 
starting material was isolated. Instead the ester was hydrolysed using aqueous NaOH 
heated to reflux giving acid 234 in 79 %, yield as the precursor for the Curtius 
rearrangement and cyclisation (Scheme 76).  
 
 
Scheme 76: Saponification of the ester 229 
 
Following the cyclisation procedure optimised on the AB-ring analogues 
(Section 2.1.1, p. 39), the acid 234 was heated with DPPA and Et3N in toluene, then 
the reaction mixture was treated with BF3·OEt2 at room temperature (Scheme 77). 
The reaction proceeded smoothly; evolution of gas during the reaction with DPPA 
and precipitation of a solid believed to be the BF2-adduct 235 during the Lewis acid 
mediated step were observed. After heating the mixture in 2M NaOH and EtOAc at 
50 °C, the cyclised and demethylated product 236 was isolated in a 34 % yield. 
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When the BF3·OEt2 step was performed at 50 °C, the product 236 was isolated in a 
slightly improved 46 % yield. The remainder of the mass balance was not identified 
in either of the reactions.   
 
 
Scheme 77: Synthesis of phenanthridone 236 by the cyclisation and demethylation of acid 234 
 
The 8,9-dimethoxy-7-hydroxyphenanthridone 236 was synthesised in an 
overall 18 % yield and 6 steps. Despite further optimisation being required, the route 
was applied to the synthesis of the 8,9-dimethoxyphenanthridone. 
 
3.3. SUCCESSFUL SYNTHESIS OF THE 8,9-
DIMETHOXYPHENANTHRIDONE 239 
The synthesis of the dimethoxy analogue was resumed at Hagemann’s ester 
206. Reduction of the ketone to afford cyclohexene 237 proceeded efficiently, 
affording the product in 83 % yield after 4 hrs (Scheme 78). 
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Scheme 78: Reduction of ketone 206 to cyclohexene 237 
 
The ester 237 was then hydrolysed using aqueous NaOH heated at reflux and 
the acid 238 was isolated in 84 % yield (Scheme 79). 
 
 
Scheme 79: Saponification of ester 237 
 
 Following the procedure for the cyclisation of 3-(3,4-
dimethoxyphenyl)propionic acid 146, acid 238 was heated at reflux with DPPA and 
Et3N in toluene, before treatment with BF3·OEt2 at 50 °C. After heating the reaction 
mixture in NaOH and EtOAc at 50 °C, two products were isolated from the reaction; 
the lactam 239 in a 34 % yield and another cyclised product 240 in 23 % yield 
(Scheme 80). There was also a 28 % yield of a mixture of products 239 and 240, in a 
ratio of 31:69, which were not separated by column chromatography, giving a total 
yield of 85 % of cyclised products. 
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Scheme 80: Cyclisation of the dimethoxy- substituted acid 238 to furnish phenanthridones 239 
and 240 
 
The product 240 was formed by the migration of the double bond to the B/C 
ring junction, to give the more thermodynamically stable tetra-substituted alkene. It 
is not known at what point the migration occurred, however the migration may 
proceed by a base catalysed mechanism (Scheme 81).  
 
 
Scheme 81: Base catalysed double bond migration 
 
Phenanthridone 239 was synthesised in an overall yield of 15 % and 240 was 
synthesised in an overall yield of 10 %. The synthesis was performed in only 6 steps 
and the final step produced two interesting analogues. Through further optimisation 
of this reaction, either of the products might be accessed selectively. The synthesis of 
these analogues has tested the scope of this synthetic route and following further 
optimisation other interesting analogues may be synthesised using this short route in 
good yields. 
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3.4. BIOLOGICAL EVALUATION 
The three compounds have been tested in an MTS cell proliferation assay 
using human HT29 colon cancer cells with 72 hrs exposure time. The compounds 
have been tested twice and an average taken.  
 
 
Figure 37: Biological activity of phenanthridones 236, 239 and 240 
 
The analogues displayed activities in the lower micromolar range (Figure 
37). Addition of the C-ring to the molecule increased the activity when compared to 
the AB-ring analogues (Section 2.3, p. 52). Inclusion of the 7-hydroxyl also 
increases activity from 37 µM to 23 µM, in keeping with the SAR patterns in the 
natural product. Interestingly, the compound 240 where the double bond has 
migrated shows only a 15-fold difference to the natural product 14 where the B/C 
ring junction is a double bond. This indicates that in this molecule, oxygenation in 
the C-ring is less important for biological activity. When the double bond sits 
between the 10b and 1 position, there is approximately a 250-fold difference in 
activity between 239 and 7-deoxy narciclasine 4; and 1500-fold difference between 
236 and narciclasine 3. 
This increase in activity with increasing size of the molecule brings 
confidence that with the introduction of oxygenation, or other polar and hydrogen 
bonding groups onto the C-ring, nanomolar activities may be achieved.  
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3.5. CONCLUSIONS AND FUTURE WORK 
3.5.1. Chemistry 
A 6-step route to the ABC-ring tricyclic core has been developed using a 
Robinson annulation and a Curtius rearrangement and intramolecular Friedel-Crafts 
acylation as key steps in the synthesis. Using this approach 8,9-dimethoxy-7-
hydroxyphenanthridone 236 was synthesised in 18 % overall yield and  8,9-
dimethoxyphenanthridone 239 was isolated 15 % overall yield. In addition, 
phenanthridone 240 was isolated in 10 % overall yield after the in-situ isomerisation 
of the double bond in 239.  
This route can now be applied to the synthesis of the 8,9-
methylenedioxyphenanthridone 241, to further test the scope of the route and access 
the third substitution pattern that was investigated in the AB-ring analogues. As 240, 
the product of double bond migration was active in the HT29 cells, the conditions 
under which this occurred should be investigated further so either of the 
regioisomers 241 or 242 can be synthesised selectively. 
 
 
Figure 38: 8,9-(Methylenedioxy)phenanthridone analogues 241 and 242 
 
A number of the steps within the route require further optimisation. The 
cyclisation of the Michael addition products using p-TsOH in refluxing toluene 
proved to be inefficient when performed on larger scales. Further investigations into 
pyrrolidine/AcOH as the catalysts for reaction may provide the cyclised product in 
better yields. It was originally envisaged that the Robinson annulation would be 
performed in one step. On reflection, it might be possible to develop the 
K2CO3/MeCN conditions for the Michael addition, heating the reaction once the 
addition has completed to give the cyclised product. Using t-BuOK in t-BuOH has 
been described for the annulation and could also be investigated.
175
 This is a bulky, 
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non-nucleophilic base with the larger potassium cation which would not cause the 
problems of chelation observed with the sodium alkoxide bases discussed in section 
3.1.3 (p. 61).  
The cyclisation of 234 to give the 8,9-dimethoxy-7-hydroxyphenanthridone 
236 also requires further investigation to increase the yields from 42 %. In a similar 
manner to the dihydroisoquinolinone 151, it may be possible to isolate and purify the 
BF2-adduct then perform the hydrolysis to increase the yield.  
 
Narciclasine contains a stereogenic centre at the 4a position, so the 
stereoselective synthesis of its analogues should be investigated. The configuration 
of the 4a position can be fixed in the Robinson annulation. Methods of achieving this 
were discussed in the introduction to the Robinson annulation (Section 1.4, p. 27) 
and can be investigated for these compounds. These include the initial synthesis of a 
chiral enamine followed by the Michael addition and cyclisation reactions, as was 
reported in the synthesis of Saudin (Scheme 82a).
80
 Alternatively, proline catalysts 
can be investigated, either in a two-step procedure to perform the cyclisation of the 
Michael addition product, or to perform the annulation in one step as has been 
described as Barbas III
98
and Swamainathan
99
 (Scheme 82b). 
 
 
Scheme 82: Methods of performing the Robinson annulation stereoselectively 
 
Narciclasine contains a 2,3,4-trioxygenated C-ring, so the synthesis of 
analogues with a functionalised C-ring should also be investigated. Originally, the 
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target compounds contained a ketone in the C-ring which would have provided a 
handle to introduce other functional groups; however this was removed to aid the 
Curtius rearrangement. Allylic oxidation of the analogues synthesised in this project 
can be investigated to reinstall the ketone. Dithiane protection of the ketone was 
discussed in Section 3.2.3 and this could be investigated as a method of retaining the 
ketone allowing modification to be made to the ring after the formation of the 
lactam. Alternatively, the modifications could be made on the Hagemann’s ester, 
prior to the cyclisation of the B-ring. Other possible methods of adding functionality 
to the ring include the use of enolate chemistry as was discussed in section 1.2 (p. 
20). Functionality could also be introduced through the use of different vinyl 
ketones, for example, methyl styryl ketones would lead to an aryl ring at the 4-
position (Scheme 83).  
 
 
Scheme 83: Introduction of functionality in the C-ring through the use of different vinyl ketones 
 
3.5.2. Biology 
As the cytotoxicity of the analogues has been evaluated against the human 
colon cancer cell line, the most active compounds should be assessed against other 
cancer cell lines to assess the consistency of their activity. The human prostate 
cancer cell line LNCaP and the human breast cancer cell line MDA-MB-231 have 
been used to test other compounds synthesised within the research group. These 
additional cell lines have been chosen as they can be easily transferred into in-vivo 
models, allowing in-vivo and in-vitro results to be easily compared. The selectivity 
of the most active compounds should also be assessed and this can be done testing 
them against a FEK-4 skin fibroblast cell line.  
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4. PRENYLATION OF ELECTRON-RICH ARENES 
4.1. INTRODUCTION 
4.1.1. The Prenyl Group 
The prenyl group is a motif commonly found in natural products and 
biologically-active molecules,
176
 for example; novobiocin 243
177
 and derrubone 
244
178
 have anti-tumour activity though inhibition of heat-shock protein 90 (Hsp90);
 
Xanthohumol 245 has anti-inflammatory activity and anti-cancer activity;
179
 and 
isobavachalcone 246 induces apoptosis and inhibits tumour promotion.
180
 It has been 
shown that prenylation can increase the lipophilicity and activity of a compound;
181
 
however, the position of the prenyl group is more important than the quantity.
176
  
 
 
Figure 39: Prenylated biologically active natural products 
 
There have been a number of reported methods of introducing the prenyl 
group to an arene (Scheme 84). A comprehensive review of ortho-prenylation of 
phenols was published in by Hoarau and Pettus.
182
 A common approach is to use 
lithium-halogen exchange or deprotonation/lithiation of an arene, followed by 
reaction with prenyl bromide (Scheme 84a). This approach has been applied to the 
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prenylation of phenols,
183
 benzenes,
184
 and indoles.
185
 Phenol is able to provide a 
useful handle for prenylation; as it can be O-prenylated, which upon a Claisen-Cope 
rearrangement gives the ortho- or para- C-prenylated phenol derivative (Scheme 
84b).
186a-c
 In the synthesis of 247, a phenol derivative was O-allylated and after a 
Claisen rearrangement to afford the ortho-allyl material, Grubbs metathesis was used 
to install the gem-dimethyl group at the terminal end of the double bond (Scheme 
84c).
187
 Direct C-prenylation of a phenol has been achieved under acidic conditions 
using zeolite catalysts at high temperatures;
188
 a silica mediated process;
189
 and by 
using oxalic acid in refluxing dioxane (Scheme 84d).
190
 However, these conditions 
have only been applied to phenols, so the challenge remains to efficiently prenylated 
other arene rings. 
 
 
Scheme 84: Methods of aryl prenylation 
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4.1.2. The Chroman Group 
Like the prenyl group, chroman is also a biologically important motif found 
in many natural products and medicinally interesting compounds such as Vitamin E 
248;
191
 cytotoxic and anti-plasmodial xanthones 249;
192
 anti-mycobacterial 
dihydrobenzopyrans 250;
193
 and the Dorsmanins A 251
194
 and B 252.
195
  
 
 
Figure 40: Biologically active chromans 
 
The main approaches to the synthesis of the chroman motif include 
nucleophilic addition of a Grignard reagent to the corresponding coumarin (Scheme 
85a);
196,197
 or addition and cyclisation of a prenyl group with a phenol in the 
presence of a catalyst (Scheme 85b). There have been a number of reported methods 
of implementing the second approach. Claisen reported the condensation of phenol 
and isoprene in 1921,
198
 then interest in the transformation resumed in the late 
1950’s and early 1960’s when Bader et al. reported the use of phosphoric acid199 and 
Dewhirst et al. reported the use of aluminium phenoxide
200
 to catalyse the addition 
and cyclisation of isoprene with phenol. In a similar manner to that reported by 
Bader, Ahluwalia et al. reported the use of ortho-phosphoric acid to catalyse the 
reaction of isoprene and a phenol in good yields.
201
 More recently Lewis acids have 
been explored as catalysts for the transformation. Montmorillonite clays;
202
 a 
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scandium triflate/ionic liquid system,
203
 a copper triflate-bipyridyl complex;
204
 and 
most recently BF3·OEt2
205
 have all been shown to catalyse the reaction. 
 
 
Scheme 85: Synthetic approaches to the chroman ring 
 
4.1.3. Bismuth (III) Triflate 
Bismuth (III) triflate is a mild, safe and easily handled Lewis acid that has 
proved to be useful in many chemical transformations, as reviewed by Gaspard-
Iloughmane,
206
 and Antoniotti.
207
 Recent applications of Bi(OTf)3 as a catalyst 
include: acetylation of alcohols;
208
 esterifications;
209
 oxa-Pictet-Spengler 
reactions;
210
 Fries and Claisen rearrangements;
211
 Mannich reactions 
212,213
 and aldol 
reactions.
214
 These papers also discuss the mechanism of action of Bi(OTf)3, 
describing it as a safe and convenient source of triflic acid which is the actual 
catalyst in the reaction.  
 
4.2. OPTIMISING THE REACTION CONDITIONS 
During our investigations, bismuth (III) triflate was found to catalyse the 
addition of isoprene to methyl 3,4,5-trimethoxycinnamate (Scheme 86). Due to the 
biological importance of the prenyl group, the mild reaction conditions and 
encouraging yield, it was decided that the transformation should be investigated 
further. 
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Scheme 86: Prenylation of methyl 3,4,5-trimethoxycinnamate 253 
 
To optimise the reaction conditions, trimethoxybenzene was used as a model 
substrate (Scheme 87). 
 
 
Scheme 87: Prenylation of trimethoxybenzene 252 
 
To verify that Bi(OTf)3 was the best catalyst for the transformation, a screen 
of acids was undertaken on a 0.5 mmol scale. The products were not isolated but the 
conversion was calculated from the 
1
H NMR spectra of the crude material (Table 9). 
A catalyst was essential for the reaction to proceed (Entry 1) and the protic acid TFA 
also had no effect on the reaction (Entry 2). Lewis acids ZrCl4 and AlCl3 did not 
catalyst the prenylation, but degradation of starting materials was observed in the 
1
H 
NMR spectra (Entries 3 and 4). Yb(OTf)3 and Zn(OTf)3 did not catalyse the reaction 
but degradation of the starting materials was not observed (Entries 5 and 6). 
Prenylation was observed when Sc(OTf)3 (Entry 7) and BF3·OEt2 (Entry 9) were 
used; however, Bi(OTf)3 (Entry 8) gave the best result with most of the starting 
material being consumed and a 70 % conversion to the mono-prenylated product. 
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Table 9: Screen of Lewis acids for the prenylation reactions 
Entry Acid 
% Starting Material 
255 
% Mono-product 
256 
% Bis-product 
257 
1 None 100 - - 
2 TFA 100 - - 
3 ZrCl4 100
a
 - - 
4 AlCl3 100
a
 - - 
5 Yb(OTf)3 100 - - 
6 Zn(OTf)2 100 - - 
7 Sc(OTf)3 58 42 - 
8 Bi(OTf)3 11 70 19 
9 BF3·OEt2 65 35 - 
a: Degradation of the starting material was observed by NMR 
 
Bismuth (III) triflate has been described as a catalyst for many 
transformations as it has the advantages of being non-toxic and easy to handle. The 
mode of action of the catalyst has been discussed by both Ollevier
213
 and Dumeunier,
 
215
 who believe triflic acid is the active catalyst, which is released upon hydrolysis of 
Bi(OTf)3 (Scheme 88, route A). An alternative explanation is a bismuth species acts 
as a Lewis acid and coordinates to the isoprene, activating it towards nucleophilic 
attack by the aryl ring (Scheme 88, route B).  
 
 
Scheme 88: Two possible mechanisms for the catalysis of prenylation 
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The determine the most probable mechanism, a series of reactions were 
performed on a 2 mmol scale, using 10 mol% Bi(OTf)3 under anhydrous conditions 
under an inert atmosphere, with a range of different additives (Table 10).  
 
Table 10: Probing the mode of action of Bi(OTf)3 
Entry Additive 
Time 
(hrs) 
Yield Starting 
Material 255 
(%) 
Yield Mono-
Product 256 
(%) 
Yield Bis-
Product 257 
(%) 
1 
Dry solvent 
and glassware 
1.25 0 62 20 
2 
1 drop (~ 20 
μL) water 
5 5 63 13 
3 
33 mol % 
DTBMP 
6 87 7 0 
4 
“Wet” solvent 
and glassware 
1.5 10 68 23 
 
When the reaction was performed using dried glassware and anhydrous 
toluene, the mono-product 256 was isolated in 62 % yield after 1.25 hrs in addition 
to the bis-product 257 in 20 % yield (Entry 1). The reaction was performed with the 
addition 1 mmol water, a sufficient amount to hydrolyse the Bi(OTf)3 to afford 0.6 
mmol TfOH (Entry 2). After 5 hrs the mono-product 256 was isolated in 63 % yield, 
in addition there was a 5 % yield of the starting material showing that the reaction 
still proceeds with the addition of water. Following the investigations of Lherbert,
209
 
the addition of 2,6-di-tert-butyl-4-dimethylpyridine (DTBMP) was explored. The 
bulky base would neutralise and deactivate any triflic acid produced, but leave the 
bismuth available to act as a Lewis acid. The addition of 33 mol% DTBMP gave an 
87 % return of unreacted starting material after 6 hrs (Entry 3), suggesting that the 
reaction is catalysed by triflic acid liberated by the hydrolysis of Bi(OTf)3. However, 
addition of too much water can have an adverse effect slowing the reaction down. A 
sufficient amount of water is introduced to the reaction by the isoprene or Bi(OTf)3 
to liberate enough TfOH to catalyse the reaction. The reaction has also been 
performed using non-anhydrous toluene without drying the glassware and the mono-
product 256 was isolated in 68 % yield, with 10 % of the starting material being 
reclaimed (Entry 4). For consistency of results, the solvent and glassware was dried 
before being used in subsequent reactions. 
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The amount of isoprene required for complete conversion of the starting 
material, with minimum bis-prenylation was also assessed (Table 11). It was found 
that 1.1 eq. and 1.5 eq. of isoprene were not sufficient to provide full consumption of 
the starting material (Entries 1 and 2). The best results were obtained using 2 eq. of 
isoprene (Entry 3), where all the starting material 255 was consumed, but with only a 
20 % yield of the bis-product 254. Increasing the amount of isoprene to 3 eq. lead to 
an increased yield of the bis-product (Entry 4).  
 
Table 11: Determining the optimal amount of isoprene needed for prenylation 
Entry 
Equivalents 
isoprene 
Time 
(hrs) 
Yield Starting 
Material 
255 (%) 
Yield Mono-
Product 256 
(%) 
Yield Bis-
Product 
257 (%) 
1 1.1 2 22 50 7 
2 1.5 1.5 8 65 2 
3 2 1.25 0 62 20 
4 3 1.25 0 41 36 
 
 
4.3. SCOPE AND LIMITATIONS 
4.3.1. Prenylation of Electron-Rich Aryl Ethers 
The optimal reaction conditions for the prenylation of trimethoxybenzene 
were found to be 2 eq. of isoprene, 10 mol % Bi(OTf)3, in anhydrous toluene at 40 
°C in a dried sealed tube under argon. These conditions were applied to a series of 
substrates to explore the scope and limitations of the reaction (Table 12).  
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Table 12: Prenylation of electron rich aromatic rings 
 
Starting 
material 
(S.M.) 
Product(s) 
Time 
(hrs) 
Yield 
Mono-
(%) 
Yield 
Bis-
(%) 
Yield 
S.M. 
(%) 
1 
 
 
1.25 62 20 - 
2 
  
7 44 - 50 
3 
 
Complicated mixture of  
products 
 - - - 
4 
 
Complicated mixture of  
products 
 - - - 
5 
  
6 15 - 85 
6 
 
 
1.5 58 30 - 
7 
  
6 47 - - 
8 
  
6 64 - - 
9 
  
6 17 - 57 
10 
  
5 <34
a
 - 56 
11 
  
6 - - 52 
12 Indole  24 - - 47 
13 N-Methylindole  24 - - 49 
14 
  
6 ~31
b
  ~31
b
 
a: The product was synthesised but contained 33 % starting material by 
1
H NMR analysis which could 
not be removed by column chromatography. b: Obtained as an inseparable mixture by column 
chromatography in a 1:1 ratio by 
1
H NMR analysis. 
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Several trends can be observed in Table 12. Firstly, the more electron 
donating groups are on the aryl ring, the more efficiently the reaction proceeds; so 
trimethoxy is better than dimethoxy which is better than monomethoxy. This can be 
seen when comparing the propionic esters, (Entries 6, 8 and 10) where the yield is 
significantly reduced when there are fewer methoxy- groups.  Secondly, other 
functional groups on the aryl ring can have a dramatic effect on reactivity. The 
reactivity of the nucleophilic carbon in the aromatic ring can be gauged by 
examining the chemical shift of the attached proton in the 
1
H NMR spectrum. 
Increasing electron density makes a proton more shielded, reducing its chemical 
shift. So it follows that the more reactive aryl rings will have protons at a reduced 
chemical shift (Figure 41).  
 
 
Figure 41: Selected 
1
H NMR shifts in CDCl3 of protons (ppm) on the electron-rich aromatic 
rings and the yields of mono-(and bis) products 
 
Trimethoxybenzene 255 (Table 12, entry 1), the bromo-analogue 258 (Entry 
2), the propionic ester 264 (Entry 6) and the cinnamic ester 253 (Entry 7) have 
chemical shifts lower than 7.00 ppm and were all prenylated with modest to good 
yields, with the bis-prenylated product also being observed in some reactions. The 
alkyl group of the cinammic ester 253 is slightly electron donating, but the aryl ring 
is in conjugation with the electron withdrawing ester group giving an overall 
reduction in electron density and reducing the reactivity of the ring as shown by the 
 103 
 
increased chemical shift of 6.74 ppm. This has been translated in the low yield of 47 
% and absence of any bis-product (Table 12, entry 7). The bromobenzene 258 was 
prenylated in only modest yield of 44 % and this may also be due to steric effects of 
the bulky bromide group (Table 12, entry 2). 
 
Electron-poor aryl rings, where a carbonyl is in direct conjugation with the 
aromatic ring gave either, in the case of ester 262, poor yields of product (Table 12, 
entry 5), or complicated mixtures which could not be separated by column 
chromatography (Entries 3 and 4). This follows the pattern in the chemical shift of 
the aryl protons, which is >7.00 in the three compounds. Despite having the highest 
chemical shift, the ester gave the best yield of prenylated product 263, whereas 
prenylated product was not isolated from the reactions with the aldehyde 260 or 
ketone 261. This may be due to the difference in reactivity in the carbonyl groups, 
resulting in side reactions giving complicated mixtures of products. One possible 
route for these side reactions is the formation of a stabilised benzylic cation resulting 
from the protonation of the carbonyl by the strong triflic acid. This would also put a 
positive charge adjacent to the ring, removing the electron density needed to perform 
the prenylation.  
To avoid this, the acetophenone 261 was protected as the acetal 277, which 
was then subjected to the prenylation conditions (Scheme 89). Bi(OTf)3 in refluxing 
THF/H2O has been described for the deprotection of acetals,
216
 however it was 
anticipated that under the anhydrous acidic conditions, the prenylation would occur 
swiftly, as was observed with trimethoxybenzene and that deprotection of the acetal 
would occur slowly, so the prenylated product 278 could be accessed. Following a 
procedure reported by Kong et al.,
217
 the acetal 277 was isolated in a poor 28 % 
yield. When the acetal was submitted to the optimised conditions, the only product 
observed was the trimethoxyacetophenone 259. Investigations in this transformation 
are currently being investigated as the products would be useful starting materials in 
the syntheses of other medicinally interesting compounds, such as chalones.
218
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Scheme 89: Synthesis of acetal protected acetophenone 259 and subsequent attempted 
prenylation 
 
Indole and N-methylindole were also investigated as possible electron-rich 
aromatics for the reaction; however neither of the substrates underwent prenylation. 
This is despite the compounds containing protons that had chemical shifts of less 
than 7.00 ppm in the 
1
H NMR spectrum. The nitrogen atom in indole is not basic, so 
the lack of reaction is not due to quenching of the triflic acid as was seen with 
DTBMP in the optimisation reactions. There was some success when the prenylation 
of furan 275 was investigated, however the product 276 could not be isolated from 
the starting material, so an accurate yield and characterization could not be obtained. 
As the furan ring contains a pendant ester group, it is thought the prenylation can be 
performed in higher yields on more electron-rich furan rings. Further investigations 
are ongoing to optimise the prenylation of heteroaromatic rings. 
 
4.3.2. Synthesis of Chromans from Phenols 
When phenols were examined as electron rich aromatic rings, the product 
observed in the reactions was a chroman, formed by the cyclisation of the prenylated 
phenol. As previously discussed, this motif is very common in natural products and 
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biologically active compounds, so the transformation was explored with a few 
examples (Table 13).  
 
Table 13: Synthesis of chromans from phenols 
 
Starting 
Material 
(S.M.) 
Product(s) 
Time 
(hrs) 
Yield 
products 
(%) 
Yield 
SM 
(%) 
1 
 
 
5 
18 
24
a
 
38, 14 
55, 26 
53, 22 
- 
2 
  
2 - - 
3 
  
5 
18 
26 
58 
55 
22 
4 
 
 
8 10, 24, 13  
5 
  
5 65 11 
6 
  
24 3 92 
7 
  
5 0 77 
a: Reaction included an aqueous work-up as part of the purification 
 
When trimethoxyphenol 279 was subjected to the reaction conditions for 5 
hrs, two products were isolated; the chroman 280 in 38 % yield and the prenylated 
product 281 resulting from a reaction at the 4-position of the phenol in 14 % yield 
(Table 13, entry 1). Ketones of similar structure to 281 have been reported 
previously by Yang et al., so are known to exist in very electron rich systems.
219
 
Further investigation found that increasing the reaction time greatly increased the 
yields of both products to 55 % and 26 % respectively after 18 hrs. The addition of a 
basic work-up to remove the Bi(OTf)3 and break up any complexes formed had no 
effect on the yield, compared to when the reaction mixture was purified directly by 
column chromatography. Monomethoxyphenol 282 was also investigated as a 
substrate and the reaction appeared to have worked by 
1
H NMR analysis; however 
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the low polarity of the product meant that it could not be separated from its 
contaminants by column chromatography (Table 13, entry 2). 
In contrast to the reactions with the benzaldehyde 258 and acetophenone 259, 
reactions with phenols containing a ketone or an ester group gave the desired 
chromans in good yields. When the conditions were applied to 4-
hydroxyacetophenone 284 for 5 hrs, the corresponding chroman 285 was isolated in 
26 % yield, with a 55 % return of unreacted starting material and degradation 
products were not observed. In a similar fashion to the reaction with 
trimethoxyphenol, the yield increased considerably to 58 % when the reaction time 
was increased to 18 hrs. The resorcinol motif is very common in natural products 
and the prenyl and chroman derivatives are also seen in nature, so acetophenone 286 
was subjected to the reaction conditions. After 5 hrs, three chroman products 287, 
288 and 289 were isolated in 10, 24 and 13 % yields respectively. It was thought that 
the yields could be improved by increasing the reaction time, but due to the poor 
regioselectivity of the reaction this was not carried out. The methyl 4-
hydroxybenzoate 290 was identified as a possible substrate and this performed very 
well in the reaction with a 65 % yield of chroman 291 after 5 hrs. These results can 
also be related to the chemical shifts of the protons on the reacting carbon atoms in 
the 
1
H NMR spectra, which are now much lower than in the trimethoxybenzene 
compounds due to the electron-donating properties of the phenol, showing that the 
aryl ring is much more reactive (Figure 42).   
 
 
Figure 42: 
1
H NMR shifts in CDCl3 of protons on the reactive carbons on the phenol ring 
 
4-Hydroxybenzoic acid 292 was also subjected to the reaction conditions as 
the corresponding chroman has shown to be a potential anti-sickling agent.
220
 
However, the chroman 293 was prepared in only 3 % after 24 hrs. This could be due 
to possible coordination of the bismuth to the carboxylic acid, removing more 
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electron density rendering the aromatic ring less reactive. Electronically, aniline is 
very similar to phenol, with lone pairs of electrons available for donation into the 
aromatic ring, so methyl 4-aminobenzoate 294 was subjected to the reaction 
conditions. The product 295 was not observed and 77 % of the unreacted starting 
material was recovered. The exact reason for its lack of activity is still unknown; 
however with a pKa of approximately 5, similar to that of DTBMP which also has a 
pKa of approximately 5, it could be forming a salt with the triflic acid, preventing it 
from acting as a catalyst.  
 
1.4. APPLICATION TO THE SYNTHESIS OF A 
NATURAL PRODUCT 
The isolation of 2-(3-methyl-2-butenyl)-3,4,5-trimethoxyphenol 296 from 
Piper clarkia was reported in 1994 by Olsen et al.,
221
 It has been synthesised 
previously in one-step from trimethoxyphenol 279 and 2-methylbut-3-en-2-ol in 
24% yield and its structure was confirmed by X-ray crystallography by Parmar et al.
 
222 
It has been shown to possess anti-invasive activity against human breast 
carcinoma cells.
223
 
 
 
Scheme 90: Current synthesis of 2-prenyltrimethoxyphenol 296
222
 
 
This was an ideal substrate to synthesis using the new methodology access 
the compound in an improved yield. However as shown in Table 13, prenylation of 
trimethoxyphenol affords the chroman 280 so a protection strategy was investigated. 
Acetylation of a phenol in the presence of Bi(OTf)3 has been reported by 
Mohammedpoor-Baltork.
224
 Combining this methodology with our optimised 
prenylation conditions would provide a one-pot protection and prenylation 
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procedure. Deprotection could be achieved using the standard conditions potassium 
carbonate in methanol.
225
  
Initially, the reaction sequence was attempted as a one-pot procedure 
(Scheme 91). The phenol 279 was stirred in toluene with acetic anhydride and 
Bi(OTf)3 for 15 mins to give the protected phenol. Isoprene was then added to the 
reaction to perform the prenylation. After 4 hrs the solvent was removed and K2CO3 
and MeOH were added to give the prenylated phenol. The product 296 was isolated 
from the reaction, in less than 44 % yield as there were minor impurities which could 
not be removed by column chromatography. The product of a Fries rearrangement 
297 was also isolated in 9 % yield. The catalysis of the Fries rearrangement by 
Bi(OTf)3 in refluxing toluene has been reported, with reaction times of 1-3 hrs.
226
  
 
 
Scheme 91: Synthesis of 296 in a one-pot procedure 
 
The synthesis was then performed in two steps, isolating and purifying the 
protected and prenylated phenol 298 before its deprotection (Scheme 92). When the 
prenylation was left for 4 hrs, the products were observed, but could not be purified 
sufficiently by column chromatography to obtain accurate yields. However, when the 
reaction time was reduced to 1 hr, the mono- and bis-prenylated acetates 298 and 
299 were isolated in 70 % and 15 % yields respectively. Two strategies were 
examined for the deprotection of the phenol. Using K2CO3 in MeOH as described by 
Bates
225
 gave the mono-product 296 in 49 % yield and the bis-product 300 in 32 % 
yield. Narendar et al.
227
 describe the use of NaOAc in EtOH/H2O for the cleavage of 
aryl acetates in high yields in the presence of a prenyl group, so this methodology 
was applied to the deprotection of the monoprenylated acetate 298. However, the 
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desired phenol 296 was isolated in only 36 % after 5 hrs. In contrast to the reaction 
using K2CO3, 39 % of the starting material was also recovered.  
 
Scheme 92: Stepwise protection/prenylation and deprotection of trimethoxyphenol 
 
The mono-prenylated phenol 296 was obtained in an overall yield of 34 % 
from 3,4,5-trimethoxyphenol, higher than the 24 % reported in the reported one-step 
procedure and the spectroscopic data was consistent with that reported by Olsen et 
al.
221
 
4.4. CONCLUSIONS AND FUTURE WORK 
A mild procedure has been discovered and developed using bismuth (III) 
triflate as a catalyst for the prenylation of electron-rich aromatic rings and the 
synthesis of chromans from phenols. This procedure has been applied to the 
synthesis of the natural product 2-(3-methyl-2-butenyl)-3,4,5-trimethoxyphenol 296 
in 34 % yield over 2 steps.  
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Further investigations are required to establish why the prenylation of 
benzaldehydes and acetophenones was not successful and then a solution can be 
developed. Compounds containing a carbonyl group that is not in conjugation with 
the aryl ring should be explored as this may establish whether it is the carbonyl 
group or its conjugation that prevents the reaction from proceeding. 
The methodology could also be extended to the prenylation of heterocycles, 
although investigations and further optimisation will be required for this to establish 
why the reactions with indole were unsuccessful.  
The procedure could also be applied to the synthesis of chroman natural 
products, such as the dorsmanins 248 and 249. 
As there is evidence that prenylation can increase the activity of a compound, 
the procedure could also be used to obtain prenylated narciclasine analogues and 
evaluate their biological activity.  
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5. EXPERIMENTAL 
GENERAL EXPERIMENTAL  
 
Chemicals, solvents and reagents used are commercially available and were 
used without further purification. Anhydrous solvents were used where indicated.  
Glassware for dry reactions was dried either by heating in an oven at 120 °C 
for at least 1hr, or heating with a hot air gun for 5 mins. The glassware was then 
allowed to cool under a stream of N2. 
TLC’s were carried out on Merck Aluminium backed TLC plates Silica Gel 
60 F254  and viewed using UV light of wavelength 254 nm and then stained with 
potassium permanganate. Merck Silica Gel (0.040-0.063 mm) was used for column 
chromatography.  Compounds were loaded as an oil, CH2Cl2 solution or dry loaded 
by adsorption onto silica.  
Melting points were obtained using a Reichert-Jung heated-stage microscope. 
Infrared spectra were recorded on a Perkin-Elmer Spectrum RXI FT-IR system and 
all values are recorded in cm
−1
. 
1
H NMR spectra were obtained on JEOL Eclipse (270 MHz), Varian 
Mercury VX (400 MHz), Bruker Avance III (400 MHz) or Bruker Avance III (500 
MHz) spectrometers. 
13
C NMR spectra were obtained on JEOL Eclipse (67.9 MHz), 
Varian Mercury VX (100 MHz) Bruker Avance III (100 MHz) or Bruker Avance III 
(125 MHz) spectrometers. The chemical shifts are recorded in parts per million 
(ppm) with reference to tetramethylsilane. The coupling constants J are quoted to the 
nearest 0.5 Hz are not rationalised. The multiplicities are assigned as a singlet (s), 
doublet (d), triplet (t), quartet (q), doublet of doublets (dd), doublet of doublet of 
doublets (ddd), doublet of triplets (dt), triplet of doublets (td) and multiplet (m). 
Pendant NMR data is given after the 
13
C NMR chemical shifts as +ve (CH and CH3) 
and –ve (C and CH2). 
Mass spectra and high resolution mass spectra were obtained on a 
micrOTOF
TM
 from Bruker Daltonics (Bremen, Germany). This is a Time-of-Flight 
mass spectrometer coupled with an electrospray source (ESI-TOF). This instrument 
can be used to measure accurate mass to 5 ppm externally calibrated and 2 ppm 
internally calibrated. Samples are introduced either by syringe pump or flow 
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injection using an autosampler in an Agilent 1100 LC system. The instrument is 
calibrated using a sodium formate solution, which is applicable to both positive and 
negative ionisation mode. These samples were analysed under standard conditions 
for small molecules in positive electrospray ionisation mode. The instrument 
acquires both accurate mass and true isotope patterns, therefore both of these 
dimensions of information are used to help determine or confirm the molecular 
formula. Ions are most often present as protonated or sodiated molecules. Data was 
processed using external calibration with the Bruker Daltonics software, 
DataAnalysis
TM
 as part of the overall hardware control software, Compass 1.1
TM
. 
Analytical RP-HPLC was performed using a Waters 2695 Alliance module 
equipped with a Waters 2996 photodiode array detector (210-350 nm). The 
chromatographic system consisted of a Hichrom Guard column for HPLC and a 
Phenomenex Synergi 4 µm Max-RP19 column (150 x 4.60 mm), using a gradient of 
5 to 65 % 0.1 % TFA in CH3CN in 0.1 % TFA in MilliQ over 15 mins. 
X-ray Crystallography: Single crystals were analysed at 150(2) K using 
graphite monochromated Mo(Kα) radiation and a Nonius Kappa CCD 
diffractometer.  The structures were solved using SHELXS-97 and refined using 
SHELXL-97. 
 
5.1. MTS CELL PROLIFERATION ASSAY PROTOCOL 
This assay uses a 96 well plate format to determine cell viability and is based 
on the Promega Cell Titer 96 Aqueous One Solution Cell Proliferation Assay. Seed 
densities of 500 cells per well were used and final drug concentrations of 500 µM, 
200 µM, 100 µM, 50 µM, 20 µM, 10 µM, 5 µM, 2 µM, 1 µM and 500 nM in 1% 
DMSO. Drugs were incubated with the HT29 cell line for 72 days prior to reading 
and IC50 curves were generated using SigmaPlot 8 software. Each IC50 value is the 
average of at least two independent experiments conducted on separate days. 
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5.2. SYNTHESIS OF AB-RING ANALOGUES 
5.2.1. Synthesis of AB-ring Analogues using the Curtius Rearrangement 
General Procedure 1: Preparation and cyclisation of the isocyanate. 
Method A: Following the procedure reported by Kimoto et al.,
53
 a solution 
of ethyl chloroformate (475 μL, 5 mmol) in acetone (1.5 mL) was added to a stirred 
solution of acid (5 mmol) and Et3N (695 μL, 5 mmol) in acetone/H2O (7.5 mL, 5:1) 
at 0 °C  open to air and allowed to warm to r.t.. After 1 hr, a solution of NaN3 (487 
mg, 7.5 mmol) in water (1.5 mL) was added in one portion and the reaction stirred 
for a further 30 mins. Upon dilution with toluene/H2O (21.8 mL, 4:3) the organic 
fraction was separated, washed with water, dried with anhydrous MgSO4 and filtered 
into a dry flask under N2. The vigorously stirred solution was heated at 90 °C for 45 
mins. The solvent was removed in vacuo the oil was cooled to 0 °C under N2 and 
BF3·OEt2 (2.5 mL) added. The reaction allowed to warm to r.t. and was stirred for 18 
hrs, then quenched with saturated aqueous NaHCO3 (25 mL) and extracted with 
EtOAc (2 x 25 mL). The combined organic fractions were washed with brine, dried 
over anhydrous MgSO4, filtered and the solvent removed in vacuo. After column 
chromatography [silica, PE-EtOAc-methanol] the product was isolated 
 
Method B: Following the procedure reported by Kimoto et al.,
53
 a solution 
of ethyl chloroformate (475 μL, 5 mmol) in acetone (1.5 mL) was added to a stirred 
solution of acid (5 mmol) and Et3N (695 μL, 5 mmol) in acetone/H2O (7.5 mL, 5:1) 
at 0 °C  open to air and allowed to warm to r.t.. After 1 hr, a solution of NaN3 (487 
mg, 7.5 mmol) in water (1.5 mL) was added in one portion and the reaction stirred 
for a further 30 mins. Upon dilution with toluene/H2O (21.8 mL, 4:3) the organic 
fraction was separated, washed with water, dried with anhydrous MgSO4 and filtered 
into a dry flask under N2. The vigorously stirred solution was heated at 90 °C for 45 
mins. The solution was then cooled to 0 °C and AlCl3 (2 g, 15 mmol) added. The 
reaction was allowed to warm to r.t. and was stirred for 18 hrs, then quenched with 
saturated aqueous NaHCO3. The white solid was removed by filtration through celite 
and washed thoroughly with EtOAc.  The aqueous layer was further extracted with 
EtOAc (20 mL). All the organic fractions were combined, washed with brine, dried 
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over anhydrous MgSO4, filtered and the solvent removed in vacuo. After column 
chromatography [silica, PE-EtOAc] the product was isolated. 
 
Method C: Diphenylphosphoryl azide (1.12 mL, 5 mmol) was added to a 
stirred solution of arylpropionic acid (5 mmol) and anhydrous Et3N (695 μL, 5 
mmol) in anhydrous toluene (15 mL) under N2 at r.t. then the reaction heated at 90 
°C  for 90 mins. On cooling the solvent was removed and the flask cooled to 0 °C 
under N2. BF3·OEt2 (2.5 mL) was added then the reaction was allowed to warm to 
r.t. and stirred for 16 hrs. The reaction was quenched to pH 10 with 2M NaOH and 
diluted with EtOAc (20 mL), then heated at 50 °C for 1 hr. After cooling to r.t. the 
phases were separated and the aqueous fraction extracted with EtOAc (2 x 20 mL). 
The combined organic fractions were washed with brine, dried over anhydrous 
Na2SO4, filtered and the solvent removed in vacuo. After column chromatography 
[silica, PE-EtOAc] the product was isolated. 
 
 
3,4-Dihydroisoquinolin-1(2H)-one (139) 
 
 
 
Following general procedure 1C, performing the cyclisation step at 80 °C, 
dihydrocinnamic acid 134 (750 mg, 5 mmol) gave dihydroisoquinolinone 139 (52 
mg, 5 %) as an amorphous solid.  
Rf [PE-EtOAc 20:80] 0.20; 
1
H NMR δH(400 MHz, CD3OD) 7.94 (1H, d, J 
8.0 Hz, C(8)H), 7.47 (1H, dd, J 8.0 and 8.0 Hz, C(6)H), 7.33 (1H, dd, J 8.0 and 8.0 
Hz, C(7)H), 7.26 (1H, d, J 8.0 Hz, C(5)H), 3.48 (2H, t, J 6.5 Hz, C(3)H2) and 2.96 
(2H, t, J 6.5 Hz, C(4)H2); 
13
C NMR δC(100 MHz, CD3OD) 168.3− (C1=O), 140.9− 
(C8a), 133.5+ (C6), 129.8− (C4a), 128.6+ (C5 or C8), 128.4+ (C5 or C8), 128.0+ 
(C7), 40.8− (C3) and 28.9− (C4); MS (+ESI) m/z 192 (M+H+, 22 %), 214 (M+Na+, 
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78) and 405 (2M+Na
+
, 100); HRMS (+ESI) Found M+Na
+
, 214.0476; C10H9NO3Na 
requires M+Na
+
 214.0480. 
Spectroscopic data is consistent with that reported by Winter et al.
228
 
 
 
3-Methyl-3-phenylbutanoic acid (141) 
 
 
 
Following the procedure reported by Andersen et al.,
229
 AlCl3 (1.20 g, 9 
mmol) was added to a stirring solution of 3-methylbut-2-enoic acid 140 (292 mg, 2.9 
mmol) under N2 and the reaction heated at 65 °C for 90 mins. The reaction mixture 
was acidified to pH 1 with conc. HCl and then extracted with EtOAc (3 x 25 mL). 
The combined organic fractions were extracted with saturated aqueous NaHCO3 (6 x 
30 mL), then the combined basic fractions were acidified to pH 1 with conc. HCl and 
extracted with EtOAc (5 x 50 mL). The combined organic fractions were dried over 
anhydrous Mg2SO4, filtered and the solvent removed in vacuo give the product 141 
(515 mg, 99 %) as a white solid without further purification. 
1
H NMR δH(270 MHz, CDCl3) 7.38-7.17 (5H, m, C(Ph)H), 2.65 (2H, s, 
C(2)H2) and 1.47 (6H, s, CH3). 
Spectroscopic data is consistent with that reported by Andersen et al.
229
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4,4-Dimethyl-3,4-dihydro-2H-isoquinolin-1-one (142) 
 
 
 
Following general procedure 1A, propanoic acid 141 (483 mg, 2.7 mmol) 
gave lactam 142 (37 mg, 8 %) as an amorphous solid. 
Rf [EtOAc] 0.41; IR νmax(thin film) 3322 (NH), 2968, 2931, 2874 (CH), 1701 
(C=O), 1530 (Ph) and 1221(CO); 
1
H NMR δH(400 MHz, CDCl3) 8.05 (1H, dd, J 8.0 
and 1.5 Hz, C(8)H); 7.49 (1H, ddd, J 8.0, 8.0 and 1.3 Hz, C(6)H); 7.36-7.29 (2H, m, 
C(5)H and C(7)H); 6.62 (1H, broad s, N(2)H); 3.30 (2H, d, J 2.7 Hz, C(3)H2) and 
1.34 (6H, s, C(4)(CH3)2); 
13
C NMR δC(100 MHz, CDCl3) 166.2− (C1=O), 147.4− 
(C8a), 132.6+ (C6); 128.2+ (C8), 127.4− (C4a), 126.6+ (C5 or C7), 123.7+ (C5 or 
C7), 52.3− (C3), 34.2− (C4) and 26.6+ (CH3); MS (+ESI) m/z 198 (M+Na
+
, 58 %) 
and 373 (2M+Na
+
, 100 %); HRMS (+ESI) Found M+Na
+
, 198.0884; C11H13NONa 
requires M+Na
+
 198.0895. 
Spectroscopic data is consistent with that reported by Ben-Ishai et al.
230
 
 
 
3-(3,4-Methylenedioxyphenyl)propionic acid (143) 
 
 
 
10 % palladium on carbon (208 mg, 0.2 mmol) was added to a vigorously 
stirred mixture of 3,4-methylenedioxycinnamic acid (2 g, 10.4 mmol) in EtOH (50 
mL). After 3 cycles of purging the flask with N2 then a vacuum, the flask was put 
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under an atmosphere of H2. After 2 hrs, the mixture was filtered through celite, 
washing thoroughly with EtOH, then the solvent removed in vacuo to afford the 
propionic acid 143 (1.97 g, 98 %) as a white solid without further purification. 
1
H NMR δH(400 MHz, CDCl3) 8.60 (1H, broad s, OH), 6.74-6.64 (3H, m, 
C(Ar)H), 5.92 (2H, s, OCH2O), 2.87 (2H, t, J 8.0 Hz, C(3)H2) and 2.63 (2H, t, J 8.0 
Hz, C(2)H2); 
13
C NMR δC(100 MHz, CDCl3) 178.6, 147,7, 146.0, 134.0, 121.1, 
108.8, 108.3, 100.9, 35.9 and 30.4. 
Spectroscopic data is consistent with that reported by Haga et al.
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7,8-Dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolin-5-one (144) 
 
 
 
Propionic acid 143 (970 mg, 5 mmol) gave, following general procedure 1A 
lactam 144 (598 mg, 63 %); and following general procedure 1C gave lactam 144 
(772 mg, 81 %) as a white solid. 
Rf [PE-EtOAc 20:80] 0.20; Mp 185-187 °C (from EtOAc); lit.,
232
 187-187.5 
°C (from PhH); IR νmax(KBr disc) 3456 (NH), 3188, 3046, 2900 (CH), 1657 (C=O), 
1610, 1479 (Ph), 1260 (CO) and 1038; 
1
H NMR δH(400 MHz, CDCl3) 7.52 (1H, s, 
C(8)H), 6.93 (1H, broad s, NH), 6.67 (1H, s, C(5)H), 6.02 (2H, s, OCH2O), 3.55 
(2H, t, J 6.5 Hz, C(3)H2) and 2.91 (2H, t, J 6.5 Hz, C(4)H2); 
13
C NMR δC(100 MHz, 
CDCl3) 166.2− (C1=O), 150.7− (C7-O), 146.8− (C6-O), 134.5− (C8a), 122.8− 
(C4a), 107.8+ (C8), 107.2+ (C5), 101.4− (OCH2O), 40.1− (C3) and 28.4− (C4); MS 
(+ESI) m/z 192 (M+H
+
, 22 %), 214 (M+Na
+
, 78) and 405 (2M+Na
+
, 100); HRMS 
(+ESI) Found M+Na
+
, 214.0476; C10H9NO3Na requires M+Na
+
 214.0480; HPLC tR 
9.5 (100 %). 
Spectroscopic data is consistent with that reported by Hanaoka et al.
232
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6,7-Dimethoxy-3,4-dihydroisoquinolin-1(2H)-one (147) 
 
 
 
Following general procedure 1C, performing the cyclisation step at 50 °C, 
propionic acid 146 (1.05g, 5 mmol) gave lactam 147 (784 mg, 76 %) as a white 
solid.  
Rf [EtOAc] 0.11; Mp 174-177 °C (from EtOAc); lit.,
233
 173 °C (from 
PhH/Et2O); IR νmax(KBr disc) 3187, 3044, 2863 (CH), 1656 (C=O), 1603, 1510, 
1481 (Ph), 1271 (CO) and 1050; 
1
H NMR δH(400 MHz, CDCl3) 7.56 (1H, s, 
C(8)H), 6.66 (1H, s, C(5)H), 6.36 (1H, broad s, NH), 3.91 (3H, s, OCH3), 3.91 (3H, 
s, OCH3), 3.54 (2H, td, J 6.5 and 3.0 Hz, C(3)H2) and 2.91 (2H, t, J 6.5 Hz, C(4)H2); 
13
C NMR δC(100 MHz, CDCl3) 166.4− (C1=O), 152.1− (C7-O), 148.0− (C6-O), 
134.5− (C8a), 122.8− (C4a), 110.1+ (C8), 109.5+ (C5), 56.0+ (OCH3), 56.0+ 
(OCH3), 40.4− (C3) and 28.0− (C4); MS (+ESI) m/z 208 (M+H
+
, 35 %), 230 
(M+Na
+
, 33) and 437 (2M+Na
+
, 100); HRMS (+ESI) Found M+Na
+
, 230.0767; 
C11H13NO3Na requires M+Na
+
 230.0787; HPLC tR 8.6 (100 %). 
Spectroscopic data is consistent with that reported by Zhu et al.
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8-(Difluoroboryloxy)-6,7-dimethoxy-3,4-dihydroisoquinolin-(2H)-one 
(148) 
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Diphenylphosphoryl azide (5.6 mL, 25 mmol) was added to a stirred solution 
of arylpropionic acid (6.0 g, 25 mmol) and anhydrous Et3N (3.5 mL, 25 mmol) in 
anhydrous toluene (75 mL) under N2 at r.t. then the reaction heated at 90 °C  for 1 hr. 
After cooling to r.t., the solvent was removed and the flask cooled to 0 °C under N2. 
BF3·OEt2 (4 mL) was added then the reaction was allowed to warm to r.t. and stirred 
for 16 hrs. The reaction mixture was diluted with THF-Et2O (1:1, 100 mL) and the 
crude solid product removed by filtration. After recrystallisation from EtOAc, the 
product (4.2 g, 63 %) was isolated as a white solid. 
Mp 237-239 °C (from EtOAc); IR νmax(KBr disc) 3326, 3303 (NH), 3027, 
2986, 2830, 1656, 1609, 1540, 1489, 1438, 1242, 1132, 1022 and 758; 
1
H NMR 
δH(400 MHz, d6-DMSO) 10.37 (1H, s, NH), 6.68 (1H, s, C(5)H), 3.87 (3H, s, 
OCH3), 3.68 (3H, s, OCH3), 3.59 (2H, t, J 7.5 Hz, C(3)H2) and 2.95 (2H, t, J 7.5 Hz, 
C(4)H2); 
13
C NMR δC(100 MHz, d6-DMSO) 165.7− (C1=O), 159.7− (C6-O or C7-
O), 152.6− (C8), 135.2− (C8a), 134.9− (C6-O or C7-O), 103.9+ (C5-H), 101.0− 
(C4a), 60.1+ (OCH3), 56.3+ (OCH3), 39.1− (C3) and 25.1− (C4); 
19
F NMR δF(376 
MHz, d6-DMSO) −144.24, −144.30; 
11
B NMR δB(128 MHz, d6-DMSO) 1.76; MS 
(+ESI) m/z 294 (M+Na
+
, 80 %) and 565 (2M+Na
+
, 60); HRMS (+ESI) Found 
M+Na
+
, 294.0726; C11H12NO4BF2Na requires M+Na
+
 294.0720. 
 
 
6,7-Dimethoxy-8-hydroxy-3,4-dihydro-2H-isoquinolin-1-one (151) 
 
 
 
Method A: Following general procedure 1C, propionic acid 149 (1.20 g, 5 
mmol) gave isoquinolinone 151 (818 mg, 73 %) and propionic acid 149 (5.95 g, 25 
mmol) gave isoquinolinone 151 (2.91 g, 52 %) as a white solid. 
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Method B: Isoquinolinone 148 (1.35 g, 5 mmol) in 2M NaOH (20 mL) and 
EtOAc (20 mL) was heated at 50 °C for 2 hrs. After cooling to r.t. the phases were 
separated and the aqueous fraction extracted with EtOAc (3 x 20 mL). The combined 
organic fractions were washed with brine, dried over anhydrous Na2SO4, filtered and 
the solvent removed in vacuo to give the isoquinolinone 151 (1.03 g, 92 %) as a 
white solid. 
Rf [EtOAc] 0.46; Mp 181-183 °C (from EtOAc); lit.,
235
 181 °C (from 
MeOH); IR νmax (KBr disc) 3481 (NH or OH), 3328 (NH or OH), 3005, 2936, 2853 
(C-H), 1649 (C=O and Ph), 1617, 1578, 1441 (Ph), 1301, 1127, 1016 (C-O) and 824; 
1
H NMR δH(400 MHz, CDCl3) 7.26 (1H, s, OH), 6.26 (1H, s, C(5)H), 6.02 (1H, 
broad s, NH), 3.89 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.54 (2H, td, J 6.5 and 2.5 
Hz, C(3)H2) and 2.92 (2H, t, J 6.5 Hz, C(4)H2); 
13
C NMR δC(100 MHz, CDCl3) 
170.4− (C1=O), 156.9− (C6 or C7), 155.9− (C8), 135.9− (C6 or C7), 135.2− (C8a), 
105.8− (C4a), 101.8+ (C5), 60.7+ (OCH3), 56.0+ (OCH3), 40.3− (C3) and 28.1− 
(C4); MS (+ESI) m/z 246 (M+Na
+
, 100 %) and 469 (2M+Na
+
, 44); HRMS (+ESI) 
Found M+Na
+
, 246.0724; C11H13NO4Na requires M+Na
+
 246.0742; HPLC tR 10.4 
(100 %). 
 
 
2,3,4,9-Tetrahydro-β-carbolin-1-one (153) 
 
 
 
Following general procedure 1A, propionic acid 152 (945 mg, 5 mmol) gave 
carbolinone 153 (684 mg, 74 %); following general procedure 1B, 152 (567 mg, 3 
mmol) gave 153 (374 mg, 67 %); and following general procedure 1C, 152 (945 mg, 
5 mmol) gave 153 (806 mg, 87 %) as a white solid. 
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Rf [EtOAc] 0.39; Mp 186-188 °C (from EtOAc); lit.,
236
 183-185 °C; IR 
νmax(KBr disc) 3212 (NH), 2935, 2871 (CH), 1664 (C=O), 1545, 1512, 1489, 1459, 
1416 (Ph and CH), 1327 and 1291 (CO and CN); 
1
H NMR δH(400 MHz, CDCl3) 
10.45 (1H, s, N(9)H), 7.58 (1H, d, J 7.5 Hz, C(5)H), 7.51 (1H, d, J 7.5 Hz, C(8)H), 
7.29 (1H, ddd, J 7.5, 7.5 and 1.0 Hz, C(7)H), 7.13 (1H, ddd, J 7.5, 7.5 and 1.0 Hz, 
C(6)H), 6.77 (1H, broad s, N(2)H), 3.72 (2H, t, J 7.0 Hz, C(3)H2) and 3.06 (2H, t, J 
7.0 Hz, C(4)H2); 
13
C NMR δC(100 MHz, CDCl3) 163.7− (C1=O), 137.6− (C8a), 
126.1− (C9a), 125.2+ (C7), 125.1− (C4b), 120.2+ (C5), 120.2+ (C6), 120.1− (C4a) 
112.7+ (C8), 42.1− (C3) and 20.8− (C4); MS (+ESI) m/z 209 (M+Na+, 61 %) and 
395 (2M+Na
+
, 100); HRMS (+ESI) Found M+Na
+
, 209.0681; C11H10N2ONa 
requires M+Na
+
 209.0691; HPLC tR 11.7 (97 %). 
Spectroscopic data is consistent with that reported by Luis et al.
237
 and 
Hamann et al.
238
 
 
 
3-(1’-Methyl-1H-indol-3’-yl)-propionic acid (159) 
 
 
 
Following the procedure reported by Compernolle,
104
 MeI (1.56 mL, 25 
mmol) was added to a rapidly stirred mixture of 3-indolepropionic acid 158 (946 mg, 
5 mmol) and KOH (1.7 g, 30 mmol), in acetone (50 mL). After 16 hrs at r.t. the 
solvent was removed in vacuo. The residue was dissolved in H2O (100 mL), KOH 
(1.4 g, 25 mmol) added and the solution stirred at reflux for 2.5 hrs. On cooling and 
acidifying to pH 2 with 6M HCl, the solid was filtered off, washed with H2O and 
dried to give product 159 (889 mg, 87 %) as a white solid without further 
purification 
IR νmax(KBr disc) 3446 (OH), 3055, 2912, 2705, 2611 (CH), 1710 (C=O), 
1473, 1424 (Ph), 1325, 1291 (CO) and 735 (CH); 
1
H NMR δH(400 MHz, CDCl3) 
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7.94 (1H, broad s, CO2H), 7.58 (1H, d, J 7.5 Hz, C(7’)H), 7.28 (1H, d, J 7.0 Hz, 
C(4’)H), 7.22 (1H, ddd, J 7.5, 7.5 and 1.1 Hz, C(6’)H), 7.10 (1H, ddd, J 7.0, 7.0 and 
1.0 Hz, C(5’)H), 6.87 (1H, s, C(2’)H), 3.73 (3H, s, NCH3), 3.10 (2H, t, J 7.5 Hz, 
C(3)H2) and 2.76 (2H, t, J 7.5 Hz, C(2)H2); 
13
C NMR δC(100 MHz, CDCl3) 178.5− 
(CO2H), 127.5− (C3’), 126.3+ (C2’), 122.1− (C3a’ or C7a’), 121.6+ (C6’), 118.8+ 
(C5’ or C7’), 118.7+ (C5’ or C7’), 113.1− (C3a’ or C7a’), 109.2+ (C4’), 34.7− (C3), 
32.6+ (NCH3) and 20.3− (C2); MS (+ESI) m/z 204 (M+H
+
, 88 %) and 226 (M+Na
+
, 
100); HRMS (+ESI) Found M+Na
+
, 226.0831; C12H13NO2Na requires M+Na
+
 
226.0844. 
 
 
9-Methyl-2,3,4,9-tetrahydro-β-carbolin-1-one (160) 
 
 
 
Method A: Following the procedure reported by Compernolle,
104
 MeI (1.8 
mL, 28 mmol) was added to a vigorously stirred mixture of KOH (1.9 g, 34 mmol) 
and 3-indolepropionic acid 158 (1.08 mg, 5.7 mmol) in acetone (60 mL). After 72 
hrs at r.t. the solvent was removed under reduced pressure. The residue was 
suspended in H2O (120 mL), KOH (1.6 g, 28 mmol) was added and the solution 
stirred at reflux for 2 hrs. After cooling to 0 °C, the solution was acidified to pH 2 
with 6M HCl and extracted with EtOAc (3 x 50 mL). The combined organic 
fractions were washed with brine, dried over Na2SO4, filtered and the solvent 
removed in vacuo to yield the crude intermediate acid 159 as a white solid. 
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Following the general procedure 1C, the crude carboxylic acid gave the lactam 160 
(0.994 g, 87 %) as a white solid. 
Method B: Following general procedure 1B, acid 159 (812 mg, 4 mmol) 
gave carbolinone 160 (385 mg, 45 %). 
Method C: MeI (311 µL, 5 mmol) was added to a vigorously stirred mixture 
of carbolinone 153 (180 mg, 0.697 mmol) and KOH (336 mg, 6 mmol) in acetone 
(10 mL) as r.t.. After 5 hrs, the reaction was quenched with 2M HCl (12 mL) and 
extracted with EtOAc (3 x 15 mL). The combined organic fractions were washed 
with brine, dried over Na2SO4, filtered and the solvent removed in vacuo.  Column 
chromatography [silica, PE-EtOAc gradient from 50:50 to 40:60] afforded gave the 
carbolinone 160 (134 mg, 69 %) as a white solid. 
Rf [PE-EtOAc 3:7] 0.37; Mp 160-162 °C (from EtOAc); lit.,
236
 157-158 °C; 
IR νmax(KBr disc) 3312 (NH), 2934, 2869 (CH), 1656 (C=O), 1489, 1467 (Ph), 1289 
(CN) and 732 (CH); 
1
H NMR δH(400 MHz, CDCl3) 7.59 (1H, d, J 8.0 Hz, C(5)H), 
7.38-7.33 (2H, m C(8)H and C(6)H), 7.15 (1H, dd, J 8.0 and 8.0 Hz, C(7)H), 5.70 
(1H, broad s, N(2)H), 4.11 (3H, s, N(9)CH3), 3.65 (2H, td, J 7.0 and 2.5 Hz, C3) and 
3.05 (2H, t, J 7.0 Hz, C4); 
13
C NMR δC(100 MHz, CDCl3) 163.3− (C=O), 139.0− 
(C8a), 125.8− (C9a), 124.9+ (C7), 124.1− (C4b), 120.3+ (C5), 120.0+ (C6), 119.8− 
(C4a), 110.2+ (C8), 41.9− (C3), 31.2+ (NCH3) and 21.1− (C4); MS (+ESI) 201 
(M+H
+
, 62 %) and 223 (M+Na
+
, 100); HRMS (+ESI) Found M+Na
+
, 223.0839; 
C12H12N2ONa requires M+Na
+
 223.0847; HPLC tR 12.1 (99 %). 
 
 
2,9-Dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-one (161) 
 
 
 
NaH (60 % dispersion in mineral oil) (100 mg, 2.5 mmol) was added to a 
vigorously stirred suspension of lactam 153 (180 mg, 0.97 mmol) in THF (3 mL) at 
0 °C under Ar. After 30 mins, MeI (155 μL, 2.5 mmol) was added and the reaction 
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stirred at r.t. for 18 hrs. The reaction was quenched with saturated aqueous NH4Cl 
(15 mL) and extracted with EtOAc (3 x 15 mL). The organic fractions were 
combined, washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and 
the solvent removed in vacuo. Column chromatography [silica, PE-EtOAc gradient 
from 70:30 to 50:50] afforded the dimethylcarbolinone 161 (113 mg, 54 %) as a 
cream solid. 
Mp 66-69 °C (Et2O); lit.,
236
 65-66 °C; IR νmax(Thin film) 2934, 1647 (C=O), 
1545, 1497, 1468, 1323, 1251, 1235 and 1074; 
1
H NMR δH(400 MHz, CDCl3) 7.49 
(1H, d, J 8.0 Hz, C(5)H), 7.29 (1H, d, J 8.0 Hz, C(8)H), 7.24 (1H, ddd, J 8.5, 7.5 and 
1.0 Hz, C(7)H), 7.06 (1H, ddd, J 8.0, 6.5 and 1.5 Hz, C(6)H), 4.04 (3H, s, N(9)CH3), 
3.58 (2H, t, J 7.0 Hz, C(3)H2), 3.05 (3H, s, N(2)CH3) and 2.97 (2H, t, J 7.0 Hz, 
C(4)H2); 
13
C NMR δC(100 MHz, CDCl3) 162.1− (C1=O), 139.0− (C8a), 126.4− 
(C9a), 124.4+ (C7), 124.0− (C4b), 120.0+ (C5), 119.9+ (C6), 118.2− (C4a), 110.1+ 
(C8), 49.9− (C3), 34.1+ (N(2)CH3), 31.17+ (N(9)CH3) and 20.6− (C4); MS (+ESI) 
m/z 215 (M+H
+
, 100 %) and 237 (M+Na
+
, 9); HRMS (+ESI) Found M+Na
+
, 
237.0956; C13H14N2ONa requires M+Na
+
 237.0998; HPLC tR 15.7 (92 %). 
 
 
3,4,5,10-Tetrahydro-2H-azepino[3,4-b]indol-1-one (163) 
 
 
 
Following general procedure 1B, butyric acid 162 (1.02 g, 5 mmol) gave 
azepinone 163 (140 mg, 14 %). Following general procedure 1C, performing the 
cyclisation step at r.t., butyric acid 162 (1.02 g, 5 mmol) gave the lactam 163 (406 
mg, 40 %); performing the cyclisation step at 50 °C 162 (1.02 g, 5 mmol) gave 
azepinone 163 (686 mg, 68 %) and performing the cyclisation at 80 °C 162 (395 mg, 
1.94 mmol) gave 163 (351 mg, 90 %) as a white solid. 
 125 
 
Rf [EtOAc] 0.42; Mp: 227-230 °C (from EtOAc); lit.,
239
 220 °C (from 
acetone); IR νmax(KBr disc) 3268 (NH), 2940, 2865 (CH), 1628 (C=O), 1545, 1481,  
1410 (Ph and CH), 1332 and 1296 (CO and CN); 
1
H NMR δH(400 MHz, CDCl3) 
9.30 (1H, broad s, N(10)H), 7.60 (1H, d, J 8.0 Hz, C(6)H), 7.41 (1H, d, J 8.0 Hz, 
C(9)H), 7.31 (1H, ddd, J 8.0, 7.0 and 1.0 Hz, C(8)H), 7.13 (1H, ddd, J 8.0, 7.0 and 
1.0 Hz, C(7)H), 6.53 (1 H, broad s, N(2)H), 3.50 (1 H, t, J 5.0 Hz, C(3)HAHB), 3.49 
(1 H, t, J 5.0 Hz, C(3)HAHB), 3.15 (2H, t, J 6.5 Hz, C(5)H2) and 2.23-2.17 (2 H, m, 
C(4)H2); 
13
C NMR δC(100 MHz, CDCl3) 165.5− (C1=O), 135.8− (C9a), 128.0− 
(C5b), 126.5− (C10a), 125.2+ (C8), 120.3+ (C6), 119.8+ (C7), 119.0− (C5a), 111.8+ 
(C9), 43.0− (C3), 26.7− (C4) and 25.8− (C5); MS (+ESI) m/z 201 (M+H+, 10 %), 
223 (M+Na
+
, 29) and 423 (2M+Na
+
, 100); HRMS (+ESI) Found M+Na
+
, 223.0848; 
C12H12N2ONa requires M+Na
+
 223.0847; HPLC tR 13.0 (100 %). 
Spectroscopic data is consistent with that reported by Thakur et al.
240
 
 
 
Methyl 4-(1’-Methyl-1H-indol-3’-yl)-butanoate (164) 
 
 
 
Following the procedure reported by Perregaard,
108
 t-BuOK (2.52 g, 22.5 
mmol) was added portionwise over 5 min to a stirred solution of indole-3-butyric 
acid 162 (1.52 g, 7.5 mmol) in anhydrous DMF (15 mL) under N2. The mixture was 
cooled to 0 °C and MeI (3.73 mL, 60 mmol) added slowly over 10 min. The reaction 
was allowed to warm to r.t. and stirred for 16 h. H2O (65 mL) was added, the layers 
separated and the aqueous fraction extracted with EtOAc (4 x 20 mL). The organic 
fractions were combined, washed with brine, dried over anhydrous Na2SO4, filtered 
and the solvent removed in vacuo. After column chromatography [silica, PE−EtOAc 
gradient from 100:0 to 0:100] the N-methyl ester 164 (1.27 g, 73%) was isolated as 
an oil. 
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Rf [PE-EtOAc, 70:30] 0.51; 
1
H NMR δH(400 MHz, CDCl3) 7.62 (1H, dd, J 
8.0 and 1.0 Hz, C(7’)H), 7.31 (1H, dd, J 8.0 and 1.0 Hz, C(4’)H), 7.25 (1H, ddd, J 
8.0, 8.0 and 1.0 Hz, C(6’)H), 7.13 (1H, ddd, J 8.0, 8.0 and 1.0 Hz, C(5’)H), 6.86 
(1H, s, C(2’)H), 3.76 (3H, s, NCH3), 3.69 (3H, s, OCH3), 2.83 (2H, t, J 7.5 Hz, 
C(4)H2), 2.42 (2H, t, J 7.5 Hz, C(2)H2) and 2.11-2.03 (2H, m, C(3)H2); 
13
C NMR 
δC(100 MHz, CDCl3) 174.1− (CO2H), 137.0− (C7a’), 127.8− (C3a’), 126.3+ (C2’), 
121.4+ (C6’), 118.9+ (C7’), 118.6+ (C5’), 114.0− (C3’), 109.1+ (C4’), 51.4+ 
(OCH3), 33.6− (C2), 32.5+ (NCH3), 25.5− (C3) and 24.3− (C4); MS (+ESI) m/z 254 
(M+Na
+
, 100 %); HRMS (+ESI) Found M+Na
+
, 254.1144; C14H17NO2Na requires 
M+Na
+
 254.1157. 
 
10-Methyl-2,3,4,5-tetrahydroazepino[3,4-b]indol-1(10H)-one (166) 
 
 
 
KOH (1.55 g, 28 mmol) was added to a rapidly stirred suspension of the ester 
164 (1.28 g, 5.6 mmol) in H2O (100 mL) at r.t. and the reaction heated at reflux for 4 
hrs. After cooling to 0 °C the solution was acidified to pH 2 with 6M HCl and 
extracted with EtOAc (3 x 30 mL). The combined organic fractions were washed 
with brine, dried over anhydrous Na2SO4, filtered and the solvent removed in vacuo 
to afford the acid intermediate acid 165 as a white solid.  
Following general procedure 1C, performing the BF3·OEt2 mediated 
cyclisation at r.t., the crude acid intermediate gave the azepinone 166 (3.9 mmol 
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scale, 301 mg, 36%) and performing the cyclisation at 50 °C gave 166 (5.56 mmol 
scale, 1.008 g, 85%) as a white solid. 
Rf [PE-EtOAc 7:3] 0.15; Mp 131-134 °C (from EtOAc); IR νmax (KBr disc) 
3467 (NH), 3277, 3139, 3055, 2931 (CH), 1658 (C=O), 1535, 1475, 1434 (Ar), 1318 
(CN) and 735 (CH); 
1
H NMR δH(400 MHz, CDCl3) 7.62 (1H, d, J 8.0 Hz, C(6)H), 
7.37 (1H, dd, J 8.0 and 1.0 Hz, C(9)H), 7.34 (1H, ddd, J 8.5, 8.0 and 1.0 Hz,  
C(8)H), 7.15 (1H, ddd, J 8.0, 6.0 and 2.0 Hz, C(7)H), 6.53 (1H, broad s, N(2)H), 
4.00 (3H, s, N(10)CH3), 3.35 (1H, t, J 6.0 Hz, C(3)HAHB), 3.34 (1H, t, J 6.0Hz, 
C(3)HAHB), 3.12 (2H, t, J 7.0 Hz, C(5)H2) and 2.17-2.11 (2H, m, C(4)H2); 
13
C NMR 
δC(100 MHz, CDCl3) 167.2− (C1=O), 138.7− (C9a), 127.8− (C10a), 126.2− (C5b), 
124.6+ (C8), 119.8+ (C6), 119.6+ (C7), 118.9− (C5a), 110.0+ (C9), 41.4− (C3), 
31.8+ (NCH3), 29.0− (C4) and 22.3− (C5); MS (+ESI) m/z 237 (M+Na
+
, 69 %) and 
451 (2M+Na
+
, 100); HRMS (+ESI) Found M+Na
+
, 237.1001; C13H14N2ONa 
requires M+Na
+
 237.1004; HPLC tR 14.3 (100 %). 
 
 
2,10-Dimethyl-2,3,4,5-tetrahydroazepino[3,4-b]indol-1(10H)-one (167) 
 
 
 
NaH (60 % dispersion in mineral oil) (120 mg, 3 mmol) was added to a 
vigorously stirred suspension of lactam 163 (187 mg, 0.935 mmol) in THF (5 mL) at 
0 °C under Ar. After 30 mins, MeI (185 μL, 3 mmol) was added and the reaction 
stirred at r.t. for 16 hrs, then quenched with saturated aqueous NH4Cl (15mL) and 
extracted with EtOAc (3 x 15 mL). The organic fractions were combined, washed 
with brine (15 mL), dried over anhydrous Na2SO4, filtered and the solvent removed 
in vacuo. After column chromatography [silica, light PE-EtOAc gradient from 100:0 
to 50:50] azepinone 167 (183 mg, 86 %) was isolated as a white solid. 
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Mp 106-110 °C (Et2O); lit.,
241
 104-106 °C (PE 60-80 °C); 
1
H NMR δH(400 
MHz, CDCl3) 7.60 (1H, ddd J 8.0, 1.0 and 1.0 Hz, C(6)H), 7.35 (1H, ddd, J 8.0, 1.0 
and 1.0 Hz, C(9)H), 7.31 (1H, ddd, J 8.0, 6.5 and 1.0 Hz, C(8)H), 7.13 (1H, ddd, J 
8.0, 6.5 and 1.0 Hz, C(7)H), 3.96 (3H, s, N(2)CH3), 3.45 (2H, dd, J 6.0 and 6.0 Hz, 
C(3)H2), 3.20 (3H, s, N(10)CH3), 3.02 (2H, dd, J 6.0 and 6.0 Hz, C(5)H2) and 2.20-
2.13 (2H, m, C(4)H2); 
13
C NMR δC(100 MHz, CDCl3) 165.3− (C1=O), 138.4− 
(C9a), 129.5− (C10a), 126.0− (C5b), 124.1+ (C8), 119.5+ (C6 or C7), 119.5+ (C6 or 
C7), 117.2− (C5a), 109.9+ (C9), 49.6− (C3), 34.9+ (N(2)CH3), 31.5+ (N(10)CH3), 
28.0− (C4) and 20.7− (C5); MS (+ESI) m/z 229 (M+H+, 100 %) and 251 (M+Na+, 
25); HRMS (+ESI) Found M+Na
+
, 251.1171; C14H16N2ONa requires M+Na
+
 
251.1160; HPLC tR 13.5 (100 %). 
 
 
5.2.2. Synthesis of AB-ring Analogues by Dehydrogenation of Lactams 
General Procedure 2: Dehydrogenation of lactam rings 
Method A: Dichlorodicyanoquinoline (452 mg, 4 mmol) was added to a 
stirred solution of lactam (0.5 mmol) in dioxane (10 mL) at r.t. under N2, then the 
reaction heated at 110 °C for between 1 and 24 hrs. After cooling, the solvent was 
removed and the residue stirred in 2M NaOH (10 mL) for 30 mins then extracted 
with EtOAc (4 x 10 mL). The combined organic fractions were washed with H2O (2 
x 10 mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered and the solvent 
removed in vacuo. After column chromatography [silica, MeOH-CH2Cl2 gradient 
from 0:100 to 5:95] the product was isolated. 
Method B: 10 % Palladium on activated carbon (7 mol%) was added to a 
vigorously stirred, degassed solution of lactam in anhydrous xylene (8 mL/mmol) 
under N2, then the reaction was heated at reflux for 24 hrs. The catalyst was removed 
by filtration through celite and washed with hot MeOH, then the solvent was 
removed in vacuo. The product was recrystallised from EtOAc, without need for 
column chromatography. 
Method C: 10 % Palladium on activated carbon (15 mol%) was added to a 
vigorously stirred, degassed solution of lactam in anhydrous xylene (8 mL/mmol) 
under N2, then the reaction was heated at reflux for 24 hrs. After cooling to r.t., the 
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mixture was diluted with MeOH, SiO2 added and then heated at reflux for 30 mins. 
The solvent was removed in vacuo and column chromatography [silica, MeOH-
CH2Cl2 gradient from 0:100 to 5:95] afforded the product. 
Method D: A degassed suspension lactam and 10 % palladium on activated 
carbon (10 mol %) in xylene (5 mL/ mmol) was heated in the microwave at 200 °C 
for 30-60 mins. The mixture was diluted with MeOH, SiO2 added and then heated at 
reflux for 30 mins. The solvent was removed in vacuo and column chromatography 
[silica, MeOH-CH2Cl2 gradient from 0:100 to 5:95] afforded the product. 
 
 
6H-1,3-Dioxolo[4,5-g]isoquinolin-5-one (172) 
 
 
 
Following general procedure 2A dihydroisoquinolinone 144 (96 mg, 0.5 
mmol) gave isoquinolinone 172 (35 mg, 37 %); following general procedure 2B 144 
(199 mg, 1.04 mmol) gave 172 (106 mg, 54 %); following procedure 2B using 33 
mol% Pd/C 144 (1.53 g, 8 mmol) gave 172 (637 mg, 42 %); and following 
procedure 2C 144 (192g, 1 mmol) gave 172 (127 mg, 67 %)  as a white solid.  
Mp sublimes above 185 °C, then recrystallises and melts 281-284 °C with 
accompanying decomposition (from EtOAc); IR νmax(KBr disc) 2907, 2847, 1654 
(C=O), 1582, 1498, 1479, 1460, 1254 and 1036; 
1
H NMR δH(400 MHz, d6-DMSO) 
11.14 (1H, broad s, NH), 7.49 (1H, s, C(8)H), 7.14 (1H, s, C(5)H), 7.05 (1 H, dd, J 
7.0 and 5.5 Hz, C(3)H), 6.44 (1H, d, J 7.0 Hz, C(4)H) and 6.15  (2H, s, OCH2O); 
13
C 
NMR δC(100 MHz, d6-DMSO) 161.1− (C1=O), 151.4− (C7-O), 147.1− (C6-O), 
135.1− (C4a or C8a), 127.5+ (C3), 121.3− (C4a or C8a), 104.7+ (C4), 104.0+ (C8), 
103.9+ (C5) and 101.8− (CH2); MS (+ESI) m/z 212 (M+Na
+
, 85 %) and 401 
(2M+Na
+
, 100); HRMS (+ESI) (Found M+Na
+
, 212.0316; C10H7NO3Na requires 
M+Na
+
 212.0324; HPLC tR 9.5 (100 %). 
Spectroscopic data is consistent with that reported by Xie et al. 
242
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6,7-Dimethoxyisoquinolin-1(2H)-one (173) 
 
 
 
Following general procedure 2A, dihydroisoquinolinone 147 (104 mg, 0.5 
mmol) gave isoquinolinone 173 (32 mg, 31 %); following general procedure 2B 147 
(207 mg, 1 mmol) gave 173 (126 mg, 61 %); and following general procedure 2C 
147 (207 mg, 1 mmol) gave 173 (178 mg, 86 %) as a white solid. 
Mp sublimes above 205 °C then recrystallises and melts at 244-246 °C 
(EtOAc), lit.,
243
 244-245 °C (from CHCl3-PhH); IR νmax(KBr disc) 2923, 2853, 1639 
(C=O), 1607, 1505, 1470 and 1273; 
1
H NMR δH(400 MHz, CD3OD) 7.70 (1H, s, 
C(8)H), 7.13 (1H, s, C(5)H), 7.09 (1 H, d, J 7.0 Hz, C(3)H), 6.34 (1H, d, J 7.0 Hz, 
C(4)H), 3.96 (3H, s, C(7)OCH3) and 3.94 (3H, s, C(6)OCH3); 
13
C NMR δC(100 
MHz, CD3OD) 164.3− (C=O), 155.6− (C7-O), 150.9− (C6-O), 135.8− (C8a), 127.3+ 
(C3), 120.7− (C4a), 107.8+ (C4, C5 or C8), 107.7+ (C4, C5 or C8), 107.7+ (C4, C5 
or C8), 56.5+ (OCH3) and 56.4+ (OCH3); MS (+ESI) m/z 206 (M+H
+
, 35 %), 228 
(M+Na
+
, 17) and 433 (2M+Na
+
, 100); HRMS (+ESI) Found M+H
+
, 206.796; 
C11H12NO3 requires M+H
+
 206.0817; HPLC tR 8.8 (100 %). 
Spectroscopic data is consistent with that reported by Sakamoto et al.
244
 
 
 
8-Hydroxy-6,7-dimethoxy-1-oxoquinoline (174) 
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Following general procedure 2B, dihydroisoquinolinone 151 (123 mg, 0.55 
mmol) gave isoquinolinone 174 (62 mg, 51 %); following general procedure 2B 
using 33 mol% Pd/C 151 (1.31 g, 5.95 mmol) gave 174 (644 mg, 49 %); following 
general procedure 2C 151 (223 mg, 1 mmol) gave 174 (85 mg, 38 %); and following 
general procedure 2D 151 (112 mg, 0.5 mmol) gave 174 (88 mg, 80 %) as a white 
solid. 
Mp sublimes above 210 °C then recrystallises, melts at 244-247 °C (from 
EtOAc); IR νmax(KBr disc) 3329 (OH), 2936, 2853 (CH), 1648, 1618, 1578, 1440, 
1382, 1303 (C-O), 1235, 1127, 1017 and 824; 
1
H NMR δH(400 MHz, d6-DMSO) 
13.26 (1H, s, OH), 11.53 (1H, s, NH), 7.11 (1H, d, J 7.0 Hz, C(3)H), 6.73 (1H, s, 
C(5)H), 6.56 (1H, d, J 7.5 Hz, C(4)H), 3.87 (3H, s, OCH3) and 3.72 (3H, s, OCH3); 
13
C NMR δC(100 MHz, d6-DMSO) 165.7− (C1=O), 157.8− (C7), 153.7− (C8), 
135.1− (C8a), 132.8− (C6), 127.8+ (C3), 106.9− (C4a), 106.7+ (C4), 97.9+ (C5), 
59.8+ (OCH3) and 55.8+ (OCH3); MS (+ESI) m/z 222 (M+H
+
, 100 %) and 244 
(M+Na
+
, 56); HRMS (+ESI) Found M+Na
+
, 244.0619; C11H11NO4Na requires 
M+Na
+
 244.0580; HPLC tR 10.6 (96 %). 
 
 
2,9-Dihydro-1H-pyrido[3,4-b]indol-1-one (175) 
 
 
 
Following general procedure 2A carbolinone 153 (93 mg, 0.5 mmol) gave 
carbolinone 175 (23 mg, 25 %); following general procedure 2A using 3 mmol 
DDQ, carbolinone 153 (93 mg, 0.5 mmol) gave carbolinone 175 (53 mg, 58 %); 
following general procedure 2B 153 (186 mg, 1 mmol) gave 175 (72 mg, 39 %); and 
following procedure 2D 153 (558 mg, 3 mmol) gave 175 (497 mg, 90 %) as a white 
solid.  
Rf [CH2Cl2-MeOH 95:5] 0.28; Mp sublimes above 236 °C (from EtOAc); 
lit.,
245
 259 °C (from PhH); IR νmax(Thin film) 2918, 1651 (C=O), 1614, 1424, 1327 
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and 725; 
1
H NMR δH(400 MHz, d6-DMSO) 11.90 (1H, s, N(9)H), 11.35 (1H, s, 
N(2)H), 8.00 (1H, d, J 8.0 Hz, C(5)H), 7.49 (1H, d, J 8.0 Hz, C(8)H), 7.38 (1H, ddd, 
J 8.0, 7.0 and 1.0 Hz, C(7)H), 7.15 (1H, ddd J 8.0, 7.0 and 1.0 Hz, C(6)H), 7.07-7.04 
(1H, m, C(3)H) and 6.96 (1H, d, J 7.0 Hz, C(4)H); 
13
C NMR δC(100 MHz, d6-
DMSO) 155.7− (C=O), 139.0− (C8a), 128.0− (C4a), 126.2+ (C7), 124.5+ (C3), 
124.2− (C9a), 122.0− (C4b), 121.3+ (C5), 119.4+ (C6), 112.4+ (C8) and 99.7+ (C4); 
MS (+ESI) m/z 185 (M+H
+
, 100 %), 207 (M+Na
+
, 20) and 391 (2M+Na
+
, 76);  
HRMS (+ESI) Found M+H
+
, 185.0710; C11H9N2O requires M+H
+
 185.0715; 
HPLC tR 10.0 (100 %). 
Spectroscopic data is consistent with that reported by Tahri
 
et al.
246
 
 
 
9-Methyl-2,9-dihydro-1H-pyrido[3,4-b]indol-1-one  (176) 
 
 
 
Following general procedure 2A carbolinone 160 (100 mg, 0.5 mmol) gave 
carbolinone 176 (22 mg, 22 %); and following general procedure 2B 160 (200 mg, 1 
mmol) after 6 days gave 176 (119 mg, 60 %) as a white solid.  
Mp 161-164 °C (from EtOAc); lit.,
247
 242-242.5 °C (from EtOH); IR 
νmax(KBr disc) 3116 (NH), 2881, 2836 (CH), 1656 (C=O) 1464, 1351, 1327, 1279, 
1215 and 949; 
1
H NMR δH(400 MHz, d6-DMSO)  11.4 (1H, s, N(2)H), 8.06 (1H, d, 
J 8.0 Hz, C(5)H), 7.62 (1H, d, J 8.5 Hz, C(8)H), 7.50 (1H, ddd, J 8.0, 7.0 and 1.0 Hz 
C(7)H), 7.23 (1H, ddd, J 8.0, 7.0 and 1.0 Hz, C(6)H), 7.07 (1H, dd, J 7.0, 7.0 Hz, 
C(3)H), 6.99 (1H, d, J 6.0 Hz, C(4)H) and 7.23 (3H, s, N(9)CH3); 
13
C NMR δC(100 
MHz, d6-DMSO) 156.4− (C1=O), 140.2− (C8a), 127.0− (C9a), 126.5+ (C7), 124.9+ 
(C3), 124.6− (C4a), 121.4+ (C5), 121.1− (C4b), 119.8+ (C6), 110.4+ (C8), 99.6+ 
(C4) and 31.0+ (N(9)CH3); MS (+ESI) m/z 199 (M+H
+
, 100 %), 221 (M+Na
+
, 40) 
and 419 (2M+Na
+
, 75); HRMS (+ESI) Found M+Na
+
, 221.0675; C12H10N2ONa 
requires M+Na
+
 221.0691; HPLC tR 14.8 (100 %). 
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2,9-Dimethyl-2,9-dihydro-1H-pyrido[3,4-b]indol-1-one (177) 
 
 
 
NaH (60 % dispersion in mineral oil) (100 mg, 2.5 mmol) was added to a 
vigorously stirred suspension of lactam 175 (144 mg, 0.78 mmol) in THF (3 mL) at 
0 °C under Ar. After 30 mins, MeI (155 μL, 2.5 mmol) was added and the reaction 
stirred at r.t. for 18 hrs. The reaction was quenched with saturated aqueous NH4Cl 
(15mL) and extracted with EtOAc (3 x 15 mL). The organic fractions were 
combined, washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and 
the solvent removed in vacuo. After column chromatography [silica, PE-EtOAc 
gradient from 100:0 to 50:50] the carbolinone 177 (90 mg, 54 %) was isolated as a 
yellow solid. 
Mp 164-166 °C (from Et2O); lit.,
247
 158.5-159 °C (from EtOH); IR νmax(Thin 
film) 309, 2926, 1648 (C=O), 1589, 1531, 1473, 1331 and 1268; 
1
H NMR δH(400 
MHz, CDCl3) 7.84 (1H, d, J 8.0 Hz, C(8)H), 7.42 (1H, ddd, J 8.0, 7.0 and 1.0 Hz, 
C(7)H), 7.36 (1H, d, J 8.0 Hz, C(5)H), 7.16 (1H, ddd, J 8.0, 8.0 and 2.0 Hz, C(6)H), 
6.97 (1H, d, J 7.0 Hz, C(3)H), 6.79 (1H, d, J 7.0 Hz, C(4)H), 4.24 (3H, s, N(9)CH3) 
and 3.60 (3H, s, N(2)CH3); 
13
C NMR δC(100 MHz, CDCl3) 156.8− (C1=O), 140.9− 
(C8a), 128.7+ (C3), 127.3− (C9a), 126.6+ (C7), 124.6− (C4a), 121.3− (C4b), 121.0+ 
(C8), 119.9+ (C6), 110.0+ (C5), 100.4+ (C4), 36.7+ (N(2)CH3) and 31.5+ 
(N(9)CH3); MS (+ESI) m/z 213 (M+H
+
, 100 %), 235 (M+Na
+
, 9); HRMS (+ESI) 
Found M+Na
+
, 235.0836; C13H16N2ONa requires M+Na
+
 235.0842; HPLC tR 14.8 
(96 %).  
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5.2.3. Pro-drug Synthesis 
8-Hydroxy-6,7-dimethoxy-1-oxo-1H-isoquinoline-2-carboxylic acid ethyl 
ester (178)  
 
 
 
Ethyl chloroformate (53 µL, 0.55 mmol) was added to a stirred suspension of 
isoquinolinone 174 (110 mg, 0.5 mmol) and Et3N (76 µL, 0.55 mmol) in anhydrous 
THF (1.5 mL) at 0 °C under N2. The reaction was allowed to warm to r.t. and stirred 
for 2 hrs, then quenched with H2O (6 mL) and extracted with EtOAc (3 x 10 mL). 
The combined organic fractions were washed with brine (10 mL), dried over 
anhydrous Na2SO4, filtered and the solvent removed in vacuo. After column 
chromatography [silica, PE-EtOAc 70:30] the carbamate product 178 (75 mg, 51 %) 
was isolated as a white solid. 
Rf [PE-EtOAc 70:30] 0.70; IR νmax(Thin film) 2980, 1941, 1770 (C=O), 1667 
(C=O), 1594, 1559, 1505, 1411, 1300, 1246, 1199 and 1127; 
1
H NMR δH(400 MHz, 
CDCl3) 12.41 (1H, s, OH), 7.46 (1H, d, J 8.0 Hz, C(3)H), 6.43 (1H, s, C(5)H), 6.38 
(1H, d, J 8.0 Hz, C(4)H), 4.52 (2H, q, J 7.0 Hz, OCH2CH3), 3.95 (3H, s, CH3), 3.91 
(3H, s, OCH3) and 1.46 (3H, t, J 7.0 Hz, OCH2CH3); 
13
C NMR δC(100 MHz, 
CDCl3) 164.9− (C1=O), 158.9− (C6 or C7), 155.9− (C8-OH), 151.7− (CO2Et), 
135.4− (C6 or C7), 133.5− (C4a or C8a), 126.1+ (C3), 108.6+ (C4), 107.2− (C4a or 
C8a), 98.6+ (C5), 65.2− (OCH2CH3), 60.7+ (OCH3), 56.1+ (OCH3) and 14.1+ 
(OCH2CH3). MS (+ESI) m/z 294 (M+H
+
, 31 %), 316 (M+Na
+
, 17) and 609 (2M+H
+
, 
100); HRMS (+ESI) Found M+H
+
, 294.0975; C14H16NO6 requires M+H
+
 294.0972. 
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8-Ethoxycarbonyloxy-6,7-dimethoxy-1-oxo-1H-isoquinoline-2-carboxylic 
acid ethyl ester (180)  
 
 
NaH (60 % dispersion in mineral oil) (80 mg, 1.2 mmol) was added to a 
vigorously stirred suspension of isoquinolinone 174 (110 mg, 0.5 mmol) in 
anhydrous THF (3 mL) at 0 °C under N2. After 45 mins, ethyl chloroformate (115 
µL, 1.2 mmol) was added, the reaction was allowed to warm to r.t. and stirred for 3 
hrs, then quenched with H2O (10 mL) and extracted with EtOAc (3 x 10 mL). The 
combined organic fractions were washed with brine (10 mL), dried over anhydrous 
Na2SO4, filtered and the solvent removed in vacuo. After column chromatography 
[silica, PE-EtOAc 70:30] the carbonate product 180 (48 mg, 26 %) was isolated as a 
white solid and the carbamate 178 (54 mg, 37 %) as white a solid. 
Rf [PE-EtOAc 60:40] 0.80; IR νmax(KBr disc) 2990, 3947, 1753 (C=O), 1731 
(C=O), 1685 (C=O), 1605, 1503, 1469, 1409, 1370, 1311, 1243, 1130, 1091, 1030, 
1006 and 975; 
1
H NMR δH(400 MHz, CDCl3) 7.44 (1H, d, J 8.0 Hz, C(3)H), 6.73 
(1H, s, C(5)H), 6.27 (1H, d, J 8.0 Hz, C(4)H), 4.44 (2H, q, J 7.0 Hz, OCH2CH3), 
4.36 (2H, q, J 7.0 Hz, OCH2CH3), 3.94 (3H, s, OCH3), 3.87 (3H, s, OCH3) and 1.42-
1.38 (6H, m, OCH2CH3); 
13
C NMR δC(100 MHz, CDCl3) 158.1− (C1=O), 157.8− 
(C6 or C7), 152.8− (NCO2Et or OCO2Et), 152.7− (NCO2Et or OCO2Et), 145.1− 
(C8), 141.7− (C6 or C7), 134.6− (C4a or C8a), 127.5+ (C3), 113.7− (C4a or C8a), 
106.4+ (C4), 105.2+ (C5), 65.1− (OCH2CH3), 64.7− (OCH2CH3), 61.5+ (OCH3), 
56.1+ (OCH3), 14.2+ (OCH2CH3) and 14.0+ (OCH2CH3); MS (+ESI) m/z 366 
(M+H
+
, 35 %), 388 (M+Na
+
, 13) and 753 (2M+Na
+
, 100); HRMS (+ESI) Found 
M+H
+
, 366.1187; C17H20NO8 requires M+H
+
 366.1183. 
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Benzyl 8-hydroxy-6,7-dimethoxy-1-oxoisoquinoline-2(1H)-carboxylate 
(179) and benzyl 8-(benzyloxycabonyloxy)-6,7-dimethoxy-1-oxoisoquinoline-
2(1H)-carboxylate (181) 
 
 
 
NaH (60 % dispersion in mineral oil) (80 mg, 2 mmol) was added to a 
vigorously stirred suspension of isoquinolinone 174 (110 mg, 0.5 mmol) in 
anhydrous THF (3 mL) at 0 °C under N2. After 45 mins, benzyl chloroformate (171 
µL, 1.2 mmol) was added. The reaction was allowed to warm to r.t. and stirred for 3 
hrs, then quenched with H2O (10 mL) and extracted with EtOAc (3 x 10 mL). The 
combined organic fractions were washed with brine (10 mL), dried over anhydrous 
Na2SO4, filtered and the solvent removed in vacuo. After column chromatography 
[silica, PE-EtOAc gradient from 100:0 to 60:40] the phenol product 179 (22 mg, 12 
%) was isolated as a white solid and carbonate product 181 (100 mg, 41 %) as an oil.  
 
 Phenol (179) 
Rf [PE-EtOAc 50:50] 0.4; 
1
H NMR δH(400 MHz, CDCl3) 12.41 (1H, s, OH) 
7.49 (2H, d, J 7.0 Hz, Ph), 7.45 (1H, d, J 8.0 Hz, C(3)H), 7.43-7.37 (3H, m, Ph), 
6.41 (1H, s, C(5)H), 6.36 (1H, d, J 8.0 Hz, C(4)H), 5.46 (2H, s, OCH2Ph), 3.94 (3H, 
s, OCH3) and 3.91 (3H, s, OCH3); 
13
C NMR δC(100 MHz, CDCl3) 164.9− (C(1)=O), 
158.9− (C6 or C7), 155.9− (C8), 151.6− (NCO2Bn), 135.4− (C6 or C7), 134.1− (C4a 
or C8a), 133.4− (Ph), 128.9+ (Ph), 128.8+ (Ph), 128.5+ (Ph), 126.0+ (C3), 108.7+ 
(C4), 107.1− (C4a or C8a), 98.7+ (C5), 70.4− (OCH2Ph), 61.7+ (OCH3) and 56.1+ 
(OCH3); MS (+ESI) m/z 356 (M+H
+
, 100 %) and 378 (M+Na
+
, 61); HRMS (+ESI) 
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Found M+Na
+
, 378.0941; C19H17NO6Na requires M+Na
+
 378.0954; HPLC tR 10.5 
(85 %). 
 
Carbonate (181) 
Decomposes in air at r.t. to 179 
Rf [PE-EtOAc 50:50] 0.26; 
1
H NMR δH(400 MHz, CDCl3) 7.50-7.47 (4H, m, 
Ph), 7.43 (1H, d, J 8.0 Hz, C(3)H), 7.38-7.30 (9H, m, Ph), 6.70 (1H, s, C(5)H), 6.24 
(1H, d, J 8.0 Hz, C(4)H), 5.42 (2H, s, CH2Ph), 5.35 (2H, s, CH2Ph), 3.91 (3H, s, 
OCH3) and 3.82 (3H, s, OCH3); 
13
C NMR δC(100 MHz, CDCl3) 158.1− (C1=O), 
157.8− (C6 or C7), 152.8− (NCO2Bn or OCO2Bn), 152.5− (NCO2Bn or OCO2Bn), 
145.0− (C8), 141.6− (C6 or C7), 135.0− (Ph), 134.5 (Ph), 128.5+ (Ph), 128.5+ (Ph), 
128.4+ (Ph), 128.3+ (Ph), 128.2+ (Ph), 128.0+ (Ph), 127.2+ (C3), 113.5− (C4a or 
C8a), 108.5− (C4a or C8a), 106.5+ (C4), 105.3+ (C5), 70.4− (CH2Ph), 69.8− 
(CH2Ph) , 61.4+ (OCH3) and 56.1+ (OCH3); MS (+ESI) m/z 356 (M-BnOCO2
-
+2H
+, 
100 %), 490 (M+H
+
, 27), 512 (M+Na
+
, 36); HRMS (+ESI) Found M+H
+
, 490.1498; 
C27H24NO8 requires M+H
+
 490.1502. 
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5.3. SYNTHESIS OF ABC-RING ANALOGUES 
5.3.1. Synthesis of the Dimethoxy Analogue 
Ethyl 3-(3’,4’-dimethoxyphenyl)-3-oxopropanoate (194) 
 
 
 
Following the procedure reported by Arnould et al.,
131
 NaH (60 % dispersion 
in mineral oil) (3 g, 75 mmol) was added portionwise over 3 mins to a stirred 
solution of 3,4-dimethoxyacetophenone 193 (9 g, 50 mmol) in diethyl carbonate 
(100 mL) at 0 °C  under N2, then the reaction was heated at 80 °C  for 1 ½ hrs. After 
cooling to r.t., the reaction was quenched with saturated aqueous NH4Cl (30 mL) and 
H2O (300 mL), then extracted with EtOAc (3 x 125 mL). The combined organic 
fractions were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered 
and the solvent removed in vacuo. After column chromatography [silica, PE-EtOAc 
65:35] β-ketoester 194 (12.13 g, 96 %) was isolated as a pale yellow oil. 
Rf [PE-EtOAc: 30:70] 0.93; 
1
H NMR δH(400 MHz, CDCl3) 7.51 (1H, dd, J 
8.0 and 2.0 Hz, C(6’)H), 7.49 (1H, d, J 2.0 Hz, C(2’)H), 6.85 (1H, d, J 8.0 Hz, 
C(5’)H), 4.17 (2H, q, J 7.0 Hz, OCH2CH3), 3.91 (5H, s, OCH3 and C(2)H2), 3.89 
(3H, s, OCH3) and 1.22 (3H, t, J 7.0 Hz, OCH2CH3); 
13
C NMR δC(100 MHz, 
CDCl3) 190.9− (C3=O), 167.6− (CO2Et), 153.7− (C3’-O or C4’-O), 149.0− (C3’-O 
or C4’-O), 129.2− (C1’), 123.4+ (C(Ar)-H), 110.2+ (C(Ar)-H), 110.0+ (C(Ar)-H), 
61.3−  (OCH2CH3), 56.0+ (OCH3), 55.9+ (OCH3), 45.6− (C2) and 14.0+ 
(OCH2CH3). 
Spectroscopic data is consistent with that reported by Jung et al.
248
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Ethyl 2-(3,4-dimethoxyphenyl)-2-hydroxy-4-oxo-1-(3-
oxobutyl)cyclohexanecarboxylate or ethyl 2-(3,4-Dimethoxyphenyl)-2-hydroxy-
4-oxo-3-(3-oxobutyl)cyclohexanecarboxylate or ethyl 2-(3,4-Dimethoxyphenyl)-
2-hydroxy-4-oxo-5-(3-oxobutyl)cyclohexanecarboxylate (204) 
 
 
 
K2CO3 (345 mg, 2.5 mmol) was added to a vigorously stirred solution of β-
ketoester 194 (252 mg, 1 mmol) in anhydrous MeCN (5 mL) at r.t. under N2. After 5 
mins, MVK (202 μL, 2.5 mmol) was added and the reaction stirred for 24 hrs at 50 
°C. The reaction was quenched with saturated aqueous NH4Cl (15 mL) then 
extracted with EtOAc (3 x 15 mL). The combined organic fractions were washed 
with brine (15 mL), dried over anhydrous Na2SO4, filtered and the solvent removed 
in vacuo. After column chromatography [silica, PE-EtOAc gradient from 80:20 to 
40:60] the product 204 (221 mg, 56 %) was isolated as a yellow oil. 
Rf [PE-EtOAc 50:50] 0.49; IR νmax(thin film) 3506 (OH), 2968 (CH), 2841 
(CH), 1731 (C=O), 1672 (C=O), 1595 (C=C), 1515 (C=C), 1463, 1416, 1264 (C-O), 
1228 (C-O), 1148, 1023 and 764; 
1
H NMR δH(400 MHz, CDCl3) 7.57-7.44 (2H, m, 
Ar C-H), 6.82 (1H, d, J 8.0 Hz, Ar C-H), 4.18-4.08 (2H, m, OCH2CH3), 3.92 (3H, s, 
OCH3), 3.91 (3H, s, OCH3), 3.01 (1H, dd J 13.0 and 3.5 Hz), 2.60 (1H, td, J 14.0 
and 4.0 Hz) 2.45 (1H, J 13.0 and 3.0 Hz) 2.32-2.16 (5H, m), 2.03 (2H, t, J 6.5 Hz), 
1.58 (1H, dt, J 14.0 and 3.5 Hz) 1.24 (1H, t, J 7 Hz) and 1.20-1.10 (5H, m); 
13
C 
NMR δC(100 MHz, CDCl3) 215.4− (ketone C=O), 196.1− (ketone C=O), 173.3− 
CO2Et), 153.1−, 149.0−, 127.8−, 123.0+, 111.2+, 109.9+, 68.8−, 61.8−, 56.6−, 
56.0+, 55.9+, 52.6+, 34.7−, 31.3+, 30.9−, 28.7+, 27.2− and 13.9+; MS (+ESI) m/z 
375 (M-H2O+H
+
, 100 %); HRMS (+ESI) Found M-H2O+H
+
, 375.1801; C21H26O6 
requires M-H2O+H
+ 
375.1802. 
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Ethyl 3',4'-dimethoxy-5-oxo-4-(3-oxobutyl)-3,4,5,6-tetrahydro-[1,1'-
biphenyl]-2-carboxylate, or ethyl 3',4'-dimethoxy-5-oxo-6-(3-oxobutyl)-3,4,5,6-
tetrahydro-[1,1'-biphenyl]-2-carboxylate, or ethyl 3',4'-dimethoxy-5-oxo-6-(3-
oxobutyl)-2,3,4,5-tetrahydro-[1,1'-biphenyl]-2-carboxylate (205)  
 
 
 
Method A: 4M HCl in dioxane (0.25 mL) was added dropwise to a stirred 
solution of alcohol 204 (119 mg, 0.30 mmol) in THF at r.t. and stirred for 3 ½ hrs, 
then the reaction was quenched with saturated aqueous NaHCO3 (10 mL) and 
extracted with EtOAc (3 x 10 mL). The combined organic fractions were washed 
with brine (10 mL), dried over anhydrous Na2SO4, filtered and the solvent removed 
in vacuo. After column chromatography [silica, PE-EtOAc gradient from 90:10 to 
70:30] the product 205 (74 mg, 66 %) was isolated as a yellow oil. 
Method B: p-TsOH (18 mg, 0.06 mmol) was added to a stirred solution of 
204 (130 mg, 0.34 mmol) in anhydrous toluene (3.5 mL) at r.t. under N2 and the 
reaction was heated at reflux for 1 hr. The reaction was quenched with saturated 
aqueous NaHCO3 (10 mL) then extracted with EtOAc (3 x 10 mL). The combined 
organic fractions were washed with brine (15 mL), dried over anhydrous Na2SO4, 
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filtered and the solvent removed in vacuo. After column chromatography [silica, PE-
EtOAc gradient from 100:0 to 75:25] the product 205 (89 mg, 72 %) was isolated as 
a yellow oil. 
Rf [PE-EtOAc 50:50] 0.58; IR νmax(KBr disc) 2951, 2856 (CH), 1730 (C=O), 
1675 (C=O), 1589, 1515, 1416, 1348, 1266 (C-O), 1221, 1151, 1022 and 765; 
1
H 
NMR δH(400 MHz, CDCl3) 7.49 (1H, d, J 8.0 Hz, C(Ar)H), 7.48 (1H, s, C(Ar)H), 
6.82 (1H, d, J 8.0 Hz, C(Ar)H), 4.12 (2H, q, J 7.0 Hz, OCH2CH3), 3.91 (3H, s, 
OCH3), 3.88 (3H, s, OCH3), 2.89 (1H, d, J 17.0 Hz), 2.72 (1H, d, J 17.0 Hz), 2.28 – 
2.00 (7H, m), 1.84 (3H, s, CH3C=O) and 1.09 (3H, t, J 7.0 Hz, OCH2CH3); 
13
C 
NMR δC(100 MHz, CDCl3) 202.8− (ketone C=O), 194.2− (ketone C=O), 173.3− 
(CO2Et), 153.1−, 149.0−, 139.6−, 130.6−, 127.8−, 122.7+, 111.3+, 109.9+, 61.6−, 
56.1−, 56.0+, 55.9+, 32.9−, 30.1−, 29.9+, 28.4−, 21.2+ and 13.9+; MS (+ESI) m/z 
375 (M+H
+
, 100 %); HRMS (+ESI) Found M+H
+
, 375.1795; C21H26O6 requires 
M+H
+
 375.1802. 
 
 
Ethyl 2-(3’,4’-dimethoxybenzoyl)-5-oxohexanoate (202) 
 
 
 
K2CO3 (834 mg, 5.5 mmol) was added to a vigorously stirred solution of β-
ketoester 194 (1.26 g, 5 mmol) in anhydrous MeCN (20 mL) at 0 °C under N2. After 
10 mins, MVK (446 μL, 5.5 mmol) was added and the reaction allowed to warm to 
r.t. and stirred for a further 2 ½ hrs. The reaction was quenched with saturated 
aqueous NH4Cl (20 mL) then extracted with EtOAc (3 x 20 mL). The combined 
organic fractions were washed with brine (20 mL), dried over anhydrous Na2SO4, 
filtered and the solvent removed in vacuo. After column chromatography [silica, PE-
EtOAc gradient from 90:10 to 60:40] the Michael addition product 202 (1.566 g, 97 
%) was isolated as a pale yellow oil. 
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Rf [PE-EtOAc 50:50] 0.53; IR νmax(Thin film) 2976, 2938, 2841, 1731 
(C=O), 1721 (C=O), 1673 (C=O), 1594, 1514, 1463, 1418, 1368, 1345, 1266, 1155 
and 1021; 
1
H NMR δH(400 MHz, CDCl3) 7.69 (1H, dd, J 8.5 and 1.5 Hz, C(6’)H), 
7.59 (1H, d, J 1.5 Hz, C(2’)H), 6.90 (1H, d, J 8.5 Hz, C(5’)H), 4.41 (1H, dd, J 8.0 
and 6.5 Hz, C(2)H), 4.14 (2H, q, J 7.0 Hz, OCH2CH3), 3.94 (6H, s, OCH3), 2.62-
2.54 (2H, m, C(4)H2), 2.25-2.17 (2H, m, C(3)H2), 2.12 (3H, s, C(6)H3) and 1.18 (3H, 
t, J 7.0Hz, OCH2CH3); 
13
C NMR δC(100 MHz, CDCl3) 208.0− (CH3C5=O), 193.8− 
(ArC=O), 170.0− (CO2Et), 153.8− (C(Ar)-O), 149.1− (C(Ar)-O), 129.0− (C1’-C), 
123.6+ (C(Ar)-H), 110.7+ (C(Ar)-H), 110.1+ (C(Ar)-H), 61.3− (OCH2CH3), 56.1+ 
(OCH3), 56.0+ (OCH3), 52.3+ (C2), 40.5− (C4), 30.0+ (C6), 23.0− (C3) and 14.6+ 
(OCH2CH3); MS (+ESI) m/z 323 (M+H
+
, 29 %) and 345 (M+Na
+
, 100 %); HRMS 
(+ESI) Found M+H
+
, 323.1491; C17H23O6 requires M+H
+
 323.1495. 
 
 
Ethyl 2-(3,4-dimethoxyphenyl)-4-oxocyclohex-2-enecarboxylate (206) 
 
 
 
Method A: Following the procedure reported by Nour et al.,
87
 pyrrolidine 
(33 μL, 0.4 mmol) and AcOH (27 μL, 0.475 mmol) were added to a stirred solution 
of Michael adduct 202 (160 mg, 0.5 mmol) in refluxing toluene (1 mL) under N2.  
After 2 ½ hrs, the reaction was cooled to r.t. and H2O (20 mL) was added, then 
extracted with EtOAc (3 x 15 mL). The combined organic fractions were washed 
with brine (15 mL), dried over anhydrous Na2SO4, filtered and the solvent removed 
in vacuo. After column chromatography [silica, PE-EtOAc gradient from 85:15 to 
75:25] cyclohexenone 206 (79 mg, 52 %) was isolated as an oil. 
Method B: p-TsOH (288 mg, 1.2 mmol) was added to a stirred mixture of 
Michael adduct 202 (975 g, 3.0 mmol) and activated 3Å molecular sieves in 
anhydrous toluene (30 mL) at r.t. under N2 and the reaction was heated at reflux for 
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38 hrs. After column chromatography [silica, PE-EtOAc gradient from 80:20 to 
70:30] the cyclised enone product 206 (644 mg, 70 %) was isolated as a yellow oil. 
Rf [PE-EtOAc 50:50] 0.30; IR νmax(thin film) 2938, 2839 (C-H), 1728 
(C=O), 1661 (C=O), 1597, 1576, 1518 (C=C), 1463, 1419, 1328, 1252 (C-O), 1151 
and 1022; 
1
H NMR δH(400 MHz, CDCl3) 7.10 (1H, dd, J 8.0 and 2.0 Hz, C(6’)H), 
7.05 (1H, d, J 2.0 Hz, C(2’)H), 6.87 (1H, d, J 8.0 Hz, C(5’)H), 6.46 (1H, s, C(3)H), 
4.11 (2H, q, J 7.0 Hz, OCH2CH3), 3.97-9.93 (1H, m, C(1)HCO2Et), 3.90 (3H, s, 
OCH3), 3.89 (3H, s, OCH3), 2.66-2.59 (1H, m, C(5)HAHB), 2.50-2.44 (2H, m, 
C(5)HAHB and C(6)HAHB), 2.43-2.35 (1H, m, C(6)HAHB), 1.15 (3H, t, J 7.0 Hz, 
OCH2CH3); 
13
C NMR δC(100 MHz, CDCl3) 198.6− (C(4)=O), 171.7− (CO2Et), 
154.9− (C1’), 151.0− (C3’-O or C4’-O), 149.1− (C3’-O or C4’-O), 130.1− (C2), 
125.5+ (C3), 119.6+ (C6’), 110.9+ (C2’), 109.1+ (C5’), 61.4− (OCH2CH3), 55.9+ 
(OCH3), 55.9+ (OCH3), 43.3+ (C1), 33.9− (C5), 26.5− (C6) and 14.0+ (OCH2CH3); 
MS (+ESI) m/z 305 (M+H
+
, 100 %) and 327 (M+Na
+
, 9); HRMS (+ESI) Found 
M+Na
+
, 327.1197; C17H20O5Na requires M+Na
+
 327.1208. 
 
 
Ethyl 3',4'-dimethoxy-5-(pyrrolidin-1-yl)biphenyl-2-carboxylate (207) 
 
 
Following the procedure reported by Boeckman,
80
 pyrrolidine (125 μL, 1.5 
mmol) and AcOH (112 μL, 2 mmol) were added to a stirred solution of 202 (160 mg, 
0.5 mmol) in refluxing toluene (6 mL) under N2. After 24 hrs, the reaction was 
cooled to r.t. and saturated aqueous Na2CO3 (15 mL) was added, then extracted with 
EtOAc (3 x 15 mL). The combined organic fractions were washed with brine (15 
mL), dried over anhydrous Na2SO4, filtered and the solvent removed in vacuo. After 
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column chromatography [silica, PE-EtOAc gradient from 100:0 to 60:40] aniline 207 
(43 mg, 25 %) was isolated as an oil and cyclohexenone 206 (25 mg, 16 %) as an oil. 
Rf [PE-EtOAc 50:50] 0.5; IR νmax(thin film) 2972, 2836 (C-H), 1694 (C=O), 
1600, 1505, 1463, 1383, 1281, 1244 (C-O), 1140, 1095 and 1028; 
1
H NMR δH(400 
MHz, CDCl3) 7.87 (1H, d, J 9.0 Hz, C(3)H), 6.88-6.84 (3H, m, C(2’)H, C(5’)H and 
C(6’)H), 6.50 (1H, dd, J 9.0 and 2.5 Hz, C(4)H), 6.39 (1H, d, J 2.5 Hz, C(6)H), 4.06 
(2H, q, J 7 Hz, OCH2CH3), 3.91 (3H, s, OCH3), 3.86 (3H, s, OCH3), 3.36-3.33 (4H, 
m, NCH2CH2), 2.03-2.01 (4H, m, NCH2CH2) and 1.04 (3H, t, J 7 Hz, OCH2CH3); 
13
C NMR δC(100 MHz, CDCl3) 168.1− (C=O), 149.6− (C2), 148.1− (C3’ or C4’), 
148.0− (C3’ or C4’), 145.0− (C1’), 136.1− (C1), 132.6− (C3), 120.5+ (C2’, C5’ or 
C6’), 116.5− (C5), 113.7+ (C6), 112.2+ (C2’, C5’ or C6’), 110.5+ (C2’, C5’ or C6’), 
109.7+ (C4), 59.9− (OCH2CH3), 55.9+ (OCH3), 55.9+ (OCH3), 47.5− (NCH2CH3), 
25.4− (NCH2CH3) and 14.0+ (OCH2CH3); MS (+ESI) m/z 356 (M+H
+
, 100 %) and 
378 (M+Na
+
, 40); HRMS (+ESI) Found M+H
+
, 356.1847; C21H26NO4 requires 
M+H
+
 356.1862. 
 
 
Ethyl 5-hydroxy-3',4'-dimethoxy-2,3,4,5-tetrahydro-[1,1'-biphenyl]-2-
carboxylate (211) 
 
 
 
CeCl3 (184 mg, 0.75 mmol) was added to a stirred solution of enone 206 
(160 mg, 0.5 mmol) in MeOH (3 mL) at r.t. then the reaction was cooled in an ice 
bath and NaBH4 (21 mg, 0.55 mmol) added. After 45 mins, the reaction was 
quenched with saturated aqueous NH4Cl (10 mL) then extracted with EtOAc (3 x 10 
mL). The combined organic fractions were washed with brine (10 mL), dried over 
anhydrous Na2SO4, filtered and the solvent removed in vacuo. After column 
chromatography [silica, PE-EtOAc gradient from 100:0 to 50:50] the alcohol product 
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211 (122 mg, 80 %) was isolated as an oil and a 75:25 mixture of diastereoisomers 
by 
1
H NMR. 
Rf [PE-EtOAc 50:50] 0.25; IR νmax(thin film) 3493 (OH), 2967, 2850 (CH), 
1729 (C=O), 1602, 1583, 1517 (C=C), 1463, 1250 (C-O), 1168 and 1026; 
1
H NMR 
δH(400 MHz, CDCl3) 6.95-6.93 (2H, m, C(2’)H and C(6’)H), 6.79 (1H, d, J 8.0 Hz, 
C(5’)H), 6.17-6.15 (1H, m, C(6)H), 4.44 (0.25H, broad s, C(5)HOH), 4.36 (0.75H, 
broad s, C(5)HOH), 4.05-3.98 (2H, m, OCH2CH3), 3.88 (3H, s, OCH3), 3.83 (3H, s, 
OCH3), 3.69 (0.25H, t, 5.5 Hz C(2)HCO2Et), 3.61 (0.75H, t, 5.5 Hz C(2)HCO2Et), 
2.16-1.68 (5H, m, C(3)H2, C(4)H2 and OH) and 1.10-1.05 (3H, m, OCH2CH3); 
13
C 
NMR δC(100 MHz, CDCl3) 174.0− (isomer A C=O), 173.7− (Isomer B C=O), 
148.7− (Isomer A), 148.7− (Isomer B), 137.6− (Isomer B), 137.2− (Isomer A), 
133.2− (Isomer B), 133.0− (Isomer A), 128.9+ (Isomer A C6, C2’, C5’ or C6’), 
128.5+ (Isomer B C6, C2’, C5’ or C6’), 118.2+ (Isomer B C6, C2’, C5’ or C6’), 
118.1+ (Isomer A C6, C2’, C5’ or C6’), 110.8+ (Isomer B C6, C2’, C5’ or C6’), 
110.8+ (Isomer A C6, C2’, C5’ or C6’), 109.2+ (C6, C2’, C5’ or C6’), 109.2+ (C6, 
C2’, C5’ or C6’), 66.1+ (Isomer A C5HOH), 65.6+ (Isomer B C5HOH), 60.7− 
(OCH2CH3), 60.6− (OCH2CH3), 55.8+ (OCH3), 55.8+ (OCH3), 43.8+ (Isomer B 
C2HCO2Et), 43.5+ (Isomer A C2HCO2Et), 29.2− (Isomer B C3 or C4), 28.9− 
(Isomer A C3 or C4), 24.2− (Isomer A C3 or C4), 23.4− (Isomer B C3 or C4) and 
14.0+ (OCH2CH3); MS (+ESI) m/z 329 (M+Na
+
, 100 %); HRMS (+ESI) Found 
M+Na
+
, 329.1352; C17H22O5Na requires M+Na
+
 329.1365. 
 
 
Ethyl 5-((tert-butyldimethylsilyl)oxy)-3',4'-dimethoxy-2,3,4,5-
tetrahydro-[1,1'-biphenyl]-2-carboxylate 212 
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t-Butyldimethylsilyl chloride (497 mg, 3.3 mmol) was added to a stirred 
solution of cyclohexenol 211 (900 mg, 3 mmol) and imidazole (225 mg, 3.3 mmol) 
in anhydrous DMF (6 mL) at 0 °C under N2 and the reaction stirred for 5 mins then 
was allowed to warm to r.t.. After 4 hrs, the reaction was quenched with saturated 
aqueous NH4Cl (25 mL) then extracted with EtOAc (3 x 20 mL). The combined 
organic fractions were washed with brine (20 mL), dried over anhydrous Na2SO4, 
filtered and the solvent removed in vacuo. After column chromatography [silica, PE-
EtOAc gradient from 80:20 to 20:80] the silyl ether 212 (960 mg, 76 %) was isolated 
as an oil and a 4:1 mixture of diastereoisomers by 
1
H NMR. 
Rf [PE-EtOAc 30:70] 0.77; IR νmax(thin film) 2932, 2856 (CH), 1732 (C=O), 
1603, 1583,  1517 (C=C), 1463, 1365, 1250 (C-O), 1168, 1084 (Si-C), 1028, 836, 
774; 
1
H NMR δH(400 MHz, CDCl3) 6.90 (1H, broad s, C(2’)H), 6.87 (1H, d, J 7.0 
Hz, C(5’)H), 6.79 (1H, dd, J 7.0 and 2.5 Hz, C(6’)H), 6.00 (0.8H, broad s, C(6)H), 
5.98 (0.2H, broad s, C(6)H), 4.46-4.42 (0.2H, m, C(5)HOSi), 4.39-4.34 (0.8H, m, 
C(5)HOSi), 4.02-3.70 (2H, m, OCH2CH3), 3.88 (3H, s, OCH3), 3.86 (3H, s, OCH3), 
3.68 (0.2H, t, J 5.0 Hz, C(2)HCO2Et), 3.56 (0.2H, t, J 5.0 Hz, C(2)HCO2Et), 2.21-
2.12 (1H, m, C(3)HAHB or C(4)HAHB), 2.04-1.89 (1H, m, C(3)HAHB or C(4)HAHB), 
1.83-1.78 (2H, m, C(3)H2 or C(4)H2), 1.07-1.03 (3H, m, OCH2CH3), 0.93 (7.2H, s, 
C(CH3)3), 0.93 (1.8H, s, C(CH3)3), 0.13 (2.4H, s, SiCH3), 0.11 (2.4H, s, SiCH3), 0.10 
(0.6H, s, SiCH3) and 0.09 (0.6H, s, SiCH3); 
13
C NMR δC(100 MHz, CDCl3) 174.2− 
(Isomer B C=O), 173.9− (Isomer A C=O), 148.6− (Isomer A), 148.6− (Isomer B), 
136.3− (Isomer B), 135.6− (Isomer A), 133.8− (Isomer B), 133.6− (Isomer A), 
130.8+ (Isomer A), 130.3+ (Isomer B), 118.3+ (Isomer B), 118.2+ (Isomer A), 
110.8+, 109.4+ (Isomer A), 109.4+ (Isomer B), 67.2+ (Isomer A CHOH), 66.6+ 
(Isomer B CHOH), 60.5− (OCH2CH3), 55.8+ (OCH3), 55.8+ (OCH3), 44.3+ (Isomer 
B C2), 43.2+ (Isomer A C2), 30.2− (Isomer B ), 29.1− (Isomer A), 25.9+ (Isomer A 
CCH3), 25.9+ (Isomer B CCH3), 24.4− (Isomer A), 24.1− (Isomer B), 18.3− (Isomer 
A CCH3), 18.2− (Isomer B CCH3), 14.0+ (OCH2CH3), -4.32+ (Isomer A SiCH3), ), -
4.36+ (Isomer B SiCH3) and -4.57+ (SiCH3); MS (+ESI) m/z 289 (M-
t
BuMe2SiOH+H
+
, 100 %) and 443 (M+Na
+
, 46); HRMS (+ESI) Found M+Na
+
, 
443.2205; C23H36O5NaSi requires M+Na
+
 443.2230. 
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5.3.2. Synthesis of the Trimethoxy-Analogue  
Ethyl 3-(3’,4’,5’-trimethoxyphenyl)-3-oxopropanoate (216) 
 
 
 
NaH (60 % dispersion in mineral oil) (3.0 g, 75 mmol) was added 
portionwise over 3 mins to a stirred solution of 3,4,5-trimethoxyacetophenone 215 
(10.5 g, 50 mmol) in diethyl carbonate (100 mL) at 0 °C  under N2, then the reaction 
was heated at 80 °C  for 1 ½ hrs. On cooling, the reaction was quenched with 
saturated aqueous NH4Cl (30 mL) and water (200 mL), then extracted with EtOAc (3 
x 120 mL). The combined organic fractions were washed with brine (100 mL), dried 
over anhydrous Na2SO4, filtered and the solvent removed in vacuo. After column 
chromatography [silica, PE-EtOAc gradient from 100:0 to 40:60] β-ketoester 216 
(13.8 g, 95 %) was isolated as a pale yellow solid. 
Rf [PE-EtOAc 50:50] 0.43; Mp 84-88 °C (from EtOAc); lit.,
249
 87-88 °C 
(from EtOH); 
1
H NMR δH(400 MHz, CDCl3) 7.20 (2H, s, C(2’)H and C(6’)H), 4.20 
(2H, q, J 7.0 Hz, OCH2CH3), 3.95 (2H, s, C(2)H2), 3.91 (3H, s, OCH3), 3.90 (6H, s, 
OCH) and 1.25 (3H, t, J 7.0 Hz, OCH2CH3); 
13
C NMR δC(100 MHz, CDCl3) 191.2− 
(C3=O), 167.5− (CO2Et), 153.1− (C(Ar)-O), 143.1− (C(Ar)-O), 131.1− (C1’-C), 
106.1+ (C2’-H), 61.5− (OCH2CH3), 61.0+ (OCH3), 56.3+ (OCH3), 46.1− (C2) and 
14.1+ (OCH2CH3); 
Spectroscopic data is consistent with that reported by Lawrence et al.
250
 
 
 
 
 
 
 
 
 148 
 
Ethyl 2-(3’,4’,5’-trimethoxybenzoyl)-5-oxohexanoate (217) 
 
 
 
K2CO3 (4.1 g, 29.7 mmol) was added to a vigorously stirred solution of β-
ketoester 216 (7.60 g, 27 mmol) in anhydrous MeCN (120 mL) at 0 °C under N2. 
After 10 mins, MVK (2.41 mL, 29.7 mmol) was added and the reaction allowed to 
warm to r.t.. After 1 ½ hrs, the reaction was quenched with saturated aqueous NH4Cl 
(20 mL), then extracted with EtOAc (3 x 100 mL). The combined organic fractions 
were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and the 
solvent removed in vacuo. After column chromatography [silica, PE-EtOAc gradient 
from 90:10 to 50:50] the product 217 (9.30 g, 98 %) was isolated as a pale yellow 
oil. 
Rf [PE-EtOAc 50:50] 0.53; IR νmax(Thin film) 2979, 2840, 1731 (C=O), 1722 
(C=O), 1681 (C=O), 1584, 1505, 1455, 1416, 1337, 1234, 1126 and 1002; 
1
H NMR 
δH(400 MHz, CDCl3) 7.37 (2H, s, C(2’)H and C(6’)H), 4.43 (1H, dd, J 9.0 and 6.0 
Hz, C(2)H), 4.19-4.13 (2H, m, OCH2CH3), 3.94 (6H, s, OCH3), 3.92 (3H, s, OCH3), 
2.64-2.55 (2H, m, C(4)H2), 2.28-2.15 (2H, m, C(3)H2), 2.13 (3H, s, C(6)H3) and 1.20 
(3H, t, J 7.5 Hz, OCH2CH3); 
13
C NMR δC(100 MHz, CDCl3) 208.0− (C5=O), 
194.2− (ArC=O), 170.0− (CO2Et), 153.1− (C(Ar)-O), 143.0− (C(Ar)-O), 130.8− 
(C1’), 106.2+ (C2’ and C6’), 61.4− (OCH2CH3), 60.9+ (OCH3), 56.3+ (OCH3), 
52.6+ (C2), 40.5− (C4), 30.0+ (C6), 23.0− (C3) and 14.0+ (OCH2CH3); MS (+ESI) 
m/z 353 (M+H
+
 100 %) and 375 (M+Na
+
, 69); HRMS (+ESI) Found M+H
+
, 
353.1601; C18H25O7 requires M+H
+
 353.1600. 
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Ethyl 2-(3’,4’,5’trimethoxyphenyl)-4-oxocyclohex-2-enecarboxylate (218) 
 
 
 
p-TsOH (2.85 g, 15.2 mmol) in toluene (225 mL) was heated at reflux with 
azeotropic removal of water using Dean-Stark trap under Ar for 1 hr, then β-
ketoester 217 (12.31 g, 34.9 mmol) was added and heated continued for a further 24 
hrs. After cooling to r.t., the solvent was removed in vacuo and column 
chromatography [silica, PE-EtOAc gradient from 100:0 to 70:30] afforded the enone 
product 218 (6.18 g, 53 %) as a pale yellow solid. 
Rf [PE-EtOAc 50:50] 0.52; Mp 107-110 °C (from Et2O); IR νmax(thin film) 
2938, 2839 (C-H), 1728 (C=O), 1661 (C=O), 1597, 1576, 1518 (C=C), 1463, 1419, 
1328, 1252 (C-O), 1151, 1022; 
1
H NMR δH(400 MHz, CDCl3) 6.72 (2H, s, C(2’)H), 
6.45 (1H, s, C(3)H), 4.13 (2H, q, J 7.0 Hz, OCH2CH3), 3.93 (1H, t, J 4.5 Hz, C(1)H), 
3.87 (9H, s, OCH3), 2.69-2.61 (1H, m, C(5)HAHB), 2.51-2.36 (3H, m, C(5)HAHB and 
C(6)H2) and 1.14 (3H, t, J 7.0 Hz, OCH2CH3); 
13
C NMR δC(100 MHz, CDCl3) 
198.5− (C4=O), 171.7− (CO2Et), 155.3− (C1’), 153.3− (C3’), 139.9− (C4’), 133.2− 
(C1), 126.7+ (C6), 103.8+ (C2’), 61.5− (OCH2CH3), 60.9+ (C(4’)OCH3), 56.2+ 
(C(3’)OCH3), 43.7+ (C1), 34.0− (C5), 26.6− (C6) and 14.1+ (OCH2CH3); MS 
(+ESI) m/z 335 (M+H
+
, 100 %); HRMS (+ESI) Found M+H
+
, 335.1495; C18H22O6 
requires M+H
+
 335.1495; HPLC tR 14.7 (98 %). 
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2-(3,4’,5’-Trimethoxyphenyl)-4-oxocyclohex-2-enecarboxylic acid (219) 
 
 
 
LiOH.H2O (1.05 g, 25 mmol) was added to a stirred suspension of ester 218 
(1.67 g, 5 mmol) in 1:1 EtOH/H2O (25 mL) at 0 °C then the reaction was allowed to 
warm to r.t. After 45 mins, the reaction was diluted with H2O (20 mL) and washed 
with Et2O (3 x 20 mL). The aqueous fraction was cooled to 0 °C and acidified to pH 
2 with 6M HCl, then extracted with Et2O (3 x 20 mL). The combined organic 
extracts were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and 
the solvent removed in vacuo to afford the acid 219 (1.19 g, 78 %) as a brown oil 
without further purification. 
Rf [CH2Cl2-MeOH 90:10] 0.41; IR νmax(thin film) 2938, 2839 (C-H), 1728 
(C=O), 1661 (C=O), 1597, 1576, 1518 (C=C), 1463, 1419, 1328, 1252 (C-O), 1151, 
1022; 
1
H NMR δH(400 MHz, CDCl3) 6.75 (2H, s, C(2’)H), 6.50 (1H, s, C(3)H), 3. 
99 (1H, dd, J 4.5, 4.0 Hz, C(1)H), 3.87 (3H, s, C(4’)OCH3), 3.86 (6H, s, 
C(3’)OCH3), 2.71-2.63 (1H, m, C(5)HAHB) and 2.54-2.40 (3H, m, C(5)HAHB and 
C(6)H2); 
13
C NMR δC(100 MHz, CDCl3) 198.8− (C4=O), 176.4− (CO2H), 154.7− 
(C1’), 153.4− (C3’), 140.2− (C4’), 132.6− (C2), 126.7+ (C3), 103.9+ (C2’), 60.9+ 
(C(4’)OCH3), 56.2+ (C(3’)OCH3), 42.8+ (C1), 33.6− (C5) and 26.3− (C6). 
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Methyl (3',4',5'-trimethoxy-5-oxo-2,3,4,5-tetrahydro-[1,1'-biphenyl]-2-
yl)carbamate (223) 
 
 
 
Diphenylphosphoryl azide (172 µL, 0.78 mmol) was added to a vigorously 
stirred solution of acid 219 (130 mg, 0.39 mmol), Na2CO3 (64 mg, 0.60 mmol) and 
NaN3 (130 mg, 2 mmol) in anhydrous acetone (3 mL) at r.t. under Ar. After 1 hr, the 
reaction was heated at reflux for 1 hr. The solvent was removed in vacuo, MeOH (4 
mL) added and the reaction stirred at r.t. for 16 hrs. The reaction was quenched with 
saturated aqueous NaHCO3 (15 mL) and extracted with EtOAc (3 x 15 mL). The 
combined organic fractions were washed with brine (10 mL), dried over anhydrous 
Na2SO4, filtered and the solvent removed in vacuo. After column chromatography 
[silica, PE-EtOAc gradient from 100:0 to 0:100] the methyl carbamate 223 (25 mg, 
19 %) was obtained as an amorphous solid. 
Rf [PE-EtOAc 50:50] 0.15; IR νmax(thin film) 3318 (NH), 2945, 2840, 1696 
(C=O), 1664 (C=O), 1578, 1508, 1452, 1416, 1345, 1244 and 1127; 
1
H NMR 
δH(400 MHz, CDCl3) 6.79 (2H, s, C(2’)H), 6.38 (1H, s, C(6)H), 5.14 (1H, broad s, 
C(2)H), 4.91 (1H, broad d, J 9.0 Hz, NH), 3.88 (3H, s, C(4’)OCH3), 3.86 (6H, s, 
C(3’)OCH3), 3.66 (3H, s, carbamate OCH3), 2.60-2.48 (2H, m, C(4)H2) and 2.36-
2.19 (2H, m, C(3)H2); 
13
C NMR δC(100 MHz, CDCl3) 198.4− (C5=O), 157.1− (C1), 
156.4− (CO2Me), 153.4− (C3’), 140.2− (C4’), 131.0− (C1’), 126.4+ (C6), 104.2+ 
(C2’), 60.9+ (C(4’)OCH3), 56.2+ (C(3’)OCH3), 52.5+ (CO2CH3), 46.6+ (C2), 33.3− 
(C4) and 29.4− (C3); MS (+ESI) m/z 336 (M+H+, 100 %) and 358 (M+Na+, 9); 
HRMS (+ESI) Found M+H
+
, 336.1441; C17H21NO6 requires M+H
+
 336.1447. 
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6-Chloro-1,2,3-trimethoxyfluoren-9-one (224) and 6,7,8-trimethoxy-1H-
fluorene-3,9(2H,9aH)-dione (225) 
 
 
 
Oxalyl chloride (175 µL, 2 mmol) and DMF (39 µL, 0.5 mmol) were added 
to the acid 219 (309 mg, 1 mmol) in CH2Cl2 (5 mL) under Ar at 0 °C and the 
reaction was allowed to warm to r.t. After 1 hr, the solvent was removed and the 
residue dissolved in acetone (5 mL), then the solution was added dropwise over 10 
mins to a stirred solution of NaN3 (130 mg, 2 mmol) in H2O (5 mL) at 0 °C and the 
biphasic mixture stirred vigorously for a further 20 mins. The reaction was diluted 
with H2O (10 mL) and extracted with EtOAc (3 x 15 mL). The combined organic 
fractions were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered 
and the solvent removed in vacuo. The orange/brown solid was treated with 
BF3·OEt2 (1 mL) under Ar and the reaction stirred at r.t. for 18 hrs. The mixture was 
quenched with 2M NaOH (10 mL) and extracted with EtOAc (3 x 15 mL). The 
combined organic fractions were washed with brine (10 mL), dried over anhydrous 
Na2SO4, filtered and the solvent removed in vacuo. After column chromatography 
[silica, PE-EtOAc gradient from 100:0 to 40:60] the fluoren-9-one product 224 (27 
mg, 9 %) was isolated as an oil and the fluoren-3,9-dione product 225 (81 mg, 28 %) 
as a solid. 
 
Fluoren-9-one (224) 
Rf [PE-EtOAc 50:50] 0.75; IR νmax(thin film) 2940, 1704 (C=O), 1605, 1476, 
1410, 1308, 1289, 1245, 1199, 1128 and 975; 
1
H NMR δH(400 MHz, CDCl3) 7.49 
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(1H, d, J 8.0 Hz, C(8)H), 7.38 (1H, d, J 1.5 Hz, C(5)H), 7.21 (1H, dd, J 8.0 and 1.5 
Hz, C(7)H), 6.80 (1H, s, C(4)H), 4.11 (3H, s, OCH3), 3.98 (3H, s, OCH3) and 3.86 
(3H, s, OCH3); 
13
C NMR δC(100 MHz, CDCl3) 189.0− (C9=O), 159.3− (C3-O), 
153.7− (C1-O), 144.6− (C4b), 142.7− (C2-O), 140.6− (C9a), 140.1− (C8a), 133.5− 
(C6-Cl), 128.6+ (C7), 124.7+ (C8), 120.0+ (C5), 118.4− (C4a), 62.2+ (OCH3), 61.4+ 
(OCH3) and 56.5+ (OCH3); MS (+ESI) m/z 305 (M+H
+
, 100 %); HRMS (+ESI) 
Found M+H
+
, 305.0587; C16H14O4Cl requires M+H
+
 305.0575. 
 
Fluoren-3,9-dione (225)  
Rf [PE-EtOAc 50:50] 0.25; Mp 152-156 °C (from EtOAc); IR νmax(thin film) 
2942, 1715 (C=O), 1660 (C=O), 1586, 1480, 1335, 1255, 1137 and 1007; 
1
H NMR 
δH(400 MHz, CDCl3) 7.26 (1H, s, C(5)H), 6.32 (1H, d, J 2.0 Hz, C(4)H), 4.06 (3H, 
s, OCH3), 3.98 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.33 (1H, ddd, J 12.5, 5.0 and 2.0 
Hz, C(9a)H), 2.66 (1H, ddd, J 17.5, 4.5 and 1.5 Hz, C(2)HAHB), 2.57 (1H, dddd, J 
13.0, 5.0, 5.0 and 2.0 Hz, C(1)HAHB), 2.47 (1H, ddd, J 15.5, 13.0 and 4.0 Hz, 
C(2)HAHB) and 1.79 (1H, ddd, J 26.5, 13.5 and 4.5 Hz, C(1)HAHB); 
13
C NMR 
δC(100 MHz, CDCl3) 198.9− (C3=O), 196.4− (C9=O), 160.1− (C(Ar)-O), 156.9− 
(C8a), 151.6− (C(Ar)-O), 145.2− (C(Ar)-O), 142.0− (C4a), 123.9− (C4b), 118.1+ 
(C4), 100.0+ (C5), 62.2+ (OCH3), 61.5+ (OCH3), 56.6+ (OCH3), 48.9+ (C9a), 37.5− 
(C2) and 23.2− (C1); MS (+ESI) m/z 289 (M+H+, 100 %) and 311 (M+Na+, 8);  
HRMS (+ESI) Found M+H
+
, 289.1076; C16H17O5 requires M+H
+
 289.1076. 
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3',4',5'-Trimethoxy-5,6-dihydro-[1,1'-biphenyl]-3(4H)-one (220) 
 
 
Oxalyl chloride (175 µL, 2 mmol) and DMF (39 µL, 0.5 mmol) were added 
to a stirred solution of acid 219 (309 mg, 1 mmol) in CH2Cl2 (5 mL) under Ar at −10 
°C. After 1 hr, the solution was added dropwise over 10 mins to a stirred of biphasic 
mixture NaN3 (130 mg, 2 mmol) in acetone/H2O (1:1, 8 mL) at 0 °C. After 20 mins, 
the reaction was diluted with H2O (10 mL) and extracted with CH2Cl2 (2 x 15 mL). 
The combined organic fractions were washed with brine (10 mL), dried over 
anhydrous Na2SO4, filtered and the solvent removed in vacuo. The orange/brown 
solid was treated with MeOH (5 mL) under Ar and the reaction stirred at r.t. for 24 
hrs. The mixture was quenched with saturated aqueous NH4Cl (10 mL) and extracted 
with EtOAc (3 x 10 mL). The combined organic fractions were washed with brine 
(10 mL), dried over anhydrous Na2SO4, filtered and the solvent removed in vacuo. 
After column chromatography [silica, PE-EtOAc gradient from 100:0 to 0:100] the 
fluoren-3,9-dione product 225 (164 mg, 57 %) was isolated as a solid and 
cyclohexenone 220 (60 mg, 23 %) as an amorphous solid. 
1
H NMR δH(400 MHz, CDCl3) 6.75 (2H, s, C(2’)H and C(6’)H), 6.39 (1H, t, 
J 1.5 Hz, C(2)H), 3.88 (9H, s, OCH3), 2.75 (2H, ddd, J 6.0, 6.0 and 1.5 Hz, C(4)H2), 
2.49 (2H, dd, J 7.0 and 6.0 Hz, C(6)H2) and 2.19-214 (2H, m, C(5)H2); 
13
C NMR 
δC(100 MHz, CDCl3) 199.8− (C3), 159.6− (C1), 153.3− (C3’ and C5’), 140.0− 
(C4’), 134.4− (C1’), 125.1+ (C2), 103.8+ (C2’ and C6’), 61.0+ (C(3’)OCH3 and 
C(5’)OCH3), 56.3+ (C(4)OCH3), 37.2− (C6), 28.3− (C4) and 22.8− (C5). 
 155 
 
Ethyl 4-oxo-2-(3’,4’,5’-trimethoxyphenyl)cyclohexanecarboxylate (226) 
and ethyl 4-hydroxy-2-(3’,4’,5’-trimethoxyphenyl)cyclohexanecarboxylate (230) 
 
 
 
10 % Palladium on activated carbon (50 mg, 0.05 mmol) was added to a 
vigorously stirred solution of ester 218 (334 mg, 1 mmol) in EtOAc (5 mL). The 
suspension was degassed then placed under an atmosphere of H2 at r.t. for 4 hrs. The 
solvent was removed in vacuo and after column chromatography [silica, PE-EtOAc 
gradient from 100:0 to 40:60] the ketone 226 (164 mg, 49 %) was isolated as an oil 
and the alcohol 230 (161 mg, 48 %) as a white solid. 
 
Ketone (226) 
Rf [PE-EtOAc 50:50] 0.51; IR νmax(thin film) 2939, 2839 (C-H), 1714 (ester 
C=O), 1590, 1510, 1462, 1423, 1331, 1251, 1176 and 1127; 
1
H NMR δH(400 MHz, 
CDCl3) 6.33 (2H, s, C(2’)H), 4.00-3.95 (2H, m, OCH2CH3), 3.77 (9H, s, OCH3), 
3.40 (1H, dt, J 10.5 and 5.0, C(2)H), 3.21 (1H, ddd, J 14.5, 10.5 and 1.0 Hz, 
C(3)HAHB), 3.04 (1H, dt, J 10.0 and 5.0 Hz, C(1)H), 2.74 (1H, dddd, J 15.0, 10.5, 
6.0 and 1.0 Hz, C(5)HAHB), 2.55 (1H, ddd, J 14.5, 5.0 and 1.0 Hz, C(3)HAHB), 2.34 
(1H, dtd, J 15.0, 5.5 and 1.5 Hz, C(5)HAHB), 2.20 (1H, ddt, J 14.0, 11.5 and 6.0 Hz, 
C(6)HAHB), 2.08-2.02 (1H, m, C(6)HAHB) and 1.07 (3H, t, J 7.0 Hz, OCH2CH3); 
13
C 
NMR δC(100 MHz, CDCl3) 210.4− (C4=O), 173.1− (CO2Et), 153.1− (C(Ar)-O), 
137.2− (C(Ar)-O), 136.5− (C1’-C), 104.8+ (C2’-H), 60.8+ (OCH3), 60.3− 
(OCH2CH3), 56.2+ (OCH3), 45.2+ (C1 or C2), 44.8+ (C1 or C2), 43.7− (C3), 38.1− 
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(C5), 26.3− (C6) and 14.0+ (OCH2CH3); MS (+ESI) m/z 337 (M+H
+
, 100 %) and 
359 (M+Na
+
, 17); HRMS (+ESI) Found M+H
+
, 337.1642; C18H24O6 requires M+H
+
 
337.1651. 
 
Alcohol (230) 
Rf [PE-EtOAc 50:50] 0.23; Mp 112-115 °C (from EtOAc); IR νmax(thin film) 
3422 (OH), 2937 (C-H), 1722 (ester C=O), 1590, 1509, 1456, 1422, 1329, 1234, 
1184 and  1125; 
1
H NMR δH(400 MHz, CDCl3) 6.43 (2H, s, C(2’)H), 3.88 (2H, q, J 
7.0 Hz, OCH2CH3), 3.80 (6H, s, C(3’)OCH3), 3.79 (3H, s, C(4’)OCH3), 3.74-3.69 
(1H, m, C(4)HOH), 2.83-2.81 (2H, m, C(1)H and C(2)H), 2.39-2.33 (1H, m, 
C(3)HAHB), 2.08-2.02 (2H, m, C(3)HAHB and C(5)HAHB), 1.90-1.71 (4H, m, 
C(5)HAHB, C(6)H2 and OH) and 0.99 (3H, t, J 7.0 Hz, OCH2CH3); 
13
C NMR δC(100 
MHz, CDCl3) 173.6− (C4=O), 152.9− (C(Ar)-O), 138.6− (C1’), 136.7− (C(Ar)-O), 
104.7+ (C2’), 70.8+ (C4), 60.8+ (OCH3), 59.7− (OCH2CH3), 56.1+ (OCH3), 44.8+ 
(C1 or C2), 43.6− (C1 or C2), 35.6− (C3), 30.7− (C6), 27.3− (C5) and 14.0+ 
(OCH2CH3); MS (+ESI) m/z 339 (M+H
+
, 100 %) and 361 (M+Na
+
, 18);  HRMS 
(+ESI) Found M+H
+
, 339.1808; C18H26O6 requires M+H
+
 339.1808. 
 
 
4-Oxo-2-(3,4,5-trimethoxyphenyl)cyclohexanecarboxylic acid (231) 
 
 
LiOH.H2O (105 mg, 2.4 mmol) was added to a stirred solution of ester 226 
(160 mg, 0.48 mmol) in EtOH/H2O (1:1, 2.5 mL) and the reaction stirred for 5 hrs at 
r.t.. The reaction was diluted with H2O (10 mL) and washed with Et2O (3 x 15 mL). 
The aqueous fraction was acidified with 6M HCl then extracted with CH2Cl2 (3 x 15 
mL). The combined organic fractions were dried over anhydrous Na2SO4, filtered 
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and the solvent removed in vacuo to afford the acid 231 (50 mg, 32 %) as white solid 
in a 59:41 mixture of diastereoisomers without further purification. 
Rf [PE-EtOAc 50:50] 0.1; 
1
H NMR δH(400 MHz, CDCl3) 6.39 (1.2H, s, 
C(2’)H), 6.36 (0.8H, s, C(2’)H), 6.13 (1H, broad s, OH), 3.78 (3.6H, s, C(3’)OCH3), 
3.77 (1.8H, s, C(4’)OCH3), 3.77 (1.4H, s, C(4’)OCH3), 3.73 (2.2H, s, C(3’)OCH3), 
3.49 (0.4H, m, C(2)H), 3.24 (0.6H, ddd J 10.5, 10.5 and 5.0 Hz, C(2)H), 3.18-3.14 
(0.4H, m, C(3)HAHB or C(5)HAHB), 3.11-3.08 (0.4H, m, C(1)H), 2.97 (0.6H, ddd, J 
10.5, 10.5 and 4.0 Hz, C(1)H) and 2.70-1.93 (5H, m, C(3)HAHB or C(5)HAHB, 
C(3)H2 or C(5)H2 and C(6)H2); 
13
C NMR δC(100 MHz, CDCl3) 210.8− (ketone 
C4=O isomer B), 208.9− (ketone C4=O isomer A), 178.2− (acid C=O isomer A), 
177.7− (acid C=O isomer B), 153.3− (C3’ isomer A), 153.1− (C3’ isomer B), 137.4− 
(C1’ or C4’), 137.1− (C1’ or C4’), 137.1− (C1’ or C4’), 136.2− (C1’ or C4’), 105.0+ 
(C2’ isomer B), 104.2+ (C2’ isomer A), 60.8+ (OCH3), 56.1+ (OCH3 isomer A), 
56.0+ (OCH3 isomer B), 47.9+ (C1 isomer A), 47.6− (C3 or C5 isomer A), 46.1+ 
(C2 isomer A), 45.0+ (C1 isomer B), 44.4+ (C2 isomer B), 43.9− (C3 or C5 isomer 
B), 39.5− (C3 or C5 isomer A), 38.2− (C3 or C5 isomer B), 28.3− (C6 isomer A) 
and 25.7− (C6 isomer B); 
 
 
7-Hydroxy-8,9-dimethoxy-1,3,4,4a,5,10b-hexahydrophenanthridine-2,6-
dione (232) 
 
 
 
Diphenylphosphoryl azide (204 µL, 0.95 mmol) was added to a stirred 
solution of arylpropionic acid 231 (0.95 mmol) and anhydrous Et3N (264 μL, 1.9 
mmol) in anhydrous toluene (3 mL) under N2 at r.t. then the reaction heated at 90 °C 
for 30 mins. After cooling to r.t., the solvent was removed in vacuo and the flask 
 158 
 
cooled to 0 °C under N2. BF3·OEt2 (2.5 mL) was added then the reaction was 
allowed to warm to r.t. and stirred for 16 hrs. The reaction was quenched to pH 10 
with 2M NaOH and extracted with EtOAc (2 x 20 mL). The combined organic 
fractions were washed with brine, dried over anhydrous Na2SO4, filtered and the 
solvent removed in vacuo. After column chromatography [silica, PE-EtOAc-MeOH 
gradient from 100:0:0 to 0:90:10] the product 232 (17 mg, 6 %) was isolated as an 
amorphous solid. 
IR νmax(thin film) 3282, 2937, 1715 (C=O), 1651, 1614, 1575, 1455, 1297, 
1239 and 1129; 
1
H NMR δH(400 MHz, CDCl3) 12.39 (0.25H, broad s, C(7)OH), 
12.24 (0.75H, broad s, C(7)OH), 6.71 (1H, broad s, N(5)H), 6.23 (0.75H, s, C(10)H), 
6.18 (0.25H, s, C(10)H), 4.06-4.04 (1H, m, C(4a)H), 3.89 (3H, s, OCH3). 3.88 (3H, 
s, OCH3), 3.19-3.14 (1H, m, C(10b)H), 2.72-2.57 (2H, m, C(1)HAHB and 
C(3)HAHB), 2.52-2.37 (2H, m, C(1)HAHB and C(3)HAHB), 2.34-2.24 (1H, m, 
C(4)HAHB) and 2.15-2.06 (1H, m, C(4)HAHB); 
13
C NMR δC(100 MHz, CDCl3) 
207.7-, 206.8-, 171.3-, 157.6-, 157.4-, 156.4-,  137.5-, 136.3, 135.8-, 129.4+, 120.2+, 
103.8-, 101.3+, 98.6+, 60.7+, 56.1+, 53.8+, 49.3+, 44.2+, 41.7-, 41.6+, 40.6+, 38.6+, 
35.5-, 30.1- and 28.8-; MS (+ESI) m/z 292 (M+H
+
, 33 %) 324 (M+Na
+
, 100); 
HRMS (+ESI) Found M+H
+
, 292.1189; C15H17NO5 requires M+H
+
 292.1179). 
 
 
Ethyl 3',4',5'-trimethoxy-2,3,4,5-tetrahydro-[1,1'-biphenyl]-2-
carboxylate (229)  
 
 
 
NaBH4 (197 mg, 5.2 mmol) was added portionwise over 3 mins to a stirred 
solution of TFA (1.2mL), AcOH (1.2 mL) and MeCN (1.2 mL) at 0 °C  under Ar. 
Ketone 218 (334 mg, 1 mmol) in CH2Cl2 (6 mL) was added and then the reaction 
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was allowed to warm to r.t. and stirred for 4 hrs. The reaction was neutralised with 
saturated aqueous NaHCO3 and extracted with CH2Cl2 (3 x 15 mL). The combined 
organic fractions were washed with brine, dried over anhydrous Na2SO4, filtered and 
the solvent removed in vacuo. After column chromatography [silica, PE-EtOAc 
gradient from 100:0 to 60:40 the ester product 229 (315 mg, 98 %) was isolated as a 
solid. 
Rf [PE-EtOAc 60:40] 0.59; Mp 75-80 °C (from CHCl3); IR νmax(thin film) 
2937, 1731 (C=O), 1581, 1509, 1458, 1414, 1339, 1243, 1152, 1127 and 1009; 
1
H 
NMR δH(400 MHz, CDCl3) 6.53 (2H, s, C(2’)H), 6.14 (1H, td, J 4.0 and 1.0 Hz, 
C(6)H), 4.06-3.97 (2H, m, OCH2CH3), 3.83 (6H, s, C(3’)OCH3), 3.80 (3H, s, 
C(4’)OCH3), 3.65-3.62 (1H, m, C(2)H), 2.88-2.20 (2H, m, C(5)H2), 2.03-1.98 (2H, 
m, C(3)H2), 1.82-1.75 (1H, m, C(4)HAHB), 1.69-1.60 (1H, m, C(4)HAHB) and 1.07 
(3H, t, J 7.0 Hz, OCH2CH3); 
13
C NMR δC(100 MHz, CDCl3) 174.6− (C=O), 153.0− 
(C3’), 137.6− (C1’ or C4’), 137.3− (C1’ or C4’), 134.9− (C1), 128.0+ (C6), 103.1+ 
(C2’), 60.8+ (C(4’)OCH3), 60.4− (OCH2CH3), 56.1+ (C(3’)OCH3), 43.9+ (C2), 
27.1− (C3), 25.5− (C5), 19.4− (C4) and 14.1+ (OCH2CH3); MS (+ESI) m/z 321 
(M+H
+
, 100 %); HRMS (+ESI) Found M+H
+
, 321.1684; C18H25O5 requires M+H
+
 
321.1702. 
 
 
Ethyl 5-acetoxy-3',4',5'-trimethoxy-2,3,4,5-tetrahydro-[1,1'-biphenyl]-2-
carboxylate (233) 
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NaBH4 (66 mg, 1.56 mmol) was added portionwise over 3 mins to a stirred 
solution of TFA (0.4 mL), AcOH (0.4 mL) and MeCN (0.4 mL) at 0 °C  under Ar. 
Ketone 218 (113 mg, 0.3 mmol) in CH2Cl2 (2 mL) was added and then the reaction 
was allowed to warm to r.t. and stirred for 90 mins. The reaction was neutralised 
with saturated aqueous NaHCO3 and extracted with CH2Cl2 (3 x 15 mL). The 
combined organic fractions were washed with brine, dried over anhydrous Na2SO4, 
filtered and the solvent removed in vacuo. After column chromatography [silica, PE-
EtOAc gradient from 100:0 to 60:40] the ester product 229 (69 mg, 72 %) was 
isolated as a white solid and acetate 233 (18 mg, 16 %) as an oil in a 0.55:0.45 
mixture of diastereoisomers. 
Rf [PE-EtOAc 60:40] 0.38; IR νmax(thin film) 2940, 1731 (C=O), 1582, 1508, 
1455, 1415, 1367, 1344, 1240, 1158 and 1127; 
1
H NMR δH(400 MHz, CDCl3) 6.56 
(1.1H, s, C(2’)H), 6.55 (0.9H, s, C(2’)H), 6.12 (0.55H, dd, J 4.0 and 1.5 Hz, C(6)H), 
6.09 (0.45H, dd, J 4.0 and 1.5 Hz, C(6)H), 5.48-5.45 (0.55H, m, C(5)H), 5.44-5.40 
(0.45H, m, C(5)H), 4.06-3.99 (2H, m, OCH2CH3), 3.84 (6H, s, OCH3), 3.83 (3H, s, 
OCH3), 3.73-3.69 (0.55H, m, C(2)H), 3.63-3.60 (0.45H, m, C(2)H), 2.20-1.74 (7H, 
m, CH3C=O, C(3)H2 and C(4)H2) 1.07 (1.35H, t, J 7.0 Hz, OCH2CH3) and 1.07 
(1.65H, t, J 7.0 Hz, OCH2CH3); 
13
C NMR δC(100 MHz, CDCl3) 173.6− (CO2Et 
isomer B), 173.3− (CO2Et isomer A), 170.9− (CH3C=O isomer B), 170.6− (CH3C=O 
isomer A), 153.1− (C3’), 139.9− (C1 isomer A), 139.7− (C1 isomer B), 138.1− 
(C4’), 135.9− (C1’ Isomer A), 135.8− (C1’ isomer B), 125.5+ (C6 isomer B), 125.3+ 
(C6 isomer A), 103.5+ (C2’ isomer A), 103.4+ (C2’ isomer B), 68.1+ (C5 isomer B), 
68.0+ (C5 isomer A), 60.9+ (C(4’)OCH3), 60.8− (OCH2CH3), 56.2+ (C(3’)OCH3), 
43.9+ (C2 isomer B), 43.6+ (C2 isomer A), 25.5− (C3 or C4 isomer A), 25.4− (C3 or 
C4 isomer B), 24.1− (C3 or C4 isomer A), 23.4− (C3 or C4isomer A), 21.4+ 
(CH3C=O isomer B), 21.3+ (CH3C=O isomer A) and 14.0+ (OCH2CH3); MS (+ESI) 
m/z 319 (M-CH3CO2H+H
+
, 100 %) and 401 (M+Na
+
, 20); HRMS (+ESI) Found 
M+Na
+
, 401.1586; C20H26O7Na requires M+Na
+
 401.1576. 
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3',4',5'-Trimethoxy-2,3,4,5-tetrahydro-[1,1'-biphenyl]-2-carboxylic acid 
(234)  
 
 
 
A stirred solution of ester 229 (315 mg, 0.98 mmol) in 1M NaOH/EtOH (1:1 
10 mL) was heated at reflux for 6 hrs. The solution was cooled to 0 °C, acidified to 
pH 2 with 6M HCl and extracted with CH2Cl2 (3 x 15 mL). The combined organic 
fractions were washed with brine (15 mL), dried over anhydrous Na2SO4, filtered 
and the solvent removed in vacuo to afford the acid 234 (226 mg, 79 %) as a white 
solid without further purification 
Mp 143-147 °C (from CHCl3); IR νmax(thin film) 3161 (OH), 2937, 1073 
(C=O), 1582, 1509, 1451, 1414, 1346, 1124 and 1004; 
1
H NMR δH(400 MHz, 
CDCl3) 6.55 (2H, s, C(2’)H), 6.20 (1H, dt, J 4.0 and 1.0 Hz, C(6)H), 3.84 (6H, s, 
C(3’)OCH3), 3.83 (3H, s, C(4’)OCH3), 3.68 (1H, t, J 4.5 Hz, C(2)H), 2.33-2.18 (2H, 
m, C(5)H2), 2.15-2.09 (1H, m, C(3)HAHB), 2.06-1.97 (1H, m, C(3)HAHB) and 1.83-
1.65 (2H, m, C(4)H2); 
13
C NMR δC(100 MHz, CDCl3) 178.8− (CO2H), 153.1− 
(C3’), 137.5− (C1’), 137.1− (C4’), 134.1− (C1), 128.6+ (C6), 103.0+ (C2’), 60.8+ 
(OCH3), 56.1+ (OCH3), 42.9+ (C2), 27.0− (C5), 25.5− (C3) and 19.1− (C4); MS 
(+ESI) m/z 293 (M+H
+
, 100 %) and 315 (M+Na
+
, 20);  HRMS (+ESI) Found 
M+Na
+
, 315.1196; C16H20O5Na requires M+Na
+
 315.1208. 
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7-Hydroxy-8,9-dimethoxy-3,4,4a,5-tetrahydrophenanthridin-6(2H)-one 
(236)  
 
 
 
Diphenylphosphoryl azide (81 μL, 0.37 mmol) and Et3N (51 μL, 0.37 mmol) 
were added to a stirred suspension of acid 234 (100 mg, 0.34 mmol) in anhydrous 
toluene (1 mL) at r.t. under Ar. The reaction was heated at 90 °C  for 45 mins, then 
the solvent was removed in vacuo and the residue treated with BF3·OEt2 (0.3 mL) 
and heated at 50 °C under Ar. After 16 hrs, the reaction mixture was quenched with 
2M NaOH (5 mL), diluted with EtOAc (2 mL) and heated at 50 °C for 4 hrs. After 
cooling, the layers were separated and the aqueous fraction further extracted with 
EtOAc (3 x 15 mL). The combined organic fractions were washed with brine (15 
mL), dried over anhydrous Na2SO4, filtered and the solvent removed in vacuo. After 
column chromatography [silica, EtOAc-PE gradient from 0:100 to 50:50] the lactam 
236 (43 mg, 46 %) was isolated as a white solid. 
Rf [EtOAc-PE 4:6] 0.26; Mp 202-205 °C (from EtOAc); IR νmax(thin film) 
3417, 2935, 1651 (C=O), 1568, 1455, 1376, 1336, 1287, 1255 and 1122; 
1
H NMR 
δH(400 MHz, CDCl3) 12.67 (1H, s, C(7)OH), 6.73 (1H, s, N(5)H), 6.51 (1H, s, 
C(10)H), 6.20 (1H, ddd, J 5.0, 2.5 and 2.5 Hz, C(1)H), 4.30-4.27 (1H, m, C(4a)H), 
3.90 (3H, s, C(9)OCH3), 3.88 (3H, s, C(8)OCH3), 2.40-2.21 (2H, m, C(2)H2), 2.16-
2.11 (1H, m, C(4)HAHB), 1.90-1.87 (1H, m, C(3)HAHB) and 1.68-1.59 (2H, m, 
C(3)HAHB and C(4)HAHB); 
13
C NMR δC(100 MHz, CDCl3) 169.7− (C6=O), 157.2− 
(C9), 155.5− (C7-OH), 136.3− (C8), 133.7− (C10b), 130.4− (C10a), 125.9+ (C1), 
104.3− (C6a), 97.4+ (C10), 60.7+ (C(8)OCH3), 56.0+ (C(9)OCH3), 50.7+ (C4a), 
29.6− (C4), 25.9− (C2) and 20.0− (C3); MS (+ESI) m/z 276 (M+H+, 100 %) and 298 
(M+Na
+
, 13); HRMS (+ESI) Found M+Na
+
, 298.1054; C15H27NO4Na requires 
M+Na
+
 298.1055; HPLC tR 13.0 (97 %). 
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5.3.3. Successful Synthesis of the Dimethoxy Analogue 
Ethyl 3',4'-dimethoxy-2,3,4,5-tetrahydro-[1,1'-biphenyl]-2-carboxylate 
(237) 
 
 
 
NaBH4 (197 mg, 5.2 mmol) was added portionwise over 3 mins to a stirred 
solution of TFA (1.2mL), AcOH (1.2 mL) and MeCN (1.2 mL) at 0 °C under Ar. 
Ketone 206 (304 mg, 1 mmol) in CH2Cl2 (6 mL) was added and then the reaction 
was allowed to warm to r.t. and stirred for 4 hrs. The reaction was neutralised with 
saturated aqueous NaHCO3 and extracted with CH2Cl2 (3 x 15 mL). The combined 
organic fractions were washed with brine, dried over anhydrous Na2SO4, filtered and 
the solvent removed in vacuo. After column chromatography [silica, PE-EtOAc 
gradient from 100:0 to 80:20] the ester product 237 (241 mg, 83 %) was isolated as a 
colourless oil. 
Rf [PE-EtOAc 60:40] 0.57; IR νmax(thin film) 2935, 1731 (C=O), 1603, 1582, 
1517, 1463, 1252, 1169, 1149, 1028 and 803; 
1
H NMR δH(400 MHz, CDCl3) 6.87 
(1H, d, J 2.0 Hz, C(2’)H), 6.84 (1H, dd, J 8.5 and 2.0 Hz, C(6’)H), 6.77 (1H, d, J 8.5 
Hz, C(5’)H), 6.12 (1H, td, J 4.0 and 1.0 Hz, C(6)H), 4.05-3.96 (2H, m, OCH2CH3), 
3.86 (3H, s, OCH3), 3.84 (3H, s, OCH3), 3.66-3.63 (1H, m, C(2)H), 2.32-2.15 (2H, 
m, C(5)H2), 2.07-1.94 (2H, m, C(3)H2), 1.83-1.73 (1H, m, C(4)HAHB), 1.69-1.60 
(1H, m, C(4)HAHB) and 1.07 (3H, t, J 7.0 Hz, OCH2CH3); 
13
C NMR δC(100 MHz, 
CDCl3) 174.7− (C=O), 148.7− (C4’), 148.2− (C3’), 134.8− (C1), 134.5− (C1’), 
127.0+ (C6), 117.8+ (C5’), 111.0+ (C6’), 109.3+ (C2’), 60.4− (OCH2CH3), 55.9+ 
(OCH3), 55.8+ (OCH3), 43.9+ (C2), 27.1− (C3), 25.5− (C5), 19.4− (C4) and 14.1+ 
(OCH2CH3); MS (+ESI) m/z 291 (M+H
+
, 93 %); HRMS (+ESI) Found M+H
+
, 
291.1593; C17H23O4 requires M+H
+
 291.1596. 
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3',4'-Dimethoxy-2,3,4,5-tetrahydro-[1,1'-biphenyl]-2-carboxylic acid 
(238) 
 
 
 
Ester 237 (212 mg, 0.73 mmol) was stirred in refluxing 1M NaOH/EtOH 
(1:1, 8 mL) for 5 hrs. The solution was then cooled to 0 °C, acidified to pH 2 with 
6M HCl and extracted with CH2Cl2 (3 x 15 mL). The combined organic fractions 
were washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and the 
solvent removed in vacuo to afford the acid 238 (160 mg, 84 %) as a white solid 
without further purification. 
Mp 102-106 °C (from CHCl3); IR νmax(thin film) 2935, 1703 (C=O), 1516, 
1463, 1251, 1168, 1145 and 1025; 
1
H NMR δH(400 MHz, CDCl3) 6.89 (1H, d, J 2.0 
Hz, C(5’)H), 6.86 (1H, dd, J 8.5 and 2.0 Hz, C(6’)H), 6.79 (1H, d, J 8.5 Hz, C(2’)H), 
6.17 (1H, td, J 4.5 and 1.0 Hz, C(6)H), 3.86 (3H, s, OCH3), 3.86 (3H, s, OCH3), 
3.69-3.67 (1H, m, C(2)H), 2.33-2.22 (2H, m, C(5)H2), 2.15-2.01 (1H, m, C(3)HAHB), 
2.04-1.95 (1H, m, C(3)HAHB) and 1.83-1.62 (2H, m, C(4)H2); 
13
C NMR δC(100 
MHz, CDCl3) 179.3− (C=O), 148.9− (C4’), 148.3− (C3’), 134.3− (C1), 133.6− 
(C1’), 127.6+ (C6), 117.6+ (C6’), 111.1+ (C5’), 109.2+ (C2’), 55.9+ (OCH3), 55.8+ 
(OCH3), 42.8+ (C2), 27.0− (C3), 25.5− (C5) and 19.4− (C4); MS (+ESI) m/z 263 
(M+H
+
, 44 %), 285 (M+Na
+
, 100); HRMS (+ESI) Found M+H
+
, 263.1284; 
C15H19O4 requires M+H
+
 263.1283. 
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8,9-Dimethoxy-3,4,4a,5-tetrahydrophenanthridin-6(2H)-one (239) and 
8,9-Dimethoxy-1,2,3,4-tetrahydrophenanthridin-6(5H)-one (240) 
 
 
 
Diphenylphosphoryl azide (131 μL, 0.61 mmol) was added to a stirred 
mixture of acid 238 (160mg, 0.61 mmol) and Et3N (84 μL, 0.61 mmol) in anhydrous 
toluene (5 mL) at r.t. under Ar. The reaction was heated at 90 °C for 1 hr, then the 
solvent was removed in vacuo and the residue was treated with BF3·OEt2 (1.5 mL) at 
r.t. under Ar. The mixture was heated at 50 °C for 16 hrs then was quenched with 
2M NaOH (15 mL), diluted with EtOAc (10 mL) and heated at 50 °C for 3 hrs. After 
cooling to r.t., the layers were separated and the aqueous fraction further extracted 
with EtOAc (3 x 15 mL). The combined organic fractions were washed with brine 
(15 mL), dried over anhydrous Na2SO4, filtered and the solvent removed in vacuo. 
After column chromatography [silica, PE-EtOAc-MeOH gradient from 100:0:0 to 
0:100:0 to 0:90:10] the lactam 239 (53 mg, 34 %) was isolated as a white solid and 
lactam 240 (37 mg, 23 %) as a white solid. 
 
Lactam (239) 
Rf [EtOAc] 0.38; Mp 250-253 °C (from EtOAc); IR νmax(thin film) 3175 
(NH), 2905, 2843, 1659 (C=O), 1591, 1555, 1508, 1469, 1456, 1425, 1381, 1277 
and  1210; 
1
H NMR δH(400 MHz, d6-DMSO) 7.85 (1H, s, N(5)H), 7.37 (1H, s, 
C(7)H), 7.08 (1H, s, C(10)H), 6.30-6.28 (1H, m, C(1)H), 4.24-4.23 (1H, m, C(4a)H), 
3.86 (3H, s, OCH3), 3.80 (3H, s, OCH3), 2.33-2.26 (1H, m, C(2)HAHB), 2.22-2.18 
(1H, m, C(2)HAHB), 2.13-2.11 (1H, m, C(4)HAHB), 1.82-1.76 (1H, m, C(3)HAHB) 
and 1.60-1.46 (2H, m, C(3)HAHB and C(4)HAHB); 
13
C NMR δC(100 MHz, d6-
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DMSO) 163.7− (C6=O), 152.0− (C9), 148.5− (C8), 130.7− (C10 a or C10 b), 130.6− 
(C10a or C10b), 123.8+ (C1), 119.9− (C6a), 109.1+ (C7), 105.5+ (C10), 55.7+ 
(C(9)OCH3), 55.4+ (C(8)OCH3), 50.3+ (C4a), 29.2− (C4), 25.2− (C2) and 19.8− 
(C3); MS (+ESI) m/z 260 (M+H
+
, 100 %) and 282 (M+Na
+
, 33); HRMS (+ESI) 
Found M+H
+
, 260.1305; C15H18NO3 requires M+H
+
 260.1281; HPLC tR 11.4 (98 
%). 
 
Lactam (240) 
Rf [EtOAc] 0.25; Mp sublimes above 255 °C then recrystallises and melts 
297-300 °C but with accompanying decomposition (from EtOAc); IR νmax(thin film) 
3735 (NH), 2918, 1637 (C=O), 1609, 1508, 1266, 1206 and 1021; 
1
H NMR δH(500 
MHz, d6-DMSO) 10.89 (1H, s, N(5)H), 7.58 (1H, s, C(10)H), 6.98 (1H, s, C(7)H), 
3.91 (3H, s, C(9)OCH3), 3.85 (3H, s, C(8)OCH3), 2.61 (2H, t, J 5.5H, C(1)H2), 2.52-
2.49 (2H, m, C(4)H2) and 1.79-1.74 (4H, m, C(2)H2 and C(3)H2); 
13
C NMR δC(125 
MHz, d6-DMSO) 160.8− (C6=O), 152.9− (C9), 147.6− (C8), 134.5− (C4a); 133.3− 
(C10a), 118.3− (C6a), 107.1+ (C10 and C10b), 102.9+ (C7), 55.6+ (C(9)OCH3), 
55.4+ (C(8)OCH3), 26.4− (C1), 22.8+ (C4), 22.1− (C2 or C3) and 21.6− (C2 or C3); 
MS (+ESI) m/z 260 (M+H
+
, 100 %), 282 (M+Na
+
, 9) and 519 (2M+Na
+
, 56); 
HRMS (+ESI) Found M+H
+
, 260.1324; C15H18NO3 requires M+H
+
 260.1281; 
HPLC tR 11.4 (100 %). 
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5.4. PRENYLATIONS 
General procedure 3: Esterification of carboxylic acids 
Following the procedure reported by Bourdron et al.,
251
 H2SO4 (1 drop/mmol) was 
added to a rapidly stirred solution of carboxylic acid in MeOH (10 mL/mmol) at r.t. 
The reaction was heated at reflux until the acid had been consumed by TLC. The 
solvent was then removed in vacuo, the residue taken up in saturated aqueous 
NaHCO3 and extracted with 3 x EtOAc. The combined organic fractions were 
washed with brine, dried over anhydrous Na2SO4, filtered and the solvent removed in 
vacuo to afford the ester without need for further purification. 
 
Methyl 3-(3’,4’,5’-trimethoxyphenyl)propanoate (262)  
 
 
 
Following general procedure 3, acid 149 (1.20 g, 5 mmol) gave ester 262 
(1.20 g, 94 %) as an oil. 
IR νmax(thin film) 2947, 2839, 1737 (C=O), 1590, 1508, 1456, 1422, 1240, 
1127 and 1009; 
1
H NMR δH(400 MHz, CDCl3) 6.41 (2H, s, C(Ar)-H), 3.83 (6H, s, 
OCH3), 3.81 (3H, s, OCH3), 3.67 (3H, s, OCH3), 2.89 (2H, t, J 8.0 Hz, C(3)H2) and 
2.62 (2H, t, J 8.0 Hz, C(2)H2); 
13
C NMR δC(100 MHz, CDCl3) 173.2− (C1=O), 
153.2− (C(Ar)-O), 136.3− (C(Ar)-O), 105.3+ (C2’ and C6’), 60.8+ (ArOCH3), 56.0+ 
(ArOCH3), 51.6+ (CO2CH3), 35.8− (C3) and 31.3− (C2). 
Spectroscopic data is consistent with reported by Kumar et al.
252
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(E)-Methyl 3-(3’,4’,5’-trimethoxyphenyl)acrylate (253) 
 
 
 
Following general procedure 3, the acid (1.19 g, 5 mmol) gave ester 253 
(1.18g, 94 %) as a white solid. 
Rf [PE-EtOAc 80:20] 0.38; 
1
H NMR δH(400 MHz, CDCl3) 7.60 (1H, d, J 
16.0 Hz, C(3)H), 6.75 (2H, s, C(2’)H and C(6’)H), 6.34 (1H, d, J 16.0 Hz, C(2)H), 
3.88 (6H, s, OCH3), 3.87 (3H, s, OCH3) and 3.80 (3H, s, OCH3); 
13
C NMR δC(100 
MHz, CDCl3) 167.4− (C1=O), 153.4− (Ar), 144.8+ (C3), 140.1− (Ar), 129.9− (Ar), 
117.0+ (C2), 105.2+ (C2’ and C6’), 60.9+ (OCH3), 56.1+ (OCH3) and 51.7+ 
(OCH3). 
Spectroscopic data is consistent with that reported by Bourdron et al.
251
 
 
 
 (E)-Methyl 3-(3’,4’-dimethoxyphenyl)acrylate (269) 
 
 
 
Following general procedure 3, the acid (1.56 g, 7.5 mmol) gave ester 269 
(1.50 g, 90 %) as a white solid.  
IR νmax(thin film) 2950, 2838, 1712 (C=O), 1636, 1599, 1514, 1464, 1438, 
1259, 1196, 1140 and 1024; 
1
H NMR δH(400 MHz, CDCl3) 7.66 (1H, d, J 16.0 Hz, 
C(3)H), 7.13 (1H, dd, J 8.5 and 2.0 Hz, C(6’)H), 7.08 (1H, d, J 2.0 Hz, C(2’)H), 6.89 
(1H, d, J 8.5 Hz, C(5’)H), 6.34 (1H, d, J 16.0 Hz, C(2)H), 3.94 (6H, s, ArOCH3) and 
3.82 (3H, s, CO2CH3); 
13
C NMR δC(100 MHz, CDCl3) 167.6− (C=O), 151.2− 
(C(Ar)-O), 149.3− (C(Ar)-O), 144.8+ (C3), 127.4− (C1’), 122.6+ (C(Ar)-H), 115.6− 
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(C2), 111.1+ (C(Ar)-H), 109.8+ (C(Ar)-H), 56.0+ (ArOCH3), 55.9+ (ArOCH3) and 
51.6+ (CO2CH3). 
Spectroscopic data is consistent with that reported by El-Batta et al.
253
 
 
 
Methyl 3,4,5-trimethoxybenzoate (262) 
 
 
 
Following general procedure 3, the acid (1.06 g, 5 mmol) gave the ester 262 
(1.05 g, 93 %) as a white solid.  
1
H NMR δH(400 MHz, CDCl3) 7.30 (2H, s, C(Ar)-H) and 3.90 (12H, s, 
OCH3); 
13
C NMR δC(100 MHz, CDCl3) 166.7− (C=O), 153.0− (C(Ar)-O), 142.3− 
(C(Ar)-O), 125.2− (C(Ar)-C), 107.0+ (C(Ar)-H), 60.9+ (OCH3), 56.3+ (OCH3) and 
52.3+ (OCH3); 
Spectroscopic data is consistent with that reported by Elsinghorst et al.
254
 
 
 
Methyl 4-hydroxybenzoate (290) 
 
 
 
Following general procedure 3, acid 292 (966 mg, 7 mmol) gave ester 290 
(1.04 g, 98 %) as a white solid. 
IR νmax(thin film) 3253 (OH), 2946, 1687 (C=O), 1608, 1585, 1517, 1438, 
1280, 1233, 1171 and 1101; 
1
H NMR δH(400 MHz, CDCl3) 7.96 (2H, d, J 9.0 Hz, 
C(Ar)-H), 6.87 (2H, d, J 9.0 Hz, C(Ar)-H), 6.03 (1H, s, OH) and 3.89 (3H, s, OCH3); 
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13
C NMR δC(100 MHz, CDCl3) 167.3− (CO2CH3), 160.1− (C4-O), 132.0+ (C(Ar)-
H), 122.5− (C1), 115.3+ (C(Ar)-H) and 52.0+ (OCH3). 
Spectroscopic data is consistent with that reported by Cuca Suarez et al.
255
 
 
 
Methyl 3-(3’,4’-dimethoxyphenyl)propanoate (267) 
 
 
 
10 % Palladium on carbon (50 mg, 0.05 mmol) was added to a vigorously 
stirred mixture of methyl 3,4-methylenedioxycinnamate 253 (819 mg, 3.69 mmol) in 
EtOH (20 mL). After 3 cycles of purging the flask with N2 then a vacuum, the flask 
was put under an atmosphere of H2. After 2 hrs, the mixture was filtered through 
celite, washing thoroughly with EtOH, then the solvent removed in vacuo to afford 
the methyl propionate 267 (821 mg, 99 %) as a colourless oil without need for 
further purification. 
1
H NMR δH(400 MHz, CDCl3) 6.84 (1H, d, J 8.5 Hz, C(5’)-H), 6.77 (1H, dd, 
J 8.5 and 2.0 Hz, C(6’)-H), 6.76 (1H, d, J 2.0 Hz, C(2’)-H), 3.90 (3H, s, ArOCH3), 
3.88 (3H, s, ArOCH3), 3.70 (3H, s, CO2CH3), 2.93 (2H, t, J 7.5 Hz, C(3)H2), 2.64 
(2H, t, J 7.5 Hz, C(2)H2); 
13
C NMR δC(100 MHz, CDCl3) 173.4− (C=O), 149.0− 
(C(Ar)-O), 147.6− (C(Ar)-O), 133.2− (C1’), 120.1+ (C(Ar)-H), 111.8+ (C(Ar)-H), 
111.4+ (C(Ar)-H), 56.0+ (ArOCH3), 55.9+ (ArOCH3), 51.6+ (CO2CH3), 36.0− (C3) 
and 30.6− (C2); 
Spectroscopic data is consistent with that reported by Moreira et al.
256
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2-Methyl-2-(3’,4’,5’-trimethoxyphenyl)-1,3-dioxolane (277) 
 
 
 
Following a procedure reported by Kong et al.,
217
 ethylene glycol (2 mL, 36 
mmol) and p-TsOH.H2O (190 mg, 1 mmol) in toluene (150 mL) were heated at 
reflux with azeotropic removal of water using Dean-Stark trap conditions for 1 hr. 
Acetophenone 261 (1.19 g, 6 mmol) was added in one portion and the reaction 
heated at reflux for a further 20 hrs. After cooling to r.t., the reaction was washed 
with saturated aqueous NaHCO3 (2 x 50 mL) and brine (2 x 50 mL), then dried over 
anhydrous Na2SO4, filtered and the solvent removed in vacuo. After column 
chromatography [silica, PE-EtOAc gradient from 100:0 to 75:25] the ketal product 
277 (428 mg, 28 %) was isolated as a yellow oil in addition to acetophenone 261 
(201 mg, 17 %). 
1
H NMR δH(400 MHz, CDCl3) 6.70 (2H, s, C(2’)H and C(6’)H), 4.04-4.00 
(2H, m, C(4)HAHB and C(5)HAHB), 3.86 (6H, s, OCH3), 3.83 (3H, s, OCH3), 3.82-
3.78 (2H, m, C(4)HAHB and C(5)HAHB) and 1.64 (3H, s, C(2)CH3); 
13
C NMR 
δC(100 MHz, CDCl3) 153.1− (C(Ar)-O), 139.2− (C1’), 137.6− (C(Ar)-O), 108.8− 
(C2), 102.4+ (C2’ and C6’), 64.5− (C4 and C5), 60.8+ (C(Ar)OCH3), 56.2+ 
(C(Ar)OCH3) and 27.7+ (C(2)CH3). 
 
 
General procedure 4: Formation of prenylated and chroman compounds  
Bi(OTf)3 (136 mg, 0.2 mmol) was added to a vigorously stirred mixture of 
substituted aryl (2 mmol) and isoprene (400 µL, 4 mmol) in anhydrous toluene (10 
ml) in a thick-walled pressure tube at r.t. under Ar. The flask was sealed and the 
reaction heated at 40 °C for between 75 mins and 24 hrs then the reaction allowed to 
cool to r.t.. After column chromatography [silica, PE-Et2O-EtOAc] the product was 
isolated. 
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1,2,3-Trimethoxy-4-(3-methylbut-2-en-1-yl)benzene (256) and 2,3,4-
trimethoxy-1,5-bis(3-methylbut-2-en-1-yl)benzene (257) 
 
 
 
Following general procedure 4, 1,2,3-trimethoxybenzene 255 (336 mg, 2 
mmol) gave, after 75 mins at 40 °C and column chromatography [silica, PE-Et2O 
gradient from 100 to 90:10], the mono-product 256 (292 mg, 62 %) as a colourless 
oil and the bis-product 257 (122 mg, 20 %) as a colourless oil. 
 
Mono-product (256) 
IR νmax(thin film) 2936, 1599, 1495, 1464, 1416, 1294, 1256, 1096 (C-O) 
and 1017; 
1
H NMR δH(400 MHz, CDCl3) 6.86 (1H, d, J 8.5 Hz, C(6)H), 6.64 (1H, 
d, J 8.5 Hz, C(5)H), 5.28 (1H, triplet of septets, J 7.5 and 1.5 Hz, ArCH2CHC), 3.91 
(3H, s, OCH3), 3.90 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.31 (2H, d, J 7.5 Hz, 
ArCH2CHC), 1.77 (3H, s,  CCH3) and 1.77 (3H, s,  CCH3); 
13
C NMR δC(100 MHz, 
CDCl3) 152.0− (C1 or C3), 151.8− (C1 or C3), 142.4− (C2), 132.0− (ArCH2CHC), 
127.9− (C4), 123.5+ (C5 or C6), 123.3+ (ArCH2CHC), 107.4+ (C5 or C6), 60.7+ 
(OCH3), 60.7+ (OCH3), 56.0+ (OCH3), 28.2− (ArCH2CHC), 25.7+ (CCH3) and 17.7 
(CCH3). 
Spectroscopic data is consistent with that of Tarselli et al.
257
  
 
Bis-product (257) 
IR νmax(thin film) 2965, 2931, 1479, 1460, 1411, 1325, 1235, 1092, 1065 and 
1015; 
1
H NMR δH(400 MHz, CDCl3) 6.67 (1H, s, C(6)H), 5.25 (2H, triplet of 
septets, J 7.0 and 1.5 Hz, ArCH2CHC), 3.91 (3H, s, OCH3), 3.83 (6H, s, OCH3), 3.27 
(4H, d, J 7.0 Hz, ArCH2CHC) and 1.74 (12H, s, C(CH3)2); 
13
C NMR δC(100 MHz, 
CDCl3) 149.8− (C2 and C4), 146.3− (C3), 132.0− (ArCH2CHC), 130.3− (C1 and 
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C5), 124.2+ (C6), 123.3+ (ArCH2CHC), 60.8+ (OCH3), 60.6+ (OCH3), 28.4− 
(ArCH2CHC), 25.7+ (CCH3) and 17.8+ (CCH3); MS (+ESI) m/z 305 (M+H
+
, 9 %); 
HRMS (+ESI) Found M+H
+
, 305.2103; C19H29O3 requires M+H
+
 305.2111. 
 
 
1-Bromo-3,4,5-trimethoxy-2-(3-methylbut-2-en-1-yl)benzene (259) 
 
 
 
Following general procedure 4, aryl bromide 258 (494 mg, 2 mmol) gave, 
after 7 hrs at 40 °C and column chromatography [silica, PE-Et2O gradient from 
100:0 to 95:5], the product 259 (275 mg, 44 %) as a colourless oil and starting 
material (246 mg, 50 %). 
Rf [PE-Et2O 70:30] 0.63; IR νmax(thin film) 2935, 1590, 1482, 1452, 1430, 
1396, 1313, 1270, 1237, 1195, 1156, 1113 (C-O), 1045 and 1019; 
1
H NMR δH(400 
MHz, CDCl3) 6.87 (1H, s, C(Ar)H), 5.12 (1H, triplet of septets, J 7.0 and 1.5 Hz, 
ArCH2CHC), 3.84, (6H, s, C(3)OCH3 and C(4)OCH3), 3.82 (3H, s, C(5)OCH3), 
3.42, (2H, d, J 7.0 Hz, ArCH2CHC), 1.79 (3H, s, CCH3) and 1.68 (3H, s, CCH3); 
13
C 
NMR δC(100 MHz, CDCl3) 152.6− (C3-O), 152.1− (C4-O or C5), 142.0− (C4-O or 
C5-O), 131.8− (ArCH2CHC), 128.1− (C2), 122.1+ (ArCH2CHC), 117.9− (C1-Br), 
112.0+ (C6), 61.1+ (C(3)OCH3 or C(4)OCH3), 60.7+ (C(3)OCH3 or C(4)OCH3), 
56.2+ (C(5)OCH3), 29.3− (ArCH2CHC), 25.7+ (CCH3) and 18.1+ (CCH3); MS 
(+ESI) m/z 315 (M+H
+
, 97 %), 317 (M+H
+
, 100) and 337 (M+Na
+
, 23); HRMS 
(+ESI) Found M+Na
+
, 337.0400; C14H19O3BrNa requires M+Na
+
 337.0415. 
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Methyl 3,4,5-trimethoxy-2-(3-methylbut-2-en-1-yl)benzoate (263)  
 
 
 
Following general procedure 4, ester 262 (452 mg, 2 mmol) gave, after 5 hrs 
at 40 °C and column chromatography [silica, PE-Et2O gradient from 100:0 to 95:5], 
the product 263 (87 mg, 15 %) as a colourless oil in addition to ester 262 (384 mg, 
85 %). 
IR νmax(thin film) 2939, 1723 (C=O), 1594, 1491, 1455, 1431, 1401, 1337, 
1222, 1154, 1115 and 1055; 
1
H NMR δH(400 MHz, CDCl3) 7.17 (1H, s, C(6)H), 
5.12 (1H, triplet of septets, J 6.5 and 1.5 Hz, ArCH2CHC), 3.91 (3H, s, OCH3), 3.86 
(3H, s, OCH3), 3.86 (3H, s, OCH3), 3.82 (3H, s, OCH3), 3.62 (2H, d, J 6.5 Hz, 
ArCH2CHC), 1.75 (3H, d, J 0.5 Hz, CCH3) and 1.66 (3H, d, J 1.0 Hz, CCH3); 
13
C 
NMR δC(100 MHz, CDCl3) 168.0− (C=O), 152.3− (C(Ar)-O), 151.0− (C(Ar)-O), 
145.7− (C(Ar)-O), 131.1− (ArCH2CHC), 130.7− (C1), 125.2− (C2), 123.8+ 
(ArCH2CHC), 109.7+ (C6), 61.0+ (OCH3), 60.7+ (OCH3), 56.1+ (OCH3), 52.0+ 
(OCH3), 25.9− (ArCH2CHC), 25.7+ (CCH3) and 17.9+ (CCH3); MS (+ESI) m/z 295 
(M+H
+
, 29 %) and 317 (M+Na
+
, 12); HRMS (+ESI) Found M+H
+
, 295.1551; 
C16H23O5 requires M+H
+
 295.1545. 
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Methyl 3-(3’,4’,5’-trimethoxy-2’-(3-methylbut-2-en-1-
yl)phenyl)propanoate (265) and methyl 3-(3’,4’,5’-trimethoxy-2’,6’-bis(3-
methylbut-2-en-1-yl)phenyl)propanoate (266) 
 
 
 
Following general procedure 4, propionic ester 264 (508 mg, 2 mmol) gave, 
after 90 mins at 40 °C and column chromatography [silica, PE-Et2O gradient from 
100:0 to 80:20], the mono-product 265 (376 mg, 58 %) as a colourless oil and the 
bis-product 266 (233 mg, 30 %) as a colourless oil. 
 
Mono-product (265) 
Rf [PE-Et2O 80:20] 0.27; IR νmax(thin film) 2935, 1739 (C=O), 1599, 1578, 
1494, 1453, 1406, 1338, 1283, 1239, 1196, 1121, 1073 and 1042; 
1
H NMR δH(400 
MHz, CDCl3) 6.53 (1H, s, C(6’)H), 5.08-5.04 (1H, m, ArCH2CHC), 3.87 (3H, s, 
OCH3), 3.86 (3H, s, OCH3), 3.84 (3H, s, OCH3), 3.71 (3H, s, CO2CH3), 3.33 (2H, d, 
J 6.5 Hz, ArCH2CHC), 2.93-2.89 (2H, m, C(3)H2) 2.60-2.56 (2H, m, C(2)H2), 1.79 
(3H, s, CCH3) and 1.71 (3H, s, CCH3); 
13
C NMR δC(100 MHz, CDCl3) 173.4− 
(C1=O), 152.1− (C(Ar)-O), 151.5− (C(Ar)-O), 140.9− (C(Ar)-O), 134.2− (C1’ or 
C2’), 131.1− (ArCH2CHC), 126.2− (C1’ or C2’), 123.8+ (ArCH2CHC), 108.4+ 
(C6’), 60.9+ (ArOCH3), 60.7+ (ArOCH3), 56.0+ (ArOCH3), 51.6+ (CO2CH3), 35.5− 
(C2), 28.3− (C3), 25.6+ (CCH3), 25.2− (ArCH2CHC) and 17.8+ (CCH3); MS (+ESI) 
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m/z 345 (M+Na
+
, 24 %); HRMS (+ESI) Found M+Na
+
, 345.1661; C18H20O5Na 
requires M+Na
+
 345.1672. 
 
Bis-product (266) 
Rf [PE-Et2O 80:20] 0.51; IR νmax(thin film) 2948, 2933, 1740 (C=O), 1463, 
1416, 1334, 1195, 1170, 1096, 1048 and 982; 
1
H NMR δH(400 MHz, CDCl3) 5.10-
5.06 (2H, m, ArCH2CHC), 3.91 (3H, s, OCH3), 3.85 (6H, s, OCH3), 3.72 (3H, s, 
CO2CH3), 3.36 (4H, d, J 6.5 Hz, ArCH2CHC), 2.93-2.89 (2H, m, C(3)H2), 2.50-2.46 
(2H, m, C(2)H2), 1.79 (6H, s, CCH3) and 1.71 (6H, s, CCH3); 
13
C NMR δC(100 
MHz, CDCl3) 173.4− (C1=O), 150.3− (C(Ar)-O), 144.8− (C(Ar)-O), 133.0− (C1’), 
131.1− (ArCH2CHC), 129.5− (C2’ and C5’), 124.0+ (ArCH2CHC), 60.8+ (OCH3), 
60.4+ (OCH3), 51.5+ (CO2CH3), 34.9− (C3), 25.7− (ArCH2CHC), 25.6+ (CCH3), 
24.8− (C2) and 17.8+ (CCH3); MS (+ESI) m/z 391 (M+H
+
, 20 %); HRMS (+ESI) 
Found M+H
+
, 391.2652; C23H35O5 requires M+H
+
 391.2479. 
 
 
(E)-Methyl 3-(3’,4’,5’-trimethoxy-2’-(3-methylbut-2-en-1-
yl)phenyl)acrylate (254) 
 
 
 
Following general procedure 4, ester 253 (504 mg, 2 mmol) gave, after 4 hrs 
at 40 °C and column chromatography [silica, PE-Et2O gradient from 100:0 to 90:10], 
the mono-product 254 (302 mg, 47 %) as a colourless oil in addition to ester 253 (90 
mg, 18 %). 
IR νmax(thin film) 2937, 1719 (C=O), 1631, 1592, 1566, 1487, 1409, 1347, 
1289, 1254, 1168, 1124; 
1
H NMR δH(400 MHz, CDCl3) 7.92 (1H, d, J 15.5 Hz, 
C(3)H), 6.87 (1H, s, C(6’)H), 6.26 (1H, d, J 15.5 Hz, C(2)H), 5.02 (1H, t, J 6.5 Hz, 
ArCH2CHC), 3.89 (3H, s, OCH3), 3.86 (3H, s, OCH3), 3.83 (3H, s, OCH3), 3.79 (3H, 
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s, OCH3), 3.42 (2H, d, J 6.5 Hz, ArCH2CHC), 1.81 (3H, s, CCH3) and 1.67 (3H, s, 
CCH3); 
13
C NMR δC(100 MHz, CDCl3) 167.4− (C=O), 151.9− (C(Ar)-O), 151.7− 
(C(Ar)-O), 144.2− (C(Ar)-O), 142.6+ (C3), 131.6− (ArCH2CHC), 129.0− (C1’ or 
C2’), 128.6− (C1’ or C2’), 123.1+ (ArCH2CHC), 118.0+ (C2), 105.3+ (C6’), 61.0+ 
(OCH3), 60.8+ (OCH3), 55.9+ (OCH3), 51.6+ (OCH3), 25.7+ (CCH3), 25.0− 
(ArCH2CHC) and 17.9+ (CCH3); MS (+ESI) m/z 343 (M+Na
+
, 11 %); HRMS 
(+ESI) Found M+Na
+
, 343.1508; C18H25O5 requires M+Na
+
 343.1516. 
 
 
Methyl 3-(4’,5’-dimethoxy-2’-(3-methylbut-2-en-1-yl)phenyl)propanoate 
(268) 
 
 
 
Following general procedure 4, ester 267 (448 mg, 2 mmol) gave, after 6 hrs 
at 40 °C and column chromatography [silica, PE-Et2O gradient from 100:0 to 90:10], 
the mono-product 268 (376 mg, 64 %) as a colourless oil. 
Rf [PE-Et2O 50:50] 0.32; IR νmax(thin film) 2934, 2851, 1737 (C=O), 1516, 
1458, 1361, 1271, 1209 and 1093; 
1
H NMR δH(400 MHz, CDCl3) 6.69 (1H, s, 
C(3’)H or C(6’)H), 6.69 (1H, s, C(3’)H or C(6’)H), 5.21 (1H, triplet of septets, J 7.0 
and 1.4 Hz, ArCH2CHC), 3.85 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.69 (3H, s, 
CO2CH3), 3.29 (2H, d, J 7.0 Hz, ArCH2CHC), 2.92-2.88 (2H, m, C(3)H2), 2.59-2.55 
(2H, m, C(2)H2), 1.75 (3H, s, CCH3) and 1.74 (3H, s, CCH3); 
13
C NMR δC(100 
MHz, CDCl3) 173.4− (C1=O), 147.5− (C(Ar)-O), 147.2− (C(Ar)-O), 132.1− 
(ArCH2CHC), 131.7− (C2’), 130.4− (C1’), 123.4+ (ArCH2CHC), 113.0+ (C3’ or 
C6’), 112.7+ (C3’ or C6’), 56.0+ (OCH3), 55.9+ (OCH3), 51.5+ (CO2CH3), 35.5− 
(C2), 31.3− (ArCH2CHC), 27.8− (C3), 25.7+ (CCH3) and 17.9+ (CCH3); MS (+ESI) 
m/z 293 (M+H
+
, 15 %) and 315 (M+Na
+
, 27); HRMS (+ESI) Found M+H
+
, 
293.1723; C17H25O4 requires M+H
+
 293.1752. 
 178 
 
(E)-Methyl 3-(4,5-dimethoxy-2-(3-methylbut-2-en-1-yl)phenyl)acrylate 
(KJ7/23/P) (270) 
 
 
 
Following general procedure 4, ester 269 (446 mg, 2 mmol) gave, after 6 hrs 
at 40 °C and column chromatography [silica, PE-Et2O gradient from 100:0 to 90:10], 
the mono-product 270 (100 mg, 17 %) as a colourless oil. 
IR νmax(thin film) 2934, 1715 (C=O), 1602, 1514, 1458, 1268, 1167 and 
1102; 
1
H NMR δH(400 MHz, CDCl3) 7.95 (1H, d, J 16.0 Hz, C(3)H), 7.05 (1H, s, 
C(3’)H or C(6’)H), 6.68 (1H, s, C(3’)H or C(6’)H), 6.24 (1H, d, J 16.0 Hz, C(2)H), 
5.16 (1H, triplet of septets, J 7.0 and 1.5 Hz, ArCH2CHC), 3.87 (3H, s, OCH3), 3.87 
(3H, s, OCH3), 3.78 (3H, s, CO2CH3), 3.40 (2H, d, J 7.0 Hz, ArCH2CHC), 1.76 (3H, 
s, CCH3) and 1.71 (3H, s, CCH3); 
13
C NMR δC(100 MHz, CDCl3) 167.7− (C1=O), 
151.0− (C(Ar)-O), 147.6− (C(Ar)-O), 142.1+ (C3), 135.5− (C2’), 132.6− 
(ArCH2CHC), 125.0− (C1’), 122.9+ (ArCH2CHC), 116.3+ (C2), 112.6+ (C3’ or 
C6’), 109.0+ (C3’ or C6’), 56.0+ (OCH3), 55.9+ (OCH3), 51.5+ (CO2CH3), 31.8− 
(ArCH2CHC), 25.7+ (CCH3) and 17.9+ (CCH3); MS (+ESI) m/z 313 (M+Na
+
, 9 %); 
HRMS (+ESI) Found M+Na
+
, 313.142; C17H22O4Na requires M+Na
+
 313.1410. 
 
 
5,6,7-Trimethoxy-2,2-dimethylchroman (280) and 3,4,5-trimethoxy-4-(3-
methylbut-2-en-1-yl)cyclohexa-2,5-dienone (281)  
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Following general procedure 4, acid 279 (368 mg, 2 mmol) gave, after 18 hrs 
at 40 °C and column chromatography [silica, PE-Et2O gradient from 100:0 to 85.15 
then PE-EtOAc gradient from 50:50 to 30:70], the chroman product 280 (279 mg, 55 
%) as an oil and ketone product 281 (132 mg, 26 %) as a white solid. 
 
Chroman (280) 
Rf [PE-Et2O 80:20] 0.52;  IR νmax(thin film) 2973, 2937, 1611, 1489, 1460, 
1413, 1324, 1203, 1158, 1131, 1098, 1045 and 1013; 
1
H NMR δH(400 MHz, CDCl3 
6.15 (1H, s, C(8)H), 3.87 (3H, s, C(6)OCH3), 3.79 (3H, s, C(5)OCH3), 3.78 (3H, s, 
C(7)OCH3), 2.63 (2H, t, J 7.0 Hz, C(4)H2), 1.73 (2H, t, J 7.0 Hz, C(3)H2), 1.30 (3H, 
s, C(2)CH3) and 1.28 (3H, s, C(2)CH3); 
13
C NMR δC(100 MHz, CDCl3) 152.4− 
(C7), 151.4− (C5), 150.0− (C8a), 135.4− (C6), 106.7− (C4a), 96.6+ (C8), 74.0− 
(C2), 61.0+ (C(5)OCH3), 60.5+ (C(6)OCH3), 55.8+ (C(7)OCH3), 32.4− (C3), 26.7+ 
(CCH3), 26.7+ (C(2)(CH3)2) and 17.0− (C4). 
Spectroscopic data was consistent with that reported by Nishikata
 
et.al.
258
 
 
Ketone (281) 
Rf [PE-EtOAc 40:60] 0.50;  Mp 106-109 °C (from CH2Cl2); IR νmax(thin film 
2934, 2852, 1659 (C=O), 1625, 1597, 1459, 1374, 1240, 1215, 1163, 1078 and 888; 
1
H NMR δH(400 MHz, CDCl3) 5.56 (2H, s, C(2)H and C(5)H), 4.66 (1H, triplet of 
septets, J 7.5 and 1.5 Hz, CH2CHCMe2), 3.73 (6H, s, C(3)OCH3), 3.08 (3H, s, 
C(4)OCH3), 2.67 (2H, d, J 7.5 Hz, CH2CHCMe2), 1.56 (3H, s, CCH3) and 1.52 (3H, 
s, CCH3); 
13
C NMR δC(100 MHz, CDCl3) 187.3− (C1=O), 169.4− (C3), 136.3− 
(C4), 115.7+ (CH2CHCMe2), 104.3+ (C2), 79.4− (CH2CHCMe2), 56.0+ 
(C(3)OCH3), 52.5 (C(4)OCH3), 35.6− (CH2CHCMe2), 25.7+ (CCH3) and 17.6+ 
(CCH3); MS (+ESI) m/z 253 (M+H
+
); HRMS (+ESI) Found M+H
+
, 253.1427; 
C14H21O4 requires M+H
+
 253.1434. 
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1-(2,2-Dimethylchroman-6-yl)ethanone (285) 
 
 
 
Following general procedure 4, acid 284 (272 mg, 2 mmol) gave, after 18 hrs 
at 40 °C and column chromatography [silica, PE-Et2O-EtOAc gradient from 100:0:0 
to 85:15:0 then 50:0:50], the product 285 (235 mg, 58 %) as a white solid in addition 
to phenol 284 (62 mg, 23 %). 
Rf [PE-Et2O 70:30] 0.63; Mp 89-93 °C (from CH2Cl2); IR νmax(thin film) 
2976, 1670 (C=O), 1537, 1498, 1419, 1358, 1289, 1265, 1156, 1117; 
1
H NMR 
δH(400 MHz, CDCl3) 7.75 (1H, d, J 2.5 Hz, C(5)H), 7.73 (1H, dd, J 8.5 and 2.5 Hz, 
C(7)H), 6.81 (1H, d, J 8.5 Hz, C(8)H), 2.83 (2H, t, J 6.5 Hz, C(4)H2), 2.54 (3H, s, 
CH3C=O), 1.84 (2H, t, J 6.5 Hz, C(3)H2) and 1.37 (6H, s, C(CH3)2); 
13
C NMR 
δC(100 MHz, CDCl3) 196.9− (C=O), 158.6− (C8a), 130.5+ (C5), 129.4− (C6), 
128.3+ (C7), 120.7− (C4a), 117.2+ (C8), 75.5− (C2), 32.5− (C3), 26.9+ (C(CH3)2), 
26.2+ (CH3C=O) and 22.4− (C4). 
Spectroscopic data is consistent with that reported by Teng
 
et al.
197
 
 
 
 
 
 
 
 
 
 
 
 
 181 
 
1-(5-Hydroxy-2,2-dimethylchroman-8-yl)ethanone (287), 1-(7-hydroxy-
2,2-dimethylchroman-6-yl)ethanone (288), and 1-(2,2,8,8-tetramethyl-
2,3,4,8,9,10-hexahydropyrano[2,3-f]chromen-6-yl)ethanone (289) 
 
 
 
Following general procedure 4, acid 286 (304 mg, 2 mmol) gave, after 8 hrs 
at 40 °C and column chromatography [silica, PE-EtOAc gradient from 100:0 to 
70:30], the chroman products 287 (46 mg, 10 %) as a white solid, 288 (105 mg, 24 
%) as a white solid and 289 (77 mg, 13 %) as an oil. 
 
Chroman (287) 
Mp 165-170 °C (from EtOAc); IR νmax(thin film) 3172 (OH), 2974, 2931, 
1638, 1583 (C=O), 1433, 1362, 1277, 1217, 1157, 1119 and 1051; 
1
H NMR δH(400 
MHz, CDCl3) 7.68 (1H, d, J 8.5 Hz, C(7)H), 7.20 (1H, broad s, OH), 6.47 (1H, d, J 
8.5 Hz, C(6)H), 2.74 (2H, t, J 7.0 Hz, C(4)H2), 2.64 (3H, s, CH3C=O), 1.87 (2H, t, J 
7.0 Hz, C(3)H2) and 1.43 (6H, s, C(2)(CH3)2); 
13
C NMR δC(100 MHz, CDCl3) 
199.7− (C=O), 159.2− (C5), 156.4− (C8a), 129.9+ (C7), 120.3− (C8), 108.5− (C4a), 
107.0+ (C6), 75.3− (C2), 32.2+ (CH3C=O), 31.6− (C3), 26.9+ (C(CH3)2) and 17.0− 
(C4). 
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Chroman (288) 
Mp 115-118 °C (from EtOAc); lit.,
259
 116-117 °C; IR νmax(thin film) 2937, 
2957, 1867, 1647, 1612, 1495, 1369, 1288, 1280, 1161, 1118, 1058 1020 and 885; 
1
H NMR δH(400 MHz, CDCl3) 12.30 (1H, s, OH), 7.41 (1H, s, C(5)H), 6.28 (1H, s, 
C(8)H), 2.71 (2H, t, J 7.0 Hz, C(4)H2), 2.70 (3H, s, CH3C=O), 1.80 (2H, t, J 7.0Hz, 
C(3)H2) and 1.33 (6H, s, C(2)(CH3)2); 
13
C NMR δC(100 MHz, CDCl3) 202.3− 
(C=O), 162.8− (C7), 161.4− (C8a), 132.2+ (C5), 113.9− (C6), 112.7− (C4a), 104.6+ 
(C8), 75.9− (C2), 32.7− (C3), 26.4+ (C(2)CH3), 26.1+ (CH3C=O) and 21.7− (C4).  
Spectroscopic data was consistent with that reported by Alhuwalia et al.259 
 
Chroman (289) 
IR νmax(thin film) 2974, 2933, 1662, 1603, 1579, 1457, 1357, 1298, 1258, 
1178, 1154, 1120 and 1096; 
1
H NMR δH(400 MHz, CDCl3) 7.48 (1H, s, C(5)H), 
2.70 (2H, t, J 7.0 Hz, C(4)H2), 2.60 (2H, t, J 7.0 Hz, C(10)H2), 2.56 (3H, s, 
CH3C=O), 1.76 (2H, t, J 7.0 Hz, C(9)H2), 1.76 (2H, t, J 7.0 Hz, C(3)H2), 1.35 (6H, s, 
C(8)(CH3)2) and 1.32 (6H, s, C(2)(CH3)2); 
13
C NMR δC(100 MHz, CDCl3) 198.6− 
(C=O), 156.2− (C10b), 153.8− (C6a), 129.2+ (C5), 120.0− (C6), 111.9− (C4a), 
109.4− (C10a), 75.3− (C2), 74.7− (C8), 32.8− (C3), 32.3+ (CH3C=O), 31.8− (C9), 
27.1+ (C(8)CH3), 26.8+ (C(2)CH3), 21.7− (C4) and 17.2+ (C10). 
Spectroscopic data was consistent with that reported by Alhuwalia et al.
259
 
 
 
Methyl 2,2-dimethylchroman-6-carboxylate (291) 
 
 
 
Following general procedure 4, phenol 290 (304 mg, 2 mmol) gave, after 5 
hrs at 40 °C and column chromatography [silica, PE-Et2O gradient from 100:0 to 
85:15] afforded the chroman 291 (285 mg, 65 %) as a white solid in addition to 
phenol 290 (32 mg, 11 %). 
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Rf [PE-Et2O 70:30] 0.61; Mp 70-74 °C (from CH2Cl2); IR νmax(thin film) 
2975, 2948 (C-H), 1716 (C=O), 1613, 1581, 1493, 1437, 1290, 1263 (C-O), 1155 
and 1118; 
1
H NMR δH(400 MHz, CDCl3) 7.78 (1H, d, J 2.0 Hz, C(5)H), 7.76 (1H, 
dd, J 8.5 and 2.0 Hz, C(7)H), 6.77 (1H, d, J 8.5 Hz, C(8)H), 3.86 (3H, s, OCH3), 
2.80 (2H, t, J 7.0 Hz, C(4)H2), 1.82 (2H, t, J 7.0 Hz, C(3)H2) and 1.34 (6H, s, 
C(2)(CH3)2); 
13
C NMR δC(100 MHz, CDCl3) 167.1− (C=O), 153.3− (C8a), 131.6+ 
(C5), 129.1+ (C7), 121.5− (C6), 120.6− (C4a), 117.2+ (C8), 75.3− (C2), 51.7+ 
(OCH3), 32.6-(C3), 26.9+ (C(CH3)2) and 22.3− (C4); 
Spectroscopic data is consistent with that reported by Batista Jr. et al.
260
 
 
 
2,2-Dimethylchroman-6-carboxylic acid (293) 
 
 
 
Following general procedure 4, acid 292 (276 mg, 2 mmol) gave, after 24 hrs 
at 40 °C and column chromatography [silica, PE-EtOAc gradient from 100:0 to 
40:60], the product 293 (14 mg, 3 %) as a white solid in addition to phenol 292 (254 
mg, 92 %). 
IR νmax(thin film) 2975, 1681 (C=O), 1608, 1578, 1443, 1411, 1324, 1296, 
1265, 1156 and 1120; 
1
H NMR δH(400 MHz, CDCl3) 7.86 (1H, d, J 2.0 Hz,  C(5)H), 
7.84 (1H, dd, J 8.5 and 2.0 Hz, C(7)H), 6.82 (1H, d, J 8.5 Hz, C(8)H), 2.84 (2H, t, J 
7.0 Hz, C(4)H2), 1.84 (2H, t, J 7.0 Hz, C(3)H2) and 1.36 (6H, s, C(CH3)2); 
13
C NMR 
δC(100 MHz, CDCl3) 172.1− (C=O), 159.1− (C8a), 132.4+ (C5), 129.9+ (C7), 
120.8− (C4a or C7), 120.7− (C4a or C7), 117.4+ (C8), 75.6− (C2), 32.5− (C3), 
26.9+ (C(CH3)2) and 22.3− (C4); MS (+ESI) m/z 207 (M+H
+
, 100 %) and 229 
(M+Na
+
, 45); HRMS (+ESI) Found M+H
+
, 207.1033; C12H15O3 requires M+H
+
 
207.1021. 
Spectroscopic data is consistent with that reported by Fatope
 
et al.
220
 
 
 184 
 
3,4,5-Trimethoxy-2-(3-methylbut-2-en-1-yl)phenol (296) and 1-(6-
hydroxy-2,3,4-trimethoxyphenyl)ethanone (297)  
 
 
 
Following a procedure reported by Mohammadpoor-Baltork
 
et al.,
224
 
Bi(OTf)3 (136 mg, 0.2 mmol) then Ac2O (283 µL, 3 mmol) were added to a stirred 
suspension of phenol 279 (368 mg, 2 mmol) in anhydrous toluene (10 mL) at r.t. 
under Ar. After 5 mins, isoprene (400 µL, 4 mmol) was added to the solution, then 
the flask was sealed and heated at 40 °C for 4 hrs. The solvent was removed and, 
following a procedure reported by Bates et al.,
225
 the residue was taken up in MeOH 
(10 mL) and K2CO3 (552 mg, 4 mmol) was added. The reaction was stirred for a 50 
mins at r.t. then quenched with saturated aqueous NH4Cl (30 mL) and extracted with 
CH2Cl2 (3 x 30 mL). The combined organic fractions were washed with brine (30 
mL), dried over anhydrous Na2SO4, filtered and the solvent removed in vacuo. 
Column chromatography [silica, PE-EtOAc gradient from 100:0 to 70:30] afforded 
the mono-prenylated product 296 (223 mg, <44 %) as a clear oil and the 
acetophenone product 297 (39 mg, 9 %) as a clear oil. 
 
Acetophenone product 297 
1
H NMR δH(400 MHz, CDCl3) 13.39 (1H, s, C(6)OH), 6.22 (1H, s, C(5)H), 
3.97 (3H, s, C(2)OCH3), 3.87 (3H, s, C(3)OCH3), 3.76 (3H, s, C(4)OCH3) and 2.63 
(3H, s, CCH3); 
13
C NMR δC(100 MHz, CDCl3) 203.3− (C=O), 161.9− (C6-OH), 
160.1− (C3), 155.2− (C2), 134.8− (C4), 108.5− (C1), 96.1+ (C5), 61.0+ (C(2)OCH3 
or C(4)OCH3), 60.9+ (C(2)OCH3 or C(4)OCH3), 56.0+ (C(3)OCH3) and 31.8+ 
(CH3C=O). 
Spectroscopic data is consistent with that reported by Combes et al.
261
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3,4,5-Trimethoxy-2-(3-methylbut-2-en-1-yl)phenyl acetate  (298) and 
3,4,5-trimethoxy-2,6-bis(3-methylbut-2-en-1-yl)phenyl acetate (299)  
 
 
 
Following the procedure reported by Mohammadpoor-Baltork
 
et al.,
224
 
Bi(OTf)3 (136 mg, 0.2 mmol) then Ac2O (283 µL, 3 mmol) were added to a stirred 
suspension of phenol (368 mg, 2 mmol) in anhydrous toluene (10 mL) at r.t. under 
Ar. After 5 mins, isoprene (400 µL, 4 mmol) was added to the solution then the flask 
was sealed and heated at 40 °C for 1 hr. After column chromatography [silica, PE-
Et2O gradient from 100:0 to 90:10] the mono-prenylated acetate 298 (414 mg, 70 %) 
was isolated as a clear oil and the bis-prenylated acetate 299 (108 mg, 15 %) as a 
clear oil. 
 
Mono-product (298) 
Rf [PE-Et2O 80:20] 0.37; IR νmax(thin film) 2937, 1767 (C=O), 1608, 1490, 
1456, 1408, 1368, 1339, 1206, 1122, 1075 and 1042; 
1
H NMR δH(400 MHz, CDCl3) 
6.38 (1H, s, C(6)H), 5.06 (1H, triplet of septets, J 7.0 and 1.5 Hz, CH2CHC), 3.85 
(3H, s, C(3)OCH3 or C(4)OCH3), 3.84 (3H, s, C(3)OCH3 or C(4)OCH3), 3.80 (3H, s, 
C(5)OCH3), 3.17 (2H, d, J 7.0 Hz, CH2CHC), 2.27 (3H, s, C=OCH3), 1.73 (3H, s, 
CCH3) and 1.66 (3H, d, J 1.0 Hz, CCH3); 
13
C NMR δC(100 MHz, CDCl3) 169.5− 
(C=O), 152.3− (C3), 151.7− (C4), 144.5− (C1), 140.5− (C5), 131.3 (C(CH3)2), 
122.7+ (CH2CHC), 120.1− (C2), 102.4+ (C6), 61.0+ (C(3)OCH3 or C(4)OCH3), 
60.8+ (C(3)OCH3 or C(4)OCH3), 56.0+ (C(5)OCH3), 25.6+ (CCH3), 23.5− 
(CH2CHC), 20.8+ (C=OCH3) and 17.7 (CCH3); MS (+ESI) m/z 295 (M+H
+
, 24 %), 
317 (M+Na
+
, 20); HRMS (+ESI) Found M+H
+
, 239.1533; C16H23O5 requires M+H
+
 
295.1545. 
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Bis-product (299) 
Rf [PE-Et2O 80:20] 0.61; IR νmax(thin film) 2935, 1765 (C=O), 1600, 1463, 
1416, 1367, 1346, 1204, 1097,. 1048 and 982; 
1
H NMR δH(400 MHz, CDCl3) 5.08 
(2H, triplet of septets, J 7.0 and 1.5 Hz, CH2CHC), 3.87 (3H, s, C(4)OCH3), 3.82 
(6H, s, C(3)OCH3 and C(5)OCH3), 3.16 (4H, broad s, CH2CHC), 2.52 (3H, s, 
C=OCH3), 1.73 (6H, d, J 1.0 Hz, CCH3) and 1.73 (6H, d, J 1.0 Hz, CCH3); 
13
C 
NMR δC(100 MHz, CDCl3) 169.3− (C=O), 150.3− (C3 and C5), 144.8− (C4), 
143.2− (C1), 131.3− (C(CH3)2), 123.7− (C2 and C5), 122.7+ (CH2CHC), 61.0+ 
(C(3)OCH3 and C(5)OCH3), 60.6+ (C(4)OCH3), 25.6+ (CCH3), 24.1− (CH2CHC), 
20.6+ CH3C=O) and 17.8+ (CCH3); MS (+ESI) m/z 363 (M+H
+
, 5 %), 385 (M+Na
+
, 
14); HRMS (+ESI) Found M+Na
+
, 385.1975 C21H30O5Na requires M+Na
+
 
385.1991. 
 
 
General Procedure 5: Hydrolysis of phenolic acetates 
Method A: Following a procedure reported by Bates et al.,
225
 K2CO3 (2 eq) 
was added to a solution of the acetate (1 eq) in MeOH (5 mL/mmol) at r.t. and the 
reaction was stirred for 2 hrs. The suspension was quenched with saturated aqueous 
NH4Cl (30 mL) and extracted with EtOAc (3 x 15 mL). The combined organic 
fractions were washed with brine (15 mL), dried over anhydrous Na2SO4, filtered 
and the solvent removed in vacuo. Column chromatography [silica, PE-EtOAc 
gradient from 100:1 to 75:25] afforded the phenol product. 
Method B: Following a procedure reported by Narender et al.,
227
 NaOAc (10 
eq) was added to a solution of the acetate (1 eq) in EtOH/H2O (10:1, 5.5 mL/mmol) 
and the reaction heated at reflux for 5 hrs. After cooling, the reaction was diluted 
with H2O (15 mL) and extracted with EtOAc (3 x 15 mL). The organic fractions 
were combined, washed with brine (15 mL), dried over anhydrous Na2SO4, filtered 
and the solvent removed in vacuo. Column chromatography [silica, PE-EtOAc 
gradient from 100:0 to 75:25] afforded the phenol product. 
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3,4,5-Trimethoxy-2-(3-methylbut-2-en-1-yl)phenol (296) 
 
 
 
Following general procedure 5A, acetate 298 (411 mg, 1.4 mmol) gave the 
phenol 296 (173 mg, 49 %) as a yellow amorphous solid. Following general 
procedure 5B, acetate 298 (132 mg, 0.45 mmol) gave the phenol 296 (41 mg, 36 %), 
in addition to acetate 298 (53 mg, 40 %). 
Rf [PE-EtOAc 75:25] 0.25; IR νmax(thin film) 3392 (OH), 2963, 1935, 1607, 
1505, 1463, 1415, 1357, 1237, 1197, 1164, 1126, 1082, 1040 and 993; 
1
H NMR 
δH(400 MHz, CDCl3) 6.20 (1H, s, C(6)H), 5.70 (1H, s, C(1)OH), 5.19 (1H, triplet of 
septets, J 7.0 and 1.5 Hz, CH2CHC), 3.83 (3H, s, OCH3), 3.79 (3H, s, OCH3), 3.72 
(3H, s, OCH3), 3.31 (2H, d, J 7.0 Hz, CH2CHC), 1.78 (3H, d, J 1.0 Hz, CCH3) and 
1.70 (3H, d, J 1.0 Hz, CCH3); 
13
C NMR δC(100 MHz, CDCl3) 151.9− (C3, C4, or 
C5), 151.9− (C3, C4, or C5), 150.9− (C1), 136.1− (C3, C4, or C5), 133.6− 
(C(CH3)2), 122.6+ (CH2CHC), 113.0− (C2), 96.6+ (C6), 61.2+ (OCH3), 61.0+ 
(OCH3), 55.9+ (OCH3), 25.7+ (CCH3), 22.8− (CH2CHC) and 17.8+ (CCH3); MS 
(+ESI) m/z 253 (M+H
+
 100 %) and 275 (M+Na
+
, 92); HRMS (+ESI) Found M+Na
+
, 
275.1272 C14H20O4Na requires M+Na
+
 275.1259. 
Spectroscopic data was consistent with that reported by Parmar et al.
222
 
 
 
3,4,5-Trimethoxy-2,6-bis(3-methylbut-2-en-1-yl)phenol (300) 
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Following general procedure 5A, acetate 299 (100 mg, 0.27 mmol) gave the 
phenol 300 (28 mg, 32 %) as an oil. 
IR νmax(thin film) 3461 (OH), 2964, 2933, 1605, 1462, 1418, 1357, 1256, 
1171, 1097, 1051 and 987; 
1
H NMR δH(400 MHz, CDCl3) 5.59 (1H, s, C(1)OH), 
5.21 (2H, triplet of septets, J 7.0 and 1.5 Hz, CH2CHC), 3.85 (3H, s, C(4)OCH3), 
3.84 (6H, s, C(3)OCH3 and C(5)OCH3), 3.34 (4H, d, J 7.0 Hz, CH2CHC), 1.80 (6H, 
d, H 1.0 Hz, CCH3) and 1.72 (6H, d, H 1.0 Hz, CCH3); 
13
C NMR δC(100 MHz, 
CDCl3) 150.1− (C3 and C5), 149.2− (C1), 140.3− (C4), 133.4− (C(CH3)2), 122.6+ 
(CH2CHC), 116.8− (C2 and C6), 61.1+ (C(3)OCH3 and C(5)OCH3), 60.9+ 
(C(4)OCH3), 25.8+ (CCH3), 23.1− (CH2CHC) and 17.8+ (CCH3); MS (+ESI) m/z 
321 (M+H
+
, 50 %); HRMS (+ESI) Found M+H
+
, 321.2066; C19H29O4 requires 
M+H
+
 321.2066. 
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7. APPENDICES 
7.1. APPENDIX 1: BIOLOGICAL DATA 
7,8-Dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolin-5-one (144) 
 
 
 205 
 
 
 
 
 
 
 
 
 
 
 
 206 
 
6,7-Dimethoxy-3,4-dihydroisoquinolin-1(2H)-one (147) 
 
 
 
 207 
 
 
 
 
 
 
 
 
 
 
 208 
 
6,7-Dimethoxy-8-hydroxy-3,4-dihydroisoquinolin-1(2H)-one (151) 
 
 
 
 209 
 
 
 
 
 
 
 
 
 
 
 210 
 
6H-1,3-Dioxolo[4,5-g]isoquinolin-5-one (172) 
 
 
 
 211 
 
 
 
 
 
 
 
 
 
 
 212 
 
6,7-Dimethoxyisoquinolin-1(2H)-one (173) 
 
 
 
 213 
 
 
 
 
 
 
 
 
 
 
 214 
 
6,7-Dimethoxy-8-hydroxyisoquinolin-1(2H)-one (174) 
 
 
 
 
 215 
 
 
 
 
 
 
 
 
 
 
 216 
 
2,3,4,9-Tetrahydro-β-carbolin-1-one (153) 
 
 
 
 217 
 
 
 
 
 
 
 
 
 
 
 218 
 
9-Methyl-2,3,4,9-tetrahydro-β-carbolin-1-one (160) 
 
 
 
 219 
 
 
 
 
 
 
 
 
 
 
 220 
 
2,9-Dimethyl-2,3,4,9-tetrahydro-β-carbolin-1-one (161) 
 
 
 
 
 221 
 
 
 
 
 
 
 
 
 
 222 
 
2,9-Dihydro-1H-pyrido[3,4-b]indol-1-one (175) 
 
 
 223 
 
 
 
 
 
 
 
 
 
 
 224 
 
9-Methyl-2,9-Dihydro-1H-pyrido[3,4-b]indol-1-one (176) 
 
 
 
 225 
 
 
 
 
 
 
 
 
 226 
 
2,9-Dimethyl-2,9-Dihydro-1H-pyrido[3,4-b]indol-1-one (177) 
 
 227 
 
 
 
 
 
 
 
 
 
 
 
 228 
 
 3,4,5,10-Tetrahydro-2H-azepino[3,4-b]indol-1-one (163) 
 
 
 
 229 
 
 
 
 
 
 
 
 
 
 
 
 230 
 
10-Methyl-3,4,5,10-tetrahydro-2H-azepino[3,4-b]indol-1-one (166) 
 
 
 
 231 
 
 
 
 
 
 
 
 
 
 
 232 
 
2,10-Dimethyl-3,4,5,10-tetrahydro-2H-azepino[3,4-b]indol-1-one (167) 
 
 
 
 
 
 
 
 
 233 
 
8-Hydroxy-6,7-dimethoxy-1-oxo-1H-isoquinoline-2-carboxylic acid ethyl 
ester (178)  
 
 
 
 
 234 
 
Benzyl 8-hydroxy-6,7-dimethoxy-1-oxoisoquinoline-2(1H)-carboxylate 
(179) 
 
 
 
 
 
 
 
 235 
 
7-Hydroxy-8,9-dimethoxy-3,4,4a,5-tetrahydrophenanthridin-6(2H)-one 
(236) 
 
 
 236 
 
 
 
 
 
 
 
 
 237 
 
8,9-Dimethoxy-3,4,4a,5-tetrahydrophenanthridin-6(2H)-one (239) 
 
 
 
 238 
 
 
 
 
 
 
 
 
 239 
 
8,9-Dimethoxy-1,2,3,4-tetrahydrophenanthridin-6(5H)-one (240) 
 
 
 
 240 
 
 
 
 
 
 
 
 241 
 
7.2. APPENDIX 2: CRYSTALLOGRAPHIC DATA 
7.2.1. 8-(Difluoroboryloxy)-6,7-dimethoxy-3,4-dihydroisoquinolin-(2H)-
one (148) 
Table 1.  Crystal data and structure refinement for 1. 
                                                        
 Identification code k08farm2 
 Empirical formula C11 H12 B F2 N O4 
 Formula weight 271.03 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21/c 
 Unit cell dimensions 
o
 
       b = 10.5440(2
o
 
       
o
 
 Volume 1182.12(4) Å
3
 
 Z 4 
 Density (calculated) 1.523 Mg/m
3
 
 Absorption coefficient 0.133 mm
-1
 
 F(000) 560 
 Crystal size 0.25 x 0.15 x 0.10 mm 
 Theta range for data collection 3.82 to 27.51 
o
. 
 Index ranges -10<=h<=10; -13<=k<=13; -19<=l<=19 
 Reflections collected 21708 
 Independent reflections 2705 [R(int) = 0.0399] 
  2171 
 Data Completeness 0.996 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.98 and 0.94 
 Refinement method Full-matrix least-squares on F
2
 
 Data / restraints / parameters 2705 / 0 / 175 
 Goodness-of-fit on F
2
 1.013 
 Final R indices [I>2 (I)] R1 = 0.0388   wR2 = 0.1003 
 R indices (all data) R1 = 0.0531  wR2 = 0.1097 
 Largest diff. peak and hole 0.244 and -0.290 eÅ
-3
 
  
 
 
Notes: H…F interactions generate 1-D chains in the lattice. 
 
 
 Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H          d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 N1-H1         0.880    2.002   156.91    2.833    F2 [ -x, y+1/2, -z+3/2 ] 
 N1-H1         0.880    2.616   142.91    3.360    F1 [ -x, y+1/2, -z+3/2 ] 
   
 
 
 242 
 
 Table 2.  Atomic coordinates ( x 10
4
) and equivalent isotropic displacement parameters (Å
2
 
x 10
3
) for 1.U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
                                                             
                                                             
  Atom   x   y   z  U(eq) 
                                  
F(1) 1729(1) 93(1) 6650(1) 43(1) 
F(2) -363(1) -483(1) 7428(1) 36(1) 
O(1) 4451(1) -2210(1) 11188(1) 33(1) 
O(2) 4219(1) -2528(1) 9361(1) 29(1) 
O(3) 2628(1) -693(1) 8138(1) 28(1) 
O(4) 1222(1) 1381(1) 7846(1) 30(1) 
N(1) 1110(2) 2700(1) 9020(1) 28(1) 
C(1) 2745(2) -530(1) 9055(1) 22(1) 
C(2) 3523(2) -1458(1) 9681(1) 23(1) 
C(3) 3629(2) -1269(1) 10631(1) 24(1) 
C(4) 2926(2) -177(1) 10960(1) 25(1) 
C(5) 2185(2) 755(1) 10341(1) 23(1) 
C(6) 1364(2) 1947(1) 10625(1) 27(1) 
C(7) 1573(2) 3061(1) 10006(1) 27(1) 
C(8) 1454(2) 1572(1) 8737(1) 24(1) 
C(9) 2114(2) 585(1) 9392(1) 21(1) 
C(10) 4450(2) -2145(2) 12162(1) 40(1) 
C(11) 3102(2) -3617(2) 9301(1) 43(1) 
B(1) 1320(2) 47(2) 7507(1) 29(1) 
                                 
  
   
 Table 3.   Bond lengths [Å] and angles [
o
] for 1. 
  
F(1)-B(1) 1.3700(18) F(2)-B(1) 1.407(2) 
O(1)-C(3) 1.3572(16) O(1)-C(10) 1.4365(18) 
O(2)-C(2) 1.3784(16) O(2)-C(11) 1.4327(18) 
O(3)-C(1) 1.3443(15) O(3)-B(1) 1.4500(19) 
O(4)-C(8) 1.3016(16) O(4)-B(1) 1.4993(19) 
N(1)-C(8) 1.3067(18) N(1)-C(7) 1.4694(18) 
N(1)-H(1) 0.8800 C(1)-C(2) 1.3905(18) 
C(1)-C(9) 1.4062(18) C(2)-C(3) 1.3991(19) 
C(3)-C(4) 1.406(2) C(4)-C(5) 1.3801(19) 
C(4)-H(4) 0.9500 C(5)-C(9) 1.3992(18) 
C(5)-C(6) 1.5097(18) C(6)-C(7) 1.518(2) 
C(6)-H(6A) 0.9900 C(6)-H(6B) 0.9900 
C(7)-H(7A) 0.9900 C(7)-H(7B) 0.9900 
C(8)-C(9) 1.4365(18) C(10)-H(10A) 0.9800 
C(10)-H(10B) 0.9800 C(10)-H(10C) 0.9800 
C(11)-H(11A) 0.9800 C(11)-H(11B) 0.9800 
C(11)-H(11C) 0.9800   
     
C(3)-O(1)-C(10) 117.83(12) C(2)-O(2)-C(11) 113.47(10) 
C(1)-O(3)-B(1) 117.40(11) C(8)-O(4)-B(1) 118.40(11) 
C(8)-N(1)-C(7) 121.88(11) C(8)-N(1)-H(1) 119.1 
C(7)-N(1)-H(1) 119.1 O(3)-C(1)-C(2) 120.07(12) 
 243 
 
O(3)-C(1)-C(9) 120.62(12) C(2)-C(1)-C(9) 119.30(12) 
O(2)-C(2)-C(1) 119.75(12) O(2)-C(2)-C(3) 121.11(11) 
C(1)-C(2)-C(3) 119.11(12) O(1)-C(3)-C(2) 114.77(12) 
O(1)-C(3)-C(4) 123.93(12) C(2)-C(3)-C(4) 121.30(12) 
C(5)-C(4)-C(3) 119.55(12) C(5)-C(4)-H(4) 120.2 
C(3)-C(4)-H(4) 120.2 C(4)-C(5)-C(9) 119.35(12) 
C(4)-C(5)-C(6) 123.39(12) C(9)-C(5)-C(6) 117.21(12) 
C(5)-C(6)-C(7) 111.69(11) C(5)-C(6)-H(6A) 109.3 
C(7)-C(6)-H(6A) 109.3 C(5)-C(6)-H(6B) 109.3 
C(7)-C(6)-H(6B) 109.3 H(6A)-C(6)-H(6B) 107.9 
N(1)-C(7)-C(6) 111.01(11) N(1)-C(7)-H(7A) 109.4 
C(6)-C(7)-H(7A) 109.4 N(1)-C(7)-H(7B) 109.4 
C(6)-C(7)-H(7B) 109.4 H(7A)-C(7)-H(7B) 108.0 
O(4)-C(8)-N(1) 118.05(12) O(4)-C(8)-C(9) 121.07(12) 
N(1)-C(8)-C(9) 120.86(12) C(5)-C(9)-C(1) 121.29(12) 
C(5)-C(9)-C(8) 120.61(12) C(1)-C(9)-C(8) 118.05(12) 
O(1)-C(10)-H(10A) 109.5 O(1)-C(10)-H(10B) 109.5 
H(10A)-C(10)-
H(10B) 
109.5 O(1)-C(10)-H(10C) 109.5 
H(10A)-C(10)-
H(10C) 
109.5 H(10B)-C(10)-
H(10C) 
109.5 
O(2)-C(11)-H(11A) 109.5 O(2)-C(11)-H(11B) 109.5 
H(11A)-C(11)-
H(11B) 
109.5 O(2)-C(11)-H(11C) 109.5 
H(11A)-C(11)-
H(11C) 
109.5 H(11B)-C(11)-
H(11C) 
109.5 
F(1)-B(1)-F(2) 109.68(12) F(1)-B(1)-O(3) 109.82(13) 
F(2)-B(1)-O(3) 110.60(12) F(1)-B(1)-O(4) 108.23(12) 
F(2)-B(1)-O(4) 106.66(12) O(3)-B(1)-O(4) 111.76(11) 
                                                    
Symmetry transformations used to generate equivalent atoms: 
                                                            
  
  
 Table 4.   Anisotropic displacement parameters (Å
2
 x 10
3
) for 1. The anisotropic 
displacement 
   factor exponent takes the form: -2 gpi
2
 [ h
2
 a*
2
 U11 + ... + 2 h k a* b* U 
                                                                                 
  Atom  U11  U22  U33  U23  U13  U12 
                                                
F(1) 67(1) 38(1) 23(1) 2(1) 12(1) 6(1) 
F(2) 37(1) 32(1) 36(1) -7(1) -1(1) -1(1) 
O(1) 35(1) 30(1) 30(1) 11(1) 3(1) 3(1) 
O(2) 28(1) 22(1) 38(1) 1(1) 9(1) 2(1) 
O(3) 35(1) 26(1) 21(1) -2(1) 6(1) 3(1) 
O(4) 43(1) 24(1) 22(1) 1(1) 1(1) 2(1) 
N(1) 32(1) 22(1) 26(1) 1(1) -1(1) 4(1) 
C(1) 21(1) 24(1) 22(1) -1(1) 6(1) -2(1) 
C(2) 19(1) 22(1) 29(1) 0(1) 6(1) 0(1) 
C(3) 19(1) 25(1) 27(1) 6(1) 3(1) -3(1) 
C(4) 24(1) 30(1) 23(1) 2(1) 6(1) -4(1) 
C(5) 19(1) 25(1) 25(1) -1(1) 5(1) -4(1) 
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C(6) 26(1) 29(1) 28(1) -3(1) 8(1) 0(1) 
C(7) 28(1) 25(1) 28(1) -5(1) 3(1) 1(1) 
C(8) 23(1) 24(1) 24(1) -1(1) 2(1) -1(1) 
C(9) 19(1) 22(1) 23(1) 0(1) 4(1) -2(1) 
C(10) 44(1) 46(1) 29(1) 16(1) 5(1) -1(1) 
C(11) 46(1) 26(1) 61(1) -8(1) 18(1) -5(1) 
B(1) 40(1) 25(1) 22(1) -1(1) 3(1) 2(1) 
  
 
   
 Table 5.   Hydrogen coordinates ( x 10
4
) and isotropic displacement 
   parameters (Å
2
 x 10
3
) for 1. 
                                     
  Atom   x   y   z  U(eq) 
                                  
H(1) 585 3258 8608 33 
H(4) 2960 -82 11605 30 
H(6A) 1924 2155 11277 33 
H(6B) 98 1796 10592 33 
H(7A) 807 3766 10119 33 
H(7B) 2806 3362 10163 33 
H(10A) 5103 -1392 12433 60 
H(10B) 5011 -2907 12474 60 
H(10C) 3237 -2092 12242 60 
H(11A) 2854 -3793 9913 65 
H(11B) 3690 -4351 9096 65 
H(11C) 1996 -3453 8853 65 
  
   
   
 Table 6.   Dihedral angles [
o
] for 1. 
                                         
  Atom1  -  Atom2  -  Atom3  -  Atom4  Dihedral 
                                                  
B(1) - O(3) - C(1) - C(2) 159.26(12) 
B(1) - O(3) - C(1) - C(9) -21.87(17) 
C(11) - O(2) - C(2) - C(1) -101.17(15) 
C(11) - O(2) - C(2) - C(3) 80.74(16) 
O(3) - C(1) - C(2) - O(2) 1.91(18) 
C(9) - C(1) - C(2) - O(2) -176.97(11) 
O(3) - C(1) - C(2) - C(3) -179.96(11) 
C(9) - C(1) - C(2) - C(3) 1.16(18) 
C(10) - O(1) - C(3) - C(2) -173.73(12) 
C(10) - O(1) - C(3) - C(4) 6.28(19) 
O(2) - C(2) - C(3) - O(1) -0.22(17) 
C(1) - C(2) - C(3) - O(1) -178.32(11) 
O(2) - C(2) - C(3) - C(4) 179.78(11) 
C(1) - C(2) - C(3) - C(4) 1.67(19) 
O(1) - C(3) - C(4) - C(5) 177.04(12) 
C(2) - C(3) - C(4) - C(5) -2.95(19) 
C(3) - C(4) - C(5) - C(9) 1.32(19) 
C(3) - C(4) - C(5) - C(6) 178.70(11) 
 245 
 
C(4) - C(5) - C(6) - C(7) 148.52(12) 
C(9) - C(5) - C(6) - C(7) -34.05(16) 
C(8) - N(1) - C(7) - C(6) -35.53(17) 
C(5) - C(6) - C(7) - N(1) 46.70(15) 
B(1) - O(4) - C(8) - N(1) -169.95(13) 
B(1) - O(4) - C(8) - C(9) 11.75(18) 
C(7) - N(1) - C(8) - O(4) -170.82(12) 
C(7) - N(1) - C(8) - C(9) 7.49(19) 
C(4) - C(5) - C(9) - C(1) 1.52(18) 
C(6) - C(5) - C(9) - C(1) -176.02(11) 
C(4) - C(5) - C(9) - C(8) -176.01(12) 
C(6) - C(5) - C(9) - C(8) 6.46(17) 
O(3) - C(1) - C(9) - C(5) 178.34(11) 
C(2) - C(1) - C(9) - C(5) -2.78(18) 
O(3) - C(1) - C(9) - C(8) -4.07(18) 
C(2) - C(1) - C(9) - C(8) 174.80(11) 
O(4) - C(8) - C(9) - C(5) -173.27(12) 
N(1) - C(8) - C(9) - C(5) 8.47(19) 
O(4) - C(8) - C(9) - C(1) 9.13(18) 
N(1) - C(8) - C(9) - C(1) -169.13(12) 
C(1) - O(3) - B(1) - F(1) 160.54(11) 
C(1) - O(3) - B(1) - F(2) -78.27(14) 
C(1) - O(3) - B(1) - O(4) 40.40(17) 
C(8) - O(4) - B(1) - F(1) -156.70(12) 
C(8) - O(4) - B(1) - F(2) 85.35(14) 
C(8) - O(4) - B(1) - O(3) -35.64(18) 
                                     
                                     
 
7.2.2. 2,3,4,9-Tetrahydro-β-carbolin-1-one (153) 
Table 1.  Crystal data and structure refinement for 1. 
                                                        
 Identification code h08farm1 
 Empirical formula C23 H21 Cl3 N4 O2 
 Formula weight 491.79 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21/c 
 Unit cell dimensions 
o
 
       
o
 
       
o
 
 Volume 2334.22(6) Å
3
 
 Z 4 
 Density (calculated) 1.399 Mg/m
3
 
 Absorption coefficient 0.421 mm
-1
 
 F(000) 1016 
 Crystal size 0.35 x 0.18 x 0.13 mm 
 Theta range for data collection 3.65 to 27.50
o
 
 Index ranges -16<=h<=16; -16<=k<=16; -19<=l<=19 
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 Reflections collected 33937 
 Independent reflections 5345 [R(int) = 0.0743] 
  3659 
 Data Completeness 0.996 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.95 and 0.88 
 Refinement method Full-matrix least-squares on F
2
 
 Data / restraints / parameters 5345 / 0 / 317 
 Goodness-of-fit on F
2
 1.036 
 Final R indices [I>2 (I)] R1 = 0.0667   wR2 = 0.1741 
 R indices (all data) R1 = 0.1011  wR2 = 0.2000 
 Largest diff. peak and hole 0.604 and -0.692 eÅ
-3
 
 
Notes: The asymmetric unti contains 2 molecules and 1 molecule of solvent of 
recrystallization (CHCl3). The latter exhibited disorder of the chlorines which 
was modeled as a 65:35 ratio. The gross structure consists of hydrogen-
bonded tapes. 
 
 
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
D-H  d(D-H)  d(H..A)  <DHA    d(D..A)   A 
 
N1-H1     0.880   1.963   169.68   2.834   O1A [ x, -y+1/2, z+1/2 ] 
 
N2-H2     0.880   1.967   170.12   2.838   O1A  
 
N1A-H1A   0.880   2.056   161.07   2.903   O1  
 
N2A-H2A 0.880   2.029   172.88   2.904   O1 [ x, -y+1/2, z-1/2 ] 
 
   
 Table 2.  Atomic coordinates ( x 10
4
) and equivalent isotropic displacement parameters (Å
2
 
x 10
3
) for 1.U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
                                                             
                                                             
  Atom   x   y   z  U(eq) 
                                  
Cl(1) 3009(4) 5314(2) 4172(2) 159(1) 
Cl(2) 4244(3) 5379(2) 2868(2) 119(1) 
Cl(3) 2224(1) 4260(1) 2450(2) 87(1) 
O(1) 4739(1) 2499(1) 3174(1) 31(1) 
N(1) 3078(2) 1770(2) 4042(1) 28(1) 
N(2) 3599(2) 1924(2) 1788(1) 31(1) 
C(1) 3857(2) 2062(2) 2705(2) 27(1) 
C(2) 2679(2) 1260(2) 1273(2) 38(1) 
C(3) 1620(2) 1433(2) 1552(2) 38(1) 
C(4) 1932(2) 1471(2) 2592(2) 30(1) 
 247 
 
C(5) 1295(2) 1362(2) 3229(2) 29(1) 
C(6) 165(2) 1130(2) 3135(2) 36(1) 
C(7) -160(2) 1070(2) 3929(2) 41(1) 
C(8) 601(2) 1226(2) 4812(2) 40(1) 
C(9) 1711(2) 1458(2) 4933(2) 33(1) 
C(10) 2041(2) 1538(2) 4126(2) 28(1) 
C(11) 2997(2) 1722(2) 3112(2) 27(1) 
C(33) 3523(4) 4638(3) 3382(3) 70(1) 
Cl(1A) 4170(5) 5491(5) 4401(6) 194(4) 
Cl(2A) 3937(7) 4980(6) 2408(4) 165(3) 
Cl(3A) 2323(2) 4337(3) 3338(4) 106(1) 
O(1A) 4851(1) 2742(2) 662(1) 35(1) 
N(1A) 6497(2) 3276(2) 2463(1) 30(1) 
N(2A) 6118(2) 3281(2) -42(1) 34(1) 
C(1A) 5793(2) 3115(2) 718(2) 30(1) 
C(2A) 7091(2) 3921(2) -24(2) 36(1) 
C(3A) 8100(2) 3676(2) 814(2) 34(1) 
C(4A) 7727(2) 3585(2) 1663(2) 29(1) 
C(5A) 8316(2) 3640(2) 2630(2) 28(1) 
C(6A) 9434(2) 3831(2) 3143(2) 34(1) 
C(7A) 9722(2) 3846(2) 4100(2) 38(1) 
C(8A) 8915(2) 3675(2) 4559(2) 37(1) 
C(9A) 7810(2) 3472(2) 4079(2) 33(1) 
C(10A) 7519(2) 3447(2) 3108(2) 29(1) 
C(11A) 6635(2) 3355(2) 1592(2) 29(1) 
                                     
  
   
 Table 3.   Bond lengths [Å] and angles [
o
] for 1. 
  
Cl(1)-C(33) 1.749(4) Cl(2)-C(33) 1.661(4) 
Cl(3)-C(33) 1.866(5) O(1)-C(1) 1.254(3) 
N(1)-C(11) 1.374(3) N(1)-C(10) 1.375(3) 
N(1)-H(1) 0.8800 N(2)-C(1) 1.332(3) 
N(2)-C(2) 1.461(3) N(2)-H(2) 0.8800 
C(1)-C(11) 1.459(3) C(2)-C(3) 1.523(4) 
C(2)-H(2C) 0.9900 C(2)-H(2B) 0.9900 
C(3)-C(4) 1.497(3) C(3)-H(3A) 0.9900 
C(3)-H(3B) 0.9900 C(4)-C(11) 1.367(3) 
C(4)-C(5) 1.427(3) C(5)-C(10) 1.411(3) 
C(5)-C(6) 1.412(3) C(6)-C(7) 1.374(4) 
C(6)-H(6) 0.9500 C(7)-C(8) 1.398(4) 
C(7)-H(7) 0.9500 C(8)-C(9) 1.380(4) 
C(8)-H(8) 0.9500 C(9)-C(10) 1.400(3) 
C(9)-H(9) 0.9500 C(33)-Cl(3A) 1.535(5) 
C(33)-Cl(2A) 1.754(7) C(33)-Cl(1A) 1.868(6) 
C(33)-H(33) 1.0000 O(1A)-C(1A) 1.255(3) 
N(1A)-C(10A) 1.373(3) N(1A)-C(11A) 1.377(3) 
N(1A)-H(1A) 0.8800 N(2A)-C(1A) 1.341(3) 
N(2A)-C(2A) 1.469(3) N(2A)-H(2A) 0.8800 
C(1A)-C(11A) 1.452(3) C(2A)-C(3A) 1.526(4) 
C(2A)-H(2A1) 0.9900 C(2A)-H(2A2) 0.9900 
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C(3A)-C(4A) 1.492(3) C(3A)-H(3A1) 0.9900 
C(3A)-H(3A2) 0.9900 C(4A)-C(11A) 1.372(3) 
C(4A)-C(5A) 1.421(3) C(5A)-C(6A) 1.404(3) 
C(5A)-C(10A) 1.417(3) C(6A)-C(7A) 1.376(4) 
C(6A)-H(6A) 0.9500 C(7A)-C(8A) 1.403(4) 
C(7A)-H(7A) 0.9500 C(8A)-C(9A) 1.380(4) 
C(8A)-H(8A) 0.9500 C(9A)-C(10A) 1.397(3) 
C(9A)-H(9A) 0.9500   
     
C(11)-N(1)-C(10) 107.55(19) C(11)-N(1)-H(1) 126.2 
C(10)-N(1)-H(1) 126.2 C(1)-N(2)-C(2) 122.42(19) 
C(1)-N(2)-H(2) 118.8 C(2)-N(2)-H(2) 118.8 
O(1)-C(1)-N(2) 122.9(2) O(1)-C(1)-C(11) 122.5(2) 
N(2)-C(1)-C(11) 114.5(2) N(2)-C(2)-C(3) 112.4(2) 
N(2)-C(2)-H(2C) 109.1 C(3)-C(2)-H(2C) 109.1 
N(2)-C(2)-H(2B) 109.1 C(3)-C(2)-H(2B) 109.1 
H(2C)-C(2)-H(2B) 107.9 C(4)-C(3)-C(2) 108.5(2) 
C(4)-C(3)-H(3A) 110.0 C(2)-C(3)-H(3A) 110.0 
C(4)-C(3)-H(3B) 110.0 C(2)-C(3)-H(3B) 110.0 
H(3A)-C(3)-H(3B) 108.4 C(11)-C(4)-C(5) 106.6(2) 
C(11)-C(4)-C(3) 120.6(2) C(5)-C(4)-C(3) 132.6(2) 
C(10)-C(5)-C(6) 119.1(2) C(10)-C(5)-C(4) 106.4(2) 
C(6)-C(5)-C(4) 134.4(2) C(7)-C(6)-C(5) 118.3(2) 
C(7)-C(6)-H(6) 120.9 C(5)-C(6)-H(6) 120.9 
C(6)-C(7)-C(8) 121.6(2) C(6)-C(7)-H(7) 119.2 
C(8)-C(7)-H(7) 119.2 C(9)-C(8)-C(7) 121.9(2) 
C(9)-C(8)-H(8) 119.1 C(7)-C(8)-H(8) 119.1 
C(8)-C(9)-C(10) 116.8(2) C(8)-C(9)-H(9) 121.6 
C(10)-C(9)-H(9) 121.6 N(1)-C(10)-C(9) 129.0(2) 
N(1)-C(10)-C(5) 108.66(19) C(9)-C(10)-C(5) 122.3(2) 
C(4)-C(11)-N(1) 110.72(19) C(4)-C(11)-C(1) 123.2(2) 
N(1)-C(11)-C(1) 125.2(2) Cl(3A)-C(33)-Cl(2) 142.2(4) 
Cl(3A)-C(33)-Cl(1) 66.5(3) Cl(2)-C(33)-Cl(1) 112.9(3) 
Cl(3A)-C(33)-
Cl(2A) 
124.1(5) Cl(2)-C(33)-Cl(2A) 28.9(3) 
Cl(1)-C(33)-Cl(2A) 134.7(4) Cl(3A)-C(33)-Cl(3) 43.9(2) 
Cl(2)-C(33)-Cl(3) 106.0(3) Cl(1)-C(33)-Cl(3) 103.1(3) 
Cl(2A)-C(33)-Cl(3) 81.3(4) Cl(3A)-C(33)-
Cl(1A) 
111.3(4) 
Cl(2)-C(33)-Cl(1A) 82.9(4) Cl(1)-C(33)-Cl(1A) 45.7(2) 
Cl(2A)-C(33)-
Cl(1A) 
111.9(5) Cl(3)-C(33)-Cl(1A) 146.9(3) 
Cl(3A)-C(33)-H(33) 102.7 Cl(2)-C(33)-H(33) 111.5 
Cl(1)-C(33)-H(33) 111.5 Cl(2A)-C(33)-H(33) 108.3 
Cl(3)-C(33)-H(33) 111.5 Cl(1A)-C(33)-H(33) 93.6 
C(10A)-N(1A)-
C(11A) 
107.66(19) C(10A)-N(1A)-
H(1A) 
126.2 
C(11A)-N(1A)-
H(1A) 
126.2 C(1A)-N(2A)-C(2A) 122.5(2) 
C(1A)-N(2A)-H(2A) 118.7 C(2A)-N(2A)-H(2A) 118.7 
O(1A)-C(1A)-N(2A) 121.7(2) O(1A)-C(1A)-
C(11A) 
123.7(2) 
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N(2A)-C(1A)-
C(11A) 
114.5(2) N(2A)-C(2A)-C(3A) 112.0(2) 
N(2A)-C(2A)-
H(2A1) 
109.2 C(3A)-C(2A)-
H(2A1) 
109.2 
N(2A)-C(2A)-
H(2A2) 
109.2 C(3A)-C(2A)-
H(2A2) 
109.2 
H(2A1)-C(2A)-
H(2A2) 
107.9 C(4A)-C(3A)-C(2A) 109.23(19) 
C(4A)-C(3A)-
H(3A1) 
109.8 C(2A)-C(3A)-
H(3A1) 
109.8 
C(4A)-C(3A)-
H(3A2) 
109.8 C(2A)-C(3A)-
H(3A2) 
109.8 
H(3A1)-C(3A)-
H(3A2) 
108.3 C(11A)-C(4A)-
C(5A) 
106.8(2) 
C(11A)-C(4A)-
C(3A) 
120.8(2) C(5A)-C(4A)-C(3A) 132.4(2) 
C(6A)-C(5A)-
C(10A) 
119.3(2) C(6A)-C(5A)-C(4A) 134.2(2) 
C(10A)-C(5A)-
C(4A) 
106.5(2) C(7A)-C(6A)-C(5A) 118.9(2) 
C(7A)-C(6A)-H(6A) 120.6 C(5A)-C(6A)-H(6A) 120.6 
C(6A)-C(7A)-C(8A) 120.8(2) C(6A)-C(7A)-H(7A) 119.6 
C(8A)-C(7A)-H(7A) 119.6 C(9A)-C(8A)-C(7A) 122.0(2) 
C(9A)-C(8A)-H(8A) 119.0 C(7A)-C(8A)-H(8A) 119.0 
C(8A)-C(9A)-
C(10A) 
117.2(2) C(8A)-C(9A)-H(9A) 121.4 
C(10A)-C(9A)-
H(9A) 
121.4 N(1A)-C(10A)-
C(9A) 
129.7(2) 
N(1A)-C(10A)-
C(5A) 
108.6(2) C(9A)-C(10A)-
C(5A) 
121.7(2) 
C(4A)-C(11A)-
N(1A) 
110.5(2) C(4A)-C(11A)-
C(1A) 
123.6(2) 
N(1A)-C(11A)-
C(1A) 
125.6(2)   
  
Symmetry transformations used to generate equivalent atoms: 
                                                            
    
 Table 4.   Anisotropic displacement parameters (Å
2
 x 10
3
) for 1. The anisotropic 
displacement 
   factor exponent takes the form: -2 gpi
2
 [ h
2
 a*
2
 U11 + ... + 2 h k a* b* U 
                                                                                 
  Atom  U11  U22  U33  U23  U13  U12 
                                                 
Cl(1) 275(4) 125(2) 122(2) -27(2) 129(3) 33(2) 
Cl(2) 143(2) 110(2) 137(2) -23(2) 93(2) -69(2) 
Cl(3) 58(1) 69(1) 126(2) -12(1) 14(1) 12(1) 
O(1) 26(1) 45(1) 24(1) 2(1) 9(1) -5(1) 
N(1) 24(1) 38(1) 22(1) 0(1) 8(1) -3(1) 
N(2) 34(1) 37(1) 23(1) -1(1) 11(1) -8(1) 
C(1) 26(1) 29(1) 25(1) 3(1) 9(1) 1(1) 
C(2) 45(2) 45(2) 25(1) -4(1) 10(1) -12(1) 
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C(3) 37(1) 46(2) 27(1) 6(1) 4(1) -14(1) 
C(4) 32(1) 28(1) 28(1) 3(1) 8(1) -5(1) 
C(5) 26(1) 27(1) 34(1) 3(1) 9(1) -3(1) 
C(6) 28(1) 32(1) 46(2) 1(1) 10(1) -4(1) 
C(7) 31(1) 35(1) 64(2) -2(1) 24(1) -3(1) 
C(8) 43(2) 36(1) 50(2) -5(1) 31(1) -4(1) 
C(9) 38(1) 33(1) 35(1) -2(1) 20(1) -1(1) 
C(10) 29(1) 27(1) 32(1) -1(1) 16(1) -2(1) 
C(11) 28(1) 30(1) 24(1) 1(1) 10(1) -3(1) 
C(33) 90(3) 50(2) 89(3) -8(2) 53(2) -6(2) 
Cl(1A) 114(4) 126(4) 299(9) -129(5) -3(4) 11(3) 
Cl(2A) 244(8) 144(6) 117(4) 63(4) 68(5) 56(5) 
Cl(3A) 36(1) 79(2) 191(4) 29(3) 18(2) -4(1) 
O(1A) 25(1) 56(1) 25(1) 3(1) 7(1) -7(1) 
N(1A) 24(1) 44(1) 23(1) -1(1) 8(1) -4(1) 
N(2A) 31(1) 48(1) 25(1) -6(1) 12(1) -11(1) 
C(1A) 26(1) 38(1) 26(1) -1(1) 10(1) -2(1) 
C(2A) 36(1) 49(2) 30(1) -3(1) 17(1) -11(1) 
C(3A) 29(1) 45(2) 34(1) -9(1) 17(1) -9(1) 
C(4A) 28(1) 31(1) 29(1) -4(1) 11(1) -2(1) 
C(5A) 28(1) 26(1) 30(1) -2(1) 9(1) -1(1) 
C(6A) 28(1) 33(1) 40(1) 1(1) 8(1) -2(1) 
C(7A) 32(1) 36(1) 39(1) 2(1) 0(1) -4(1) 
C(8A) 40(1) 38(1) 27(1) 2(1) 0(1) -4(1) 
C(9A) 36(1) 35(1) 27(1) 2(1) 8(1) -2(1) 
C(10A) 26(1) 31(1) 28(1) -1(1) 7(1) -1(1) 
C(11A) 25(1) 39(1) 24(1) -2(1) 10(1) -3(1) 
  
 
   
 Table 5.   Hydrogen coordinates ( x 10
4
) and isotropic displacement 
   parameters (Å
2
 x 10
3
) for 1. 
                                     
  Atom   x   y   z  U(eq) 
                                  
H(1) 3682 1922 4500 34 
H(2) 3997 2244 1480 37 
H(2C) 2911 530 1388 46 
H(2B) 2515 1394 598 46 
H(3A) 1261 2089 1284 45 
H(3B) 1083 866 1312 45 
H(6) -358 1018 2539 43 
H(7) -918 920 3875 49 
H(8) 346 1171 5344 47 
H(9) 2226 1557 5535 40 
H(33) 3965 4020 3679 84 
H(1A) 5866 3140 2584 36 
H(2A) 5734 2994 -571 40 
H(2A1) 6891 4656 -2 44 
H(2A2) 7293 3807 -603 44 
H(3A1) 8448 3021 706 41 
H(3A2) 8665 4230 901 41 
 251 
 
H(6A) 9983 3948 2835 41 
H(7A) 10476 3974 4455 45 
H(8A) 9135 3698 5220 44 
H(9A) 7270 3355 4396 40 
 
